WO2019168847A1 - Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors - Google Patents

Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors Download PDF

Info

Publication number
WO2019168847A1
WO2019168847A1 PCT/US2019/019582 US2019019582W WO2019168847A1 WO 2019168847 A1 WO2019168847 A1 WO 2019168847A1 US 2019019582 W US2019019582 W US 2019019582W WO 2019168847 A1 WO2019168847 A1 WO 2019168847A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
membered
independently selected
aryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/019582
Other languages
English (en)
French (fr)
Inventor
Xiaozhao Wang
Pei Gan
Heeoon HAN
Taisheng Huang
Matthew S. MCCAMMANT
Chao QI
Ding-Quan Qian
Liangxing Wu
Wenqing Yao
Zhiyong Yu
Fenglei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201980027624.3A priority Critical patent/CN112384515B/zh
Priority to JP2020567459A priority patent/JP7474709B2/ja
Priority to PE2020001285A priority patent/PE20211001A1/es
Priority to EP19713602.1A priority patent/EP3759112A1/en
Priority to IL276873A priority patent/IL276873B2/en
Priority to PE2024003132A priority patent/PE20251291A1/es
Priority to BR122023024273-4A priority patent/BR122023024273A2/pt
Priority to CR20230030A priority patent/CR20230030A/es
Priority to CA3092470A priority patent/CA3092470A1/en
Priority to BR112020017421-1A priority patent/BR112020017421A2/pt
Priority to CN202311603774.9A priority patent/CN117903140A/zh
Priority to KR1020207027865A priority patent/KR20200139153A/ko
Priority to MX2020008949A priority patent/MX2020008949A/es
Priority to IL303087A priority patent/IL303087B2/en
Application filed by Incyte Corp filed Critical Incyte Corp
Priority to EA202092016A priority patent/EA202092016A1/ru
Priority to CR20200441A priority patent/CR20200441A/es
Priority to AU2019227607A priority patent/AU2019227607C1/en
Publication of WO2019168847A1 publication Critical patent/WO2019168847A1/en
Priority to PH12020551332A priority patent/PH12020551332A1/en
Anticipated expiration legal-status Critical
Priority to CONC2020/0011908A priority patent/CO2020011908A2/es
Priority to AU2022283611A priority patent/AU2022283611B2/en
Priority to JP2023096889A priority patent/JP7624476B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention provides imidazopyrimidine and triazolopyrimidine compounds that modulate the activity of adenosine receptors, such as subtypes A2A and A2B, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory' diseases, cardiovascular diseases, and neurode generative diseases.
  • Adenosine is an extracellular signaling molecule that can modulate immune responses through many immune cell types.
  • Adenosine was first recognized as a physiologic regulator of coronary vascular tone by Drury and Szent-Gyorgyu (Sachdeva, S. and Gupta, M. Saudi Pharmaceutical Journal, 2013, 21, 245-253), however it was not until 1970 that Sattin and Rail showed that adenosine regulates cell function via occupancy of specific receptors on the cell surface (Sattin, A., and Rail, T.W., 1970. Mol. Pharmacol. 6, 13-23; Hasko', G., at al, 2007, Pharmacol. Ther. 113, 264-275).
  • Adenosine pla s a vital role in various other ph siological functions. It is involved in the synthesis of nucleic acids, when linked to three phosphate groups; it forms ATP, the integral component of the cellular energy system. Adenosine can be generated by the enzy matic breakdown of extracellular ATP, or can be also released from injured neurons and glial cells by passing the damaged plasma membrane (Tautenhahn, M. et al.
  • Adenosine produces various pharmacological effects, both in periphery and in the central nervous system, through an action on specific receptors localized on cell membranes (Matsumoto, T. et al. Pharmacol. Res., 2012, 65, 81- 90).
  • Alternative pathways for extracellular adenosine generation have been described. These pathways include the production of adenosine from nicotinamide dinucleotide (NAD) instead of ATP by the concerted action of CD38, CD203a and CD73.
  • NAD nicotinamide dinucleotide
  • CD73 -independent produc tion of adenosine can also occur by other phosphates such as alkaline phosphatase or prostate- specific phosphatase.
  • adenosine receptor There are four known subtypes of adenosine receptor in humans including Al, A2A, A2B, and A3 receptors. Al and A2A are high affinity receptors, whereas A2B and A3 are low affinity receptors. Adenosine and its agonists can act via one or more of these receptors and can modulate the activity of adenylate cyclase, the enzyme responsible for increasing cyclic AMP (cAMP). The different receptors have differential stimulatory and inhibitory effects on this enzyme. Increased intracellular concentrations of cAMP can suppress the activity' of immune and inflammatory cells (Livingston, M. et al., In fiamm. Res., 2004, 53, 171-178).
  • the A2A adenosine receptor can signal in the periphery and the CNS, with agonists explored as anti-inflammatory' drugs and antagonists explored for neurodegenerative diseases (Carlsson, I. et al., J. Med. Chem., 2010, 53, 3748-3755). In most cell types the A2A subtype inhibits intracellular calcium levels whereas the A2B potentiates them. The A2A receptor generally appears to inhibit inflammatory response from immune cells (Borrmann, T. et al., J. Med. Chem., 2009, 52(13), 3994-4006).
  • A2B receptors are highly expressed in the gastrointestinal tract, bladder, lung and on mast cells (Antonioli, L et ah, Nature Reviews Cancer, 2013, 13, 842-857).
  • the A2B receptor although structurally closely related to the A2A receptor and able to activate aden late cyclase is functionally different. It has been postulated that this subtype may utilize signal transduction systems other than adenylate cyclase (Livingston, M. et ah, Inflamm. Res., 2004, 53, 171-178).
  • the A2B adenosine receptor is a low affinity receptor that is thought to remain silent under physiological conditions and to be activated in consequence of increased extracellular adenosine levels (Ryzhov, S. et al.
  • Neoplasia 2008, 10, 987-995.
  • Activation of A2B adenosine receptor can stimulate adenylate cyclase and phospholipase C through activation of Gs and Gq proteins, respectively.
  • Coupling to mitogen activated protein kinases has also been described (Borrmann, T. et al., J. Med. Chem., 2009, 52(13), 3994-4006).
  • Adenosine signalin can be a critical regulatory mechanism that protects tissues against excessive immune reactions.
  • Adenosine can negatively modulate immune responses through many immune cell types, including T -cells, natural-killer cells, macrophages, dendritic ceils, mast cells and myeloid-derived suppressor cells (Allard, B. et al. Current Opinion m Pharmacology, 2016, 29, 7-16).
  • adenosine was mainly generated from extracellular ATP by CD39 and CD73. Multiple cell types can generate adenosine by expressing CD39 and CD73. This is the case for tumor cells, T-effector cells, T-regulatory cells, tumor associated macrophages, myeloid derived suppressive cells (MDSCs), endothelial cells, cancer- associated fibroblast (CAFs) and mesenchymal stromal/stem cells (MSCs).
  • adenosine level in solid tumors is unusually high compared to normal physiological conditions.
  • A2A are mostly expressed on l mphoid -derived cells, including T-effecior cells, T regulatory cells and nature killing cells. Blocking A2A receptor can prevent downstream immunosuppressive signals that temporarily inactivate T ceils.
  • A2B receptors are mainly expressed on monocyte-derived cells including dendritic cells, tumor-associated
  • Blocking A2B receptor in preclinical models can suppress tumor growth, block metastasis, and increase the presentation of tumor antigens.
  • A2A/A2B In terms of safety profile of ADORA2A/ADORA2B (A2A/A2B) blockage, the A2A and A2B receptor knockout mice are all viable, showing no growth abnormalities and are fertile (Allard, B. et ai. Current Opinion in Pharmacology, 2016, 29, 7-16).
  • A2A KQ mice displayed increased levels of pro-inflammatory cytokines only upon challenge with LPS and no evidence of inflammation at baseline (Antonioli, L. et al.. Nature Reviews Cancer, 2013, 13, 842-857).
  • A2B KG mice exhibited normal platelet, red blood, and white cell counts but increased inflammation at baseline (TNF-alpha, IL-6) in naive A2B KO mice (Antonioli, L.
  • mice also exhibited increased vascular adhesion molecules that mediate inflammation as well leukocyte adhesion/rolling; enhanced mast-cell activation; increased sensitivity to IgE -mediated anaphylaxis and increased vascular leakage and neutrophil influx under hypoxia (Antonioli, L. et al., Nature Reviews Cancer, 2013, 13, 842-857).
  • the present invention relates to, inter alia, compounds of Formula (I):
  • the present invention further provides pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a
  • the present invention further provides methods of inhibiting an activity of an adenosine receptor, comprising contacting the receptor with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
  • the present invention further provides methods of treating a disease or a disorder associated with abnormal expression of adenosine receptors, comprising administering to said patient a therapeutically effective amount of a compound of Formula (I), or a
  • the present invention further provides a compound of Formula (I), or a
  • the present invention further provides use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in any of the methods described herein.
  • the present invention relates to, inter alia, compounds of Formula (i):
  • X is N or CR :
  • Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C&-34 aryl, C3- M cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CS- M ar l-Cw alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ⁇ alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- of R 1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R d substituents;
  • R 2 is selected from H, D, halo, C - 6 alkyl, C - 6 haloalkyl, C 2-6 alkenyl, C2-6 alkynyl, CV 14 aryl, Cs-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C S-M aryl-Ci- 6 alkyl-, Cs-u cycloalky l-Ci- 6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, CN, N0 2 , OR a2 , SR a2 , NHOR ai , C(0)R b2 ,
  • NR c2 S(0)R b2 N R SiOi R K' .
  • heterocycloalkyl, Ce-w aryl-Ci-6 alkyl-, C3..14 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl- of R ⁇ are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected substituents;
  • R 3 is selected from H, D, halo, Ci-s alkyl, Ci-s haloalkyl, C 2-6 alkenyl, alkynyl, de ⁇ n ary!, C3-34 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heierocycloalkyl, C * aryl-Ci- 6 alkyl-, CVw cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl) ⁇ Ci- 6 alkyl-, (4-14 member
  • heterocycloalkyl C M * aryl-C -6 alkyl-, C 3-14 cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl) ⁇ C 1-6 alkyl- of R 3 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R ⁇ substituents;
  • Cy 1 is Cfs-M aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the C S-M aryl, Cs-ncycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 11 substituents;
  • Cy 1 is not pyridin-4-yl optionally substituted with i, 2, 3, or 4 independently selected R ⁇ substituents;
  • Cy 1 is not pyrimidin-4-yl optionally substituted with 1, 2, or 3, independently selected R substituents;
  • Cy 1 is not quinolin-4-yl optionally substituted with 1 , 2, 3, 4, 5, or 6 independently selected R b substituents;
  • Cy is C &-34 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heierocycloalkyl, wherein the Ce-u aryl, C 3-H cycloalky 1, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with l, 2, 3, 4, 5, 6, 7, or 8 independently selected R b substituents;
  • each R a! , R c l , R ds , R a2 , R c2 , R d2 , R a3 , R c3 , and R d3 is independently selected from H, Ci. 6 alkyl, C - 6 haloalkyl, alkenyl, C 2-6 alkynyl, CX- H aryl, C 3U4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heierocycloalkyl, Ce-n aryl-C 3-5 alkyl-, Cs-i + cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4- 14 membered heterocycloalkyl)-Ci- 6 alkyl-, wherein the Cj-e alkyl, C2-6 alkenyl, C2-6 alkynyi, Ce-u aryl, €3-5+
  • any R ci and R al attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroary l or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R° substituents;
  • R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R° substituents;
  • R c3 and R d3 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R & substituents;
  • each R bl , R h3 , and R b3 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyi, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i4 aryl-Cs- 6 alkyl-, Cs-w cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyi, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci- 6 alkyl-
  • each R ei , R 5 , and R e3 is independently selected from H, OH, CN, Ci- 6 alkyl, Ci- 6 alkoxy, Cj- 6 haloalkyl, Ci-ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyi, C 6 -i4 aryl, C3- M cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w aiyl-Cj-6 alkyl-, G3- H cycloalkyl-Ci- 6 alkyl-, (5-14 membered heteroaryl)-C ]-6 alkyl-, and (4-14 membered heterocy cloalky 1)-C 1.5 alky 1-;
  • each R g , R g2 , R iJ , and R g3 is independently selected from H, Cj- 6 alkyl, C]- 6 aikoxj r , Ci- 6 haloalkyl, Cj-e haloalkoxy, C2-6 alkenyl, C2-6 alkynyi, €5-54 aryl, 63-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CM* aryl-Ci-6 alkyl-, C3-14 cycloalkyl- Ci-6 alkyl-, (5-14 membered heteroai l)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R 112 , R l2 , R !l3 , and R 1J is independently selected from H, C - & alkyl, C - & haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryl, C3-1 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, e- aryl-C *- 6 alkyl-, C3- K cycioalkyl-C -6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl) ⁇ C 1-6 alkyl-;
  • each R j , R ki , R J C and R k3 is independently selected from OH, C -e alkoxy, and Ci- 6 haloaikoxy;
  • R j2 and R k2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci- 6 alkyl and C 1-6 haloalkyl;
  • R JJ and R kJ attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalky 1 group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci-e alkyl and Ci- 6 haloalkyl;
  • each R b , R c , R d , R e , R f , and R° is independently selected from D, halo, oxo, Cj- & alkyl, Ci-6 haloalkyl, C 2- e alkenyl, C2-6 alkynyl, C&-14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u ary l-C -6 alkyl-, C3-14 cycloalk l-Cw alkyl- (5-14 membered heteroaryi)-Ci-6 alkyl-, (4-14 membered heterocycloalkyi)-Ci-6 alkyl-, CN, NO2, OR a4 , SR a4 , NHOR 84 , C(0)R M , C(0)NR c4 R d4 , C(0)NR c4 (0R a4 ), C(0)0R 34 .
  • NR c4 S(0)NR c4 R d4 , NR c4 S(0) 2 R b4 , NR c4 S(0)(-NR e4 )R b4 , NR c4 S(0) 2 NR c4 R d4 , S(0)R b4 , S(0)NR c+ R d+ , S(0) 2 R b+ , S(0) 2 NR c4 R d4 , 0S(0)( NR e4 )R b4 , 0S(0) 2 R b4 , SF s , P(0)R f4 R g4 , 0P(0)(0R h4 )(0R 14 ), P(0)(0R h4 )(0R 4 ), and BR.
  • heterocycloalkyl Ce-u aryl-C 1.5 alkyl-, C3-14 cycloalk I-C1-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C ue alkyl- of R B , R c , R D , R E , R F , and R° are each optionally substituted with 1 , 2, 3, 4, 5, 6, 7, or 8 independently selected
  • each R a4 , R c+ , and R d4 is independently selected from H, C i-s alkyl, C i-s haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryd, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocy cloalkyl, Ce-u aryl-C i-e alkyl-, C 3 -i cycloalkyl-C - 6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, C f .- aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u
  • each R fc4 is independently selected from H, Cne alkyl, Cne haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- aryd, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl CM* aryl-C [-6 alkyl-, C3-14 cycloalkyl-Cj-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl) ⁇ C 1-6 alkyl-, wherein the Ci-s alkyl €2-5 alkenyl, C2-S alkynyl, C&-14 aryd, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, M * aryl-C i-b alkyl-, C3- K cycloalkyl-Cj-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl- of R° 4 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R H substituents; each R 84
  • each R f4 and R g4 is independently selected from H, C -- 6 alkyl, Ci-e alkoxy, Ci- 6 haloalkyl, Ci-ghaloalkoxy, C2-6 alkenyl, €2-5 alkynyl, aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C i-b alkyl-, C3-14 cycloalkyl- Ci- d alkyl-, (5-14 membered heteroaiyl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R M and R 14 is independently selected from H, Ci-s alkyl, Ci ⁇ haloalkyl, C2-6 alkenyl, €2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i4 aryl-Cj-e alkyd-, Cs-w cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaiyl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R j4 and R K4 is independently selected from OH, Cj-saikoxy, and Ci-ehaloalkoxy; or, any R j4 and R k+ attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Cne alkyl and Cj- 6 haloalkyl; each R H is independently selected from D, halo, oxo, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-& alkynyl, Ce-u aryl, C B-H cycloalkyl, 5-14 tnembered heteroaryd, 4-14 membered heterocycloalkyl, Ce-n aiyl-Ci-6 alkyl-, Cs- H cycloalkyi-Ci-e alkyl-, (5-14 membered hetero
  • heterocycloalkyl Ce-u aryl-C i-e alkyl-, C B -i4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl- of R 1 ! are each optionally substituted with 1, 2, 3, or 4 independently selected R 1 substituents;
  • each R a ⁇ R c5 , and R d> is independently selected from H, Cj-b alkyl, Cj-b haloalkyl, C2-6 alkenyl, C 2- e alkynyl, €5-14 aryl, CB-H cycloalkyl, 5-14 membered heteroaryd, 4-14 membered heterocycloalkyl, Ce-n aryl-C 1 -5 alkyd-, CB-H cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the Ci-e alkyl, C 2-& alkenyl, C 2-& alkynyl, Ce-w aryl, C B-M cycloalkyl, 5-14 membered heteroaryd, 4-14 membered heterocycloalkyl, Ce-u aryl-Cj-e alky
  • each R b5 is independently selected from H, Cue alkyd, Cue haloalkyl, C 2-6 alkenyl, C 2-& alkynyl, C&-14 aryl, C B-H cycloalk l, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce-u aryd-C i-e alkyl-, C3-i4 cycloalkyd-Ci-6 alkyl-, (5-14 membered heteroaryi)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyi) ⁇ C 1-6 alkyl-, wherein the Ci- 6 alkyl, C 2 -e alkenyl, C 2-6 alkynyl, C &-J 4 aryl, CB-H cycloalkyl, 5-14 membered heteroaryd, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-e alkyl-, Ci-u cycloalkyl-C -6 alky' 1-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloa3kyl)-Ci-6 alkyl- of R 03 are each optionally substituted with 1, 2, 3, or 4 independently selected R 1 substituents;
  • each R e5 is independently selected from H, OH, CN, C M alkyl, Ci-e alkoxy, Ci- 6 haloalkyl, Ci-ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ca-u aryl, C;-w cycloalkyi, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aiyl-Ci- 6 alkyl-, Cs-u cycloalkyi- C M alkyl-, (5-14 membered heteroaryl) -C - 6 alkyl-, and (4-14 membered heterocycioalkyl)-C - 6 alkyl-;
  • each R 6 and R p is independently selected from H, Cm, alkyl, Ci « alkoxy, Ci- 6 haloalkyl, Ci- 6 haloalkoxy, C>;-s alkenyl, C2-6 alkynyl, C K aryl, C3- S 4 cycloalkyl, 5-14 membered heteroary l, 4-14 membered heterocycloalkyl, C M 4 ary l-Ci- 6 alkyl-, C3-14 cycloalky 1- C [- 6 alkyl-, (5-14 membered heteroaiyl)-Ci- 6 alkyl-, and (4-14 membered heteroeycloalkyli-Ci- 6 alkyl-;
  • each R tD and R 15 is independently selected from H, C alkyl, C M haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, Cj-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce- aryl-C 1.5 alkyl-, C3-14 cycloalky 1-C M alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C alkyl-;
  • each R j5 and R k5 is independently selected from OH, Ci-e alkoxy, and C -ehaloalkoxy; or, any R
  • each R ! is independently selected from D, halo, oxo, C , alkyl, C , haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, Ce-u aryl, Cs-u cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary 1-C M alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ]-6 alkyl-, and (4-14 membered heterocycioalkyl)-Ci- 6 alkyl-, CN, N(3 ⁇ 4, OR ab , SR ®6 , NHGR a5 , C(0)R b6 , C(0)NR c6 R d6 , C(0)NR c6 (0R a6 ). C(0)GR af> , GC(G)R b6 ,
  • heterocycloalkyl, Ce-i aiyl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl- of R l are each optionally substituted with 1 , 2, 3, or 4 independently selected R J substituents;
  • each R a5 , R c6 , and R d6 is independently selected from H, C i-s alkyl, C i-s haloalkyl, C M alkenyl, CM alkynyl, C&-14 aryl, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryd-C M alkyl-, C3-i4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the C M alkyl, C 2-6 alkenyl, C2-6 alkynyl, Ci.-u aryl, C J-M cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-e alkyl
  • R 06 and R dR attached to the same N atom, together with the N atom to winch they are attached, form a 5- or 6-membered heteroary l or a 4-14 membered heterocycloalkyl group, wiierein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R b6 is independently selected from H, CM alkyl, CM haloalkyl, C 2 -s alkenyl, C 2 -6 alkynyl, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered
  • heterocycloalkyl Ce-w ary I-C1-& alkyl-, C3-1 4 cycloalkyl-Cw alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyi)-Ci-6 alkyl-, wiierein the C alkyl, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Cs-w aryi-C M alkyl-, CVw cycloalkyl-C M alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1 ⁇ 2 alkyl- of R b6 are each optionally substituted with 1 , 2, 3, or 4 independently selected R:' substituents;
  • each R ®6 is independently selected from H, OH, CN, Ci-e alkyl, Cue lkoxy, Ci-e haloalkyl, Ci-ghaloalkoxy, C2-6 alkenyl, C 2 « alkynyl, Ce-n aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce-u axyl-Ci-e alkyl-, C3-14 cycloalkyl- Ci- d alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alky 1-;
  • each R ® and R s ° is independently selected from H, Ci-e alkyl, Ci-e alkoxy, Ci-e haloalkyl, Cwehaloalkoxy, C2-6 alkenyl, C 2-f, alkynyl, Ce-w aryl, C3-W cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce-i4 aryl-Cj- 6 alkyl-, Cs-w cycloalkyi- Ci-, (5-14 membered heteroaryi) -Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-Ci. & alkyi-;
  • each R h6 and R 16 is independently selected from H, Cj-e alkyl, Cj-b haloalkyl, C M alkenyl, C 2-6 alkynyl, C &-J 4 aryl, C3-1 4 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce-w ary l-Ci- 6 alkyl-, C -i+ cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-;
  • each R j6 and R k6 is independently selected from OH, C -s alkoxy, and C i-ehaloalkoxy; or, any R j6 and R k6 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci-e alkyl and Ci- 6 haloalkyl; each R: 1 is independently selected from D, halo, oxo, C - 6 alkyl, C - 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryl, Caur cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce- aryl-C 1.5 alkyl-, C 3-14 cycloalky I-C 1-6 alkyl-, (5-14 membered heteroarv'l)-C
  • Ci- 5 alkyl C 2.s alkenyl, C 2.s alkynyl, Ct,-u aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4- 14 membered
  • heterocycloalkyl Ce-w ary' l-Ci- 6 alkyl-, C -i+ cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl- of R J are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R a/ , R c ', and R d ' is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, €2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6 -i4 aiyl-Ci- 6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaiyl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1 ⁇ 2 alkyl- wherein the Ci- 6 alkyl, C 2-6 alkenyl, C2-6 alkymyl, Ce-i+ aryl, Ci-n cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u ary l-C
  • each R b? is independently selected from H, Ci-b alkyl, Cue haloalkyl, C2-6 alkenyl, C 2 -e alkynyl, C &-J 4 aryl, Cs-u cycloalkyl, 5-14 membered heteroaryl, 4- 14 membered heterocycloalkyl, Ce-w aryl-Ci-e alkyl-, Cj-i + cycloalkyl-Cj-e alkyl-, (5-14 memhered heteroaryl)-Cj- 6 alkyl-, and (4-14 membered heterocycloa3kyl)-Ci- 6 alkyl-, wherein the Cj- 6 alkyl, C2-6 alkenyl, C2-6 alkyny!, C &-K aryl, Cs- M cyeloalkyi, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CS- M ar l-Cw alkyl
  • each R c/ is independently selected from H, OH, CN, Ci-e alkyl, C2-6 alkenyl, C3-6 alkoxy, Ci- 6 haloalkyl, Ci-ehaloalkoxy, C2-6 alkynyl, Ce-ir aryl, C3-34 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl;
  • each R 17 and R s? is independently selected from H, Ci- 6 alkyl, Cj-5 alkoxy, C M;
  • haloalkyl Ci-ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i4 aiyl-Ci-e alkyl-, C3-14 cycloalkyl- Ci- 6 alkyl-, (5-14 membered heteroaiyll-Ci-g alkyl-, and (4-14 membered heterocycloalkyl)-Ci- s alkyl-;
  • each R h/ and R" is independently selected from H, Ci-s alkyl, C M haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&.34 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C M ar I-C1- & alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R J / and R*' is independently selected from OH, C 3-6 alkoxy, and Ci-ehaloalkoxy ; or, any R J ' and R k/ attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C3-6 alkyl and C [- 6 haloalkyl;
  • each R K is independently selected from H, D, OH, halo, oxo, CN, C(Q)OH, NH 2 ,
  • any heteroaryl group of any of the above-recited substituents optionally comprises an N-oxide on any ring-forming nitrogen
  • X is N or CR ;
  • R 1 is selected from H, Cj- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, and C M haloalkyl;
  • R 2 is selected from H, D, halo, C 3 -6 alkyl, C3 -6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- 1 aryl, C3-34 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i4 aryi-C -6 alkyl-, C3- M cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaiyl)-C -6 alky 1-, (4-14 membered heterocycloalkyl)-C M alkyl-, CN, NO?, OR 32 , SR 32 , NHQR 32 , C(0)R b2 ,
  • CiOiNR ⁇ R : . C(0)NR c2 (0R a2 ), C(G)OR a2 , 0C(0)R b2 , 0C(0)NR c2 R d2 , X R R 12 .
  • heterocycloalkyl CX-w aryl-Cs-6 alkyl-, C3-i 4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- of R 2 are each optionally substituted with 1 , 2, 3, 4, 5, 6, 7, or 8 independently selected R c substituents;
  • R 3 is selected from H, D, halo, C M alkyl, C M haloalkyi, C M alkenyl, C M alkynyl, Ce- 14 and, C3.14 cycloalkyl 5-14 membered heteroaryl, 4-14 membered heterocycloalk l, Ce-14 aryd-C -6 alkyl-, C3-14 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, (4-14 membered heterocycloalkyl)-Ci.. 6 alkyl-, CN, NG 2 , OR a3 , SR 33 , NHGR a3 , C(0)R w ,
  • CiOiNR ⁇ R CiOiNR ⁇ R ; . C(0)NR c3 (QR a3 ), C(0)0R a3 , 0C(0)R b3 , 0C(0)NR c3 R d3 , N RdC.
  • heterocycloalkyl Ce-w ary 1-CM alkyl-, C3-14 cycloalkyl-C alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C M alkyl- of R 3 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R ! substituents;
  • Cy 1 is C M 4 aryl, C J-M cycloalky 3, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the Ce-u aryl C3-i 4 cycloalkyl, 5-14 membered heteroaiyl, or 4-14 membered heterocycloalkyl is optionally substituted with l, 2, 3, 4, 5, 6, 7, or 8 independently selected R E substituents;
  • Cy 2 is Ce- H aryl, C 3- i4 cycloalkyl, 5-14 membered heteroaiyl, or 4-14 membered heterocycloalkyl, wherein the Ce-i 4 aryl, C3-14 cycloalky 1, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R b substituents;
  • each R a 6 R° 2 , R d2 , R a3 , R c3 , and R d3 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryl, C3 -14 cycloalkyl, 5-14 membered heteroaryl, 4- 14 membered heterocycloalkyl, C &-K aryl -Ci-s alkyl-, C 3-i 4cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci ⁇ alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, wherein the Cj-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, CM* aryl, C3-W cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalky
  • R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1 , 2, 3, or 4 independently selected R 11 substituents;
  • R cJ and R d3 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R° substituents;
  • each R b2 , and R bJ is independently selected from H, Cs- 6 alkyl, Cs- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&-14 aryl, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CM* aiyl-C i-b alkyl-, C3-14 cycloalkyl-Cj-e alkyl-, (5-14 membered heteroaryi)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyi) ⁇ C 1-6 alkyl-, wherein the Ci-s alkyl, €2-5 alkenyl, C2- S alkynyl, C&-14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, M * aryl-Ci-e alkyl-, C 3-
  • each R f2 , R s3 , R f3 , and R s3 is independently selected from H, Ci- 6 alkyl, Ci-e alkoxyy Ci haloalkyl, Cj-ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyi, C &-J 4 aryl, C 3- u cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C M 4 ary l-Ci-6 alkyl-, C3-14 cycloalky 1- C [-6 alkyl-, (5-14 membered heteroaiyl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R h , R , R a3 , and R' 3 is independently selected from H, Ci. & alkyl, Ci. & haloalkyl, C2-6 alkenyl, C2-6 alkynyi, Ce-u aryl, C3-14 eycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-e alkyl-, Cs-u cycloalky l-Ci-6 alkyl-, (5-14 membered heteroaryd)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C i-e alkyl-;
  • each R j2 , R k2 , R 3 , and R* 3 is independently selected from OH, Cwalkoxy, and Ci-e haloalkoxy;
  • R j2 and R K attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci- 6 alkyl and C 1-6 haloalkyl;
  • R j3 and R ⁇ 3 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1 , 2, 3, or 4 substituents independently selected from Ci-e alkyl and C ue haloalkyl;
  • each R c , R D , R b , R f , and R° is independently selected from D, halo, oxo, Ci « alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyi, Ce-u aryl, C3-14 eycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u ary l-Ci- 6 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, (4-14 membered heterocycloalky l)-Ci- 6 alkyl-, CN, N0 2 , OR 34 , SR a4 , N ⁇ iOR n C(0)R m , C(0)NR c4 R d4 , C(0)NR c4 (0R a4 ), C(0)0R a4
  • R c , R D , R 11 , R b , and R' J are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R h substituents;
  • each R 34 , R c4 , and R d4 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C - & alkenyl, C 2-& alkynyi, CVu aryl, Cj-u eycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci- 6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci ⁇ alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 a!kynyl, Ce-i + aiyl, C3-14 cycloalkyl, 5-14 membered heteroaiyl, 4-14 membered heterocycloalkyl, C -u aryl-Ci
  • each R w is independently selected from H, Ci- 6 alky l, Ci-e haloalkyi, C2-6 alkenyl, C2-0 alkynyl, Ce-w aryl, C3-H cycloalkyl, 5-14 membered heteroaiyl, 4-14 membered
  • heterocycloalkyl Cg-ir aiyl-Ci-6 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C M aryl, Ci- K cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cs-w aryi-Cj-g alkyl-, C3-14 cycloalky l-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C i-e alkyl- ofR 04 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R H substituents;
  • each R f4 and R 84 is independently selected from H, Ci-e alkyl, Ci- 6 alkoxy, Ci ⁇ haloalkyi, Ci-ehaloalkoxj , C2-6 alkenyl, C2-6 alkynyl, Ca-u aryl, C3-i4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C & -u aryd-Ci-e alkyl-, C3-1 cycloalky 1- Ci- f, alkyl-, (5-14 membered heteroaryl) -Cj- 6 alkyl-, and (4-14 membered heterocyc!oalkyl)-Cj- 6 alkyl-;
  • each R h4 and R 14 is independently selected from H, Ci- 6 alkyl, C1-6 haloalkyi, C2-6 alkenyl, C 2-6 alkynyl, C&-14 aryl, C-t-u cycloalkyl, 5-14 membered heteroaiyl, 4-14 membered heterocycloalkyl, Ce-w ary l-Ci-6 alkyl-, C3-14 cycloalkyl-Cw alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycioalkyi)-Cs- 6 alkyl-;
  • each R ⁇ ' 4 and R k4 is independently selected from OH, Cj-g alkoxy, and Ci-ghaloalkoxy; or, any R j4 and R k+ attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Cj- 6 alkyl and Cj- 6 haloalkyl; each R H is independently selected from D, halo, oxo, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ce-w aryl, Cj-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-ir aiyl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroary
  • heterocycloalkyl Ce-u aryl-C i-e alkyl-, C3-i4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl- of R 1 ! are each optionally substituted with 1, 2, 3, or 4 independently selected R 1 substituents;
  • each R 85 , R c5 , and R d> is independently selected from H, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C 2- e alkynyl, C ⁇ 5-i4 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i4 aryl-Cj-e alkyd-, Cs-w cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wherein the Ci-e alkyl, C 2-6 alkenyl, C 2-& alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Cj-e alky
  • each R b5 is independently selected from H, Cue alkyl. Cue haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C&-14 aryl, €3-14 cycloalky 1, 5-14 membered heteroaryl, 4-14 membered
  • each R e5 is independently selected from H, OH, CN, CM alkyl, Ci-e alkoxy, Ci- 6 haloalkyl, Ci-ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ca-u aryl, C;-w cycloalkyi, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aiyl-Ci- 6 alkyl-, Cs-u cycloalkyi- CM, alkyl-, (5-14 membered heteroaryl) -C - 6 alkyl-, and (4-14 membered heterocycioalkyl)-C - 6 alkyl-;
  • each R 6 and R p is independently selected from H, Cm, alkyl, Ci «alkoxy, Ci- 6 haloalkyl, Ci- 6 haloalkoxy, C>;-s alkenyl, C2-6 alkynyl, C K aryl, C3- H cycloalkyl, 5-14 membered heteroary l, 4-14 membered heterocycloalkyl, C M 4 ary l-Ci- 6 alkyl-, C 3 -1 4 cycloalky 1- C [- 6 alkyl-, (5-14 membered he teroaryli-Ci- f , alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R tD and R 15 is independently selected from H, C alkyl, C M haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, Cj-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce- aryi-C 1.5 alkyl-, C3-1 cycloalky l-Ci-6 alkyl-, (5-14 membered
  • heteroaryl Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
  • each R j5 and R k5 is independently selected from OH, Ci-salkoxy, and C -ehaloalkoxy; or, any R
  • each R ! is independently selected from D, halo, oxo, C , alkyl, C , haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, Ce-u aryl, Cs-ucycloalkyi, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary 1-C M alkyl-, C3-14 eyeloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C ]-6 alkyl-, CN, N(3 ⁇ 4, OR ab , SR ®6 , NHOR a5 , C(0)R b6 , C(0)NR c6 R d6 , C(G)NR c6 (OR a6 ). C(0)OR af> , OC(0)R b6 ,
  • heterocycloalkyl, Ce-ir aiyl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl- of R l are each optionally substituted with 1 , 2, 3, or 4 independently selected R J substituents;
  • each R a5 , R c6 , and R d6 is independently selected from H, C i-s alkyl, C i-s haloalkyl, C 2-6 alkenyl, C 2 -s alkynyl, C&-14 aryl, C 3 ..
  • R 06 and R dR attached to the same N atom, together with the N atom to winch they are attached, form a 5- or 6-membered heteroary l or a 4-14 membered heterocycloalkyl group, wiierein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R b6 is independently selected from H, Cj- 6 alkyl, Cj- 6 haloalkyl, C 2 -s alkenyl, C 2 -6 alkynyl, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered
  • heterocycloalkyl Ce-w ary I-C1-& alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wiierein the Cj-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Cs-w aryi-Cj- 6 alkyl-, CVw cycloalkyl-C i-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1 ⁇ 2 alkyl- of R b6 are each optionally substituted with 1 , 2, 3, or 4 independently selected R:' substituent
  • each R ®6 is independently selected from H, OH, CN, Ci-e alkyl, Cue lkoxy, Ci-e haloalkyl, Ci-ghaloalkoxy, C2-6 alkenyl, C 2 « alkynyl, Ce-n aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce-u axyl-Ci-e alkyl-, C3-14 cycloalkyl- Ci- d alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alky 1-;
  • each R ® and R s ° is independently selected from H, Ci-e alkyl, Ci-e alkoxy, Ci-e haloalkyl, Cwehaloalkoxy, C2-6 alkenyl, C 2-f, alkynyl, Ce-w aryl, C3-W cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce- 14 aryl-Cj- 6 alkyl-, Cs-w cycloalkyi- Ci-, (5-14 membered heteroaryi) -Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-Ci. & alkyi-;
  • each R h6 and R 16 is independently selected from H, Cj-e alkyl, Cj-e haloalkyl, C 2 _6 alkenyl, C 2 -e alkynyl, C &-J 4 aryl, C3-14 cycloalkyl, 5-14 membered heteroary i, 4-14 membered heterocycloalkyl, Ce-w ary l-Ci ⁇ alkyl-, Cs-i+ cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-;
  • each R j6 and R k6 is independently selected from OH, C -s alkoxy, and C i-ehaloalkoxy; or, any R j6 and R k6 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C -e alkyl and Ci- 6 haloalkyl; each R: 1 is independently selected from D, halo, oxo, C - 6 alkyl, C - 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce- aryl-C 1.5 alkyl-, C3-1 cycloalky I-C1-6 alkyl-, (5-14 membered heteroaryl)-C
  • heterocycloalkyl Ce-w ary 1-C 1-6 alkyl-, C -ir cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl- of R J are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R a/ , R c ', and R d ' is independently selected from H, Ci- 6 alkyl, Ci-e haloalkyl, C2-6 alkenyl, €2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-ir aryl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroatyl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- wherein the Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-i4 aryl, Ci- H cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u ary l-Ci-e
  • each R b? is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ci.-n aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4- 14 membered heterocycloalkyl, Ce-u ary l-Ci-6 alkyl-, C -i + cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] ⁇ alkyl-, and (4-14 membered heterocycloa3kyl)-Ci- 6 alkyl-, wherein the Cj-6 alkyl, C ?
  • R fc7 are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R c/ is independently selected from H, OH, CN, C3-6 alkyl, C2-6 alkenyl, C3-6 alkoxy, Ci ⁇ haloalkyi, Ci-ehaloalkoxy, C 2-6 aikynyl, C 6 -i 4 aryl, C3-34 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl;
  • each R 17 and R s? is independently selected from H, Ci- 6 alkyl, Cs- 6 alkoxy, C M> haloalkyl, Ci-ehaloalkoxy, C2-6 alkenyl, C2-6 aikynyl, Ce- aryl, C 3-i 4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C M 4 aiyl-Ci-e alkyl-, C 3-34 cycloalkyl- Ci- 6 alkyl-, (5-14 membered heteroaiyll-Ci-g alkyl-, and (4-14 membered heterocycloalkyl)-C ].
  • each R h/ and R 1 ' is independently selected from H, Ci-s alkyl, Ci-b haloalkyl, C2-6 alkenyl, C2-6 aikynyl, C &.24 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ar I-C1-& alkyl-, C3- 14 cycloalkyl-Cr-e alkyl-, (5-14 membered
  • heteroaryl C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R J / and R*' is independently selected from OH, C 3-6 alkoxy, and Ci-ehaloalkoxy ; or, any R J ' and R k/ attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C -6 alkyl and C - 6 haloalkyl;
  • each R K is independently selected from H, D, OH, halo, oxo, CN, C(0)0H, NH 2 ,
  • any heteroaryl group of any of the above-recited substituents optionally comprises an N-oxide on any ring-forming nitrogen.
  • X is CR :
  • Ci -6 aikyi, C‘ alkenyl, C2-6 alkynyl, C&- K axyl, C B-M cycloalkyl, 5-14 mem bered heteroaryl, 4-14 membered heterocycloalkyl, CS- M ar l-Cw alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 aikyl-, and (4-14 membered heterocycloalkyl)-C ]-6 aikyi- of R 1 are each optionally substituted with i, 2, 3, 4, 5, 6, 7, or 8 independently selected R d substituents;
  • R 2 is selected from H, D, halo, C - 6 alkyl, C - 6 haloalkyl, C 2-6 alkenyl, C2-6 alkynyl, C i4 aryl, Cs- cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C S-M aryl-Ci4s alkyl-, Cs-u cycloalky l-Ci- 6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, (4-14 membered heterocycloalkyl)-C ! -e alkyl-, CN, N ⁇ 3 ⁇ 4, OR 82 , SR 32 , NHOR 32 , C(0)R b2 ,
  • NR c2 S(0)R b2 N R S;()i R K' .
  • heterocycloalkyl Ce-w ary i-C 1-6 alkyl-, Ca-i + cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-C 1.6 alkyl- of R ⁇ are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R substituents;
  • R ;i is selected from H, D, halo, Ci. & alkyl, Ci. & haloalkyl, C 2.. e alkenyl, C2-6 alkynyl, Ce- i4 aryl, C 3-34 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C M * aryl-C - 6 alkyl-, Cs- H cycloaikyl-C 1-6 alkyl-, (5-14 membered heteroaryi) ⁇ Ci- 6 alkyl-, (4-14 membered heterocycloalky l)-Ci- 5 alkyl-, CN, NO ... OR a3 , SR fr M )OR :: . C(0)R b3 ,
  • heterocycloalkyl Ce-u aryl-C i-b alkyl-, C3-i 4 cycloalkyl-C - 6 alkyl-, (5-14 membered heteroaryi)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyi) ⁇ C 1-6 alkyl- of R J are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 17 substituents;
  • Cy ! is Ce-w aiyl, Ca-u cycloalkyl, 5-14 membered heteroaryi, or 4-14 membered heterocycloalkyl, wherein the C 5-14 aryl, C3-! 4 cycloalkyl, 5- 14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1 2, 3, 4, 5, 6 7, or 8 independently selected R substituents;
  • Cy 1 is not pyridin-4-yl optionally substituted with 1, 2, 3, or 4 independently selected R' substituents;
  • Cy ! is not pyrimidm-4-yl optionally substituted with 1, 2, or 3, independently selected R K substituents;
  • Cy 1 is not quinolin-4-yl optionally substituted with 1, 2, 3, 4, 5, or 6 independently selected R E substituents;
  • Cy 2 is C b -14 aryl, C -w cycloalkyl, 5-14 membered heteroaryi, or 4-14 membered heterocycloalkyl, wherein the C 5-14 aryl, C3- M cycloalkyl, 5- 14 membered heteroaryi, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R " substituents;
  • each R 31 , R ci , R d! , R 82 , R c2 , R d2 , R 33 , R 03 , and R ® is independently selected from H, Gi ⁇ ft alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryl, C3-i 4 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce-w ary l-C -6 alkyl-, C 3-14 cycloalky I-C 1-6 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkylj-Ci-e alkyl-, wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Gs- 14 aryl, C 3-14 cycloalkyl, 5-14 membered
  • R cl , R ® , R 3 , R c2 , R d2 , R 83 , R", and R d ’ are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R° substituents;
  • R c2 and R d2 attached to the same N atom, together with the N atom to winch they are attached, form a 5- or 6-membered heteroaryi or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryi or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R° substituents;
  • R c3 and R d3 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryi or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroary l or 4-14 membered heterocycloalkyl group is optionally substituted with 1 , 2, 3, or 4 independently selected R° substituents;
  • each R bl , R b2 , and R b3 is independently selected from H, C alkyl, C M haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&-14 aryl, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C M alkyl-, Ci- H cycloalkyl-C M alkyl-, (5-14 membered heteroaryi)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyi) ⁇ C 1-6 alkyl-, wherein the C alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci.-u aryd, C3-14 cycloalky 1, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cs-ir aryl-Ci-e alkyl-, Ch- M cyc
  • each R el , R e2 , and R e is independently selected from H, OH, CN, C1-6 alkyl.
  • each R g , R g , R fi , and R g3 is independently selected from H, CM alkyl.
  • each R llZ , R l2 , R 03 , and R 1 is independently selected from H, C M alkyl.
  • each R ⁇ ' 3 , R k2 , R jJ , and R k is independently selected front OH, C M alkoxy, and C M haloalkoxy;
  • R j2 and R K attached to the same B atom, together wdth the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted wdth 1, 2, 3, or 4 substituents independently selected from C M alkyl and C M haloalkyl;
  • each R b , R c , R d , R b , R f , and R° is independently selected from D, halo, oxo, Ci-e alkyl, Ci- & haloalkyl, C 2-6 alkenyl, C2-6 alkysiyl, C H aryl, C3- H cyeloalkyl, 5-14 membered heteroatyl, 4-14 membered heteroeyeloaikyl, Ce-w aiyl-Ci-6 alkyl-, C3- H cycloalkyl-Ci-e alkyl-, (5-14 membered hetero
  • heteroeyeloaikyl CM* aiy r l-C i-b alkyl-, C3-14 cycloalkyl-Cj-e alkyl-, (5- 14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl) ⁇ C 1-6 alkyl- of R B , R c , R D , R ⁇
  • R ⁇ and R° are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R H substituents;
  • each R a4 , R c+ , and R d4 is independently selected from H, Ci- & alkyl, Ci- & haloalkyl, C 2.. e alkenyl, C 2-6 alkynyl, Ci.-u aryl, C -u cyeloalkyl, 5-14 membered heteroaryl, 4-14 membered heteroeyeloaikyl, Ce-w ary 1-C 1-6 alkyl-, C 3-i 4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl-, wherein the Ci.
  • each R b4 is independently selected from H, Cue alkyl. Cue haloalkyl, C 2-6 alkenyl, C 2-& alkynyl, C&-14 aryl, €3-14 cyeloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • each R f4 and R 8 * is independently selected from H, Cm, alkyl, Cwalkoxy, Ci- 6 haloalkyl, Cwhaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C K aryl, C 3-i 4 cycloalkyl, 5-14 membered heteroary l, 4-14 membered heterocycloalkyl, C M 4 ary' i-C 1-6 alkyl-, C 3-i 4 cycloalky 1- C - 6 alkyl-, (5-14 membered heteroaryli-Ci- f , alkyl-, and (4-14 membered heterocycloaikyli-Ci- 6 alkyl-;
  • each R h4 and R l4 is independently selected from H, Ci. & alkyl, Ci. & haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, Cj-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce- aryl-C 1.5 alkyl-, Cs-u cycloa kyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
  • each R j4 and R“ 4 is independently selected from OH, Cwalkoxy, and Cwhaloalkoxy; or, any R
  • each R H is independently selected from D, halo, oxo, Cw alkyl, Cw haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryl, C 3- u cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary l-Cw alkyl-, C 3-14 cycloalkyl-Cw alkyl-, (5-14 membered heteroaryl)-Cw alkyl-, (4-14 membered heterocy oalky -Cw alkyl-, CN, NO2, OR 35 , SR a5 , NHOR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)NR c5 (0R a5 ), C(0)0R 35 , 0C(0)R bs , 0C(0)NR c5 R d5 .
  • heterocycloalkyl, Ce-ir aiyl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-C]-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- of R fl are each optionally substituted with 1 , 2, 3, or 4 independently selected R* substituents;
  • each R a5 , R c5 , and R d5 is independently selected from H, C i-s alkyl, Ci-s haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&-14 aryl, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryd-C i-e alkyl-, C3-i4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the Ci-s alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci.-u aryl, C J-M cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-
  • R 05 and R da attached to the same N atom, together with the N atom to winch they are attached, form a 5- or 6-membered heteroary l or a 4-14 membered heterocycloalkyl group, wirerein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R ! substituents;
  • each R to is independently selected from H, Cj- 6 alkyl, Cj- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl C w ary I-C1- & alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wirerein the Cj-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cs-w aryl-Ci-e alkyl-, CVw cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1 ⁇ 2 alkyl- of R b5 are each optionally substituted with 1 , 2, 3, or 4 independently selected R 1 substituent
  • each R e5 is independently selected from H, OH, CN, Ci-e alkyl, Ci-e alkoxy, Ci-e haloalkyl, Ci-ehaioalkoxy, C2-6 alkenyl, €2-5 alkynyl, C G-M aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u axyl-Ci-e alkyl-, Cj-w cycloalkyl- Ci- d alkyl-, (5-14 membered heteroaryi)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alky 1-;
  • each R f5 and R 85 is independently selected from H, Ci-e alkyl Ci-ealkoxy, Ci-e haloalkyl, Ci-ehaloalkoxy, C2-6 alkeny l, Ci-t, alkynyl, Ce-w aiyl, C3- W cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ob- aryl-Cj- 6 alkyl-, Cs-w cycloalkyi- Ci-, (5-14 membered heteroaryl) -Ci- 6 alkyl-, and (4-14 membered heterocycloaikyl)-Ci- & alkyi-;
  • each R 115 and R 15 is independently selected from H, Cj-e alkyl, Cj-b haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, C &-J 4 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary i-Ci-6 alkyl-, C -i + cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] ⁇ alkyl-, and (4-14 membered heterocycloa3kyl)-Ci-6 alkyl-;
  • each R Ji and R ’ ° is independently selected from OH, C -salkoxy, and Ci-ehaloalkoxy; or, any R jd and R k5 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci-e alky l and Ci- 6 haloalkyl;
  • each R l is independently selected from D, halo, oxo, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 a!kynyl, Ce-u aryl, Caur cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce- aryl-C 1-5 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered
  • heteroaryl C 1-6 alkyl-, and (4-14 membered heteroeyeloalkyi)-Ci-s alkyl-, CN, N0 2 , OK a5 , SR 36 , NHOR a6 , C(0)R b6 , C(0)NR c6 R d6 , C(0)NR c6 (0R a6 ), C(0)OR a6 , OC(0)R b6 ,
  • heteroaryi)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky i)-C 1.6 alkyl- of R 1 are each optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R a6 , R cf> , and R d6 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2.6 alkenyl, C 2-& alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-ir aryl-Ci-6 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered
  • each R b6 is independently selected from H, Ci- 6 alkyl, Cue haloalkyl, C 2-6 alkenyl, C2-6 alkynyl, C &-J 4 aryl, C B-M cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, 65- 14 ary 1-6 i-e alkyl-, C -i + cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] ⁇ alkyl-, and (4-14 membered heterocycloa3kyl)-Ci- 6 alkyl-, wherein the C - 6 aikyi, alkenyl, C 2-6 alkyny!, 5-14 aryl, € 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, 65- 14 ar l-Cw alkyl-, C 3-14 cycloalkyl
  • each R e6 is independently selected from H, OH, CN, Ci-e alkyl, Ci-e alkoxy, Ci- & haloalkyl, Ci-ehaioalkoxy', 6 2-5 alkenyl, C 2-6 alkynyl, 6 5-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, 6 5-14 aryl-6 1-5 aikyi-, C 3-14 cycloalky 1- 6 1 -5 alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-C ] - 6 alkyl-;
  • each R f6 and R g6 is independently selected from H, Ci-e alkyl, Ci-e alkoxy, Ci- & haloalkyl, C -ehaloalkoxy, C 2-6 alkenyl, 6 2-5 alkynyl, 6 5-14 aryi, 6 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, 6 5-14 ary l-Ci- 6 alkyl-, C 3..14 cycloalky 1- C i-6 alkyl-, (5-14 membered heteroaryl)-6i-s alkyl-, and (4-14 membered heterocycloalkyl)-C i- 6 alkyl-;
  • each R h6 and R l6 is independently selected from H, C - 6 alkyl, 6 1-5 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, 6 5-14 aryl, 6 3 -1 4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, 5- 1 aryl-6 1.5 alkyl-, C 3-14 cycloalky l-Ci-6 alkyl-, (5-14 membered heteroarvd)-C 1-6 alkyl-, and (4-14 membered heteroeyeloalkyl)-Ci-s alkyl-;
  • each R Jf> and R* 6 is independently selected from OH, Ci-ealkoxy, and Ci-ehaloalkoxy; or, any R j6 and R kb attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalky 1 group optionally substituted with 1, 2, 3, or 4 substituents independently selected from 61- 5 alkyl and Ci- 6 haloalky l;
  • each R J is independently selected from D, halo, oxo, Ci- 6 alkyl, 6 1-5 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, 6 5.14 aryd, 6 3-1 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, 5-14 ar l-Cw alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered
  • heterocycloalkyl C M * aiyl-Ci-e alkyl-, C3-14 cycloalkyl-Cj-e alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heteroeycloalkyl)-Ci-s alkyl- of R J are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R a7 , R c7 , and R d is independently selected from H, Cj- 6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, Ce-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C M * ar I-C1-& alkyl-, C3-14 cycloalkyl-Cw alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl- wherein the C1-6 alkyl, C 2-& alkenyl, C 2 « alkynyl, Ce-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C w ary l-Ch-s alkyl-, C 3-i 4 cycl
  • R substituents are each optionally substituted with 1, 2, 3, or 4 independently selected R substituents; or any R c/ and R d7 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R b7 is independently selected from H, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, Ce- aryd, C 3-i 4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce- aryl-C 1.5 alkyl-, C3-14 cycloalky l-Ci-6 alkyl-, (5-14 membered heteroaryd)-C 1-6 alkyl-, and (4-14 membered heterocycloalkylVC i-s alkyl-, wherein the Ci-s alkyl, C 2 - s alkenyl, C 2 -s alkynyl, C&-14 aryd, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cg-w aryl-Ci-e alkyl-, C 3 -u cycloalk l-Ci-d alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl- of R 0/ are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R s ' is independently selected from H, OH, CN, Ci-e alkyl, C2-6 alkenyl, C 1-6 alkoxy, Ci. & haloalkyl, Cj-shaloalkoxy, C 2 -e alkynyl, Ce-ir aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl;
  • each R f? and R g/ is independently selected from H, Ci-e alkyl, Cue alkoxy, Ci-e haloalkyl, C;i- f! haloalkoxy, C 2-6 alkeny l, C 2-& alkynyl, Ce-w aiyl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, €b- aryl-Cj- 6 alkyl-, Cs-w cycloalkji- Ci- 6 alkyl-, (5-14 membered heteroaryl) -C1-6 alkyl-, and (4-14 membered heterocycloalky 1)-Ci. & alkyd-;
  • each R h? and R 1 ' is independently selected from H, Ci-g alkyl, Cj ⁇ haloalkyl, C 2-6 alkenyl, C 2 -e alkynyl, C &-J 4 aryd, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • J2 heterocycloalkyl Ce-w ary 1-C 1-6 alkyl-, Cj-i + cycloalkyl-Cj-e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalky 1)-Cw alkyl-;
  • each R j7 and R k ' is independently selected from OH, Cj-salkoxy, and Ci-shaloalkoxy; or, any R j ' and R k/ attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci-e alkyl and Ci-e haloalkyl;
  • each R is independently selected from H, D, OH, halo, oxo, CN, C(0)0H, NH 2 , NO2, SFs, Cj- 6 alkyl, Cj-e alkoxy, Ci-ehaloalkoxy, Cj-e haloalkyl, C2-6 alkenyl, C 2 -e alkynyl, Ce ⁇ l aryl, C B-M cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalky 1, Ce-u aryl-Ci- 6 alkyl-, CVw cyctoalkyl-Ci-e alkyl-, (5-14 membered heteroaryi)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-; and
  • any heteroaryl group of any of the above-recited substituents optionally comprises an N-oxide on any ring-forming nitrogen.
  • X is CR 3 ;
  • R ! is selected from H, Ci-b alkyl, C2-6 alkenyl, C2-6 alkynyl, and Ci-b haloalkyl;
  • R 2 is selected from H, D, halo, Cj- 6 alkyl, Cj- 6 haloalkyl, C2.-6 alkenyl, C2-6 alkynyl, CV i4 aryl, Cs-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CX- M aryl-Ci- 6 alkyl-, Cs-u cycloalky l-Ci- 6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, (4-14 membered heterocycloalkyl)-C !-e alkyl-, CN, N ⁇ 3 ⁇ 4, OR 82 , SR 32 , NHOR 32 , C(0)R b2 ,
  • NR c2 S(0)R b2 N R S;()i R K' .
  • heterocycloalkyl Ce-w aryl-Ci-6 alkyl-, Cj-i + cycloalkyl-Cj-e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalky 1)-Cw alkyl- of R ⁇ are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R substituents;
  • R 3 is selected from H, D, halo, Ci. & alkyl, Ci. & haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- i 4 aiyl, €3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CV14 aryl-Ci- 6 alkyl-, C S-H cycloalky l-C 1-6 alkyl-, (5-14 membered heteroaryl) ⁇ Ci- 6 alkyl-, (4-14 membered heterocy cloalkyl)-C 1-6 alkyl-, CN, N0 2, OR a3 , SR a3 , NHOR a3 , C(0)R b3 ,
  • Ci-e alkyl C 2-6 alkenyl, C 2-6 alkynyl, Ci.-n aryl, C B-U cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce-w ary l-Ci- 6 alkyl-, C -i + cycloalkyl-C -e alkyl-, (5-14 membered heteroaryi)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky i)-Ci- 6 alkyl- of R 3 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 13 substituents;
  • Cy ! is Ce-w aryl, C -u cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the C 5-14 aryl, C 3-! 4 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R or R M substituents;
  • Cy 2 is Ce-w aryl, C B-M cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the Ce-w aryl, C 3 -i 4 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R r substituents;
  • each R 3i , R c ⁇ R d2 , R aJ , R c3 , and R d3 is independently selected from H, C . 6 alkyl, C . 6 haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, Cs-n aryl, Cs-wcycloalkyl, 5-14 membered heteroaryl, 4- 14 membered heterocycloalkyl, C ⁇ 5 -i 4 ary l-Ci-6 alkyl-, C 3-14 cycloalky 1-Cw alkyl-, (5-14 membered he ternary l)-Ci- & alkyl-, and (4-14 membered heterocycloalkyl)-Cw alkyl-, wherein the C - 6 alkyl, C 2 -g alkenyl, C 2-6 alkynyl, Ce-u aryl, C 3 -i 4 cycloalkyl, 5-14 membered heteroaryl
  • R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroary l or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R° substituents;
  • R c3 and R d3 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroary l or 4-14 membered heterocycloalkyl group is optionally substituted with 1 , 2, 3, or 4 independently selected R° substituents;
  • each R fc2 and R b3 is independently selected from H, Ci-e alkyl, Ci-e haloalkyl, C 2-6 alkenyl, C2-6 alkynyl, C&-14 aryl, C3..14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce-u aryl-C i-e alkyl-, C3-i 4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryi)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyi) ⁇ C 1-6 alkyl-, wherein the Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, Ci.-u aryd, C3-14 cycloalky 1, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-e alkyl-, Cs-u
  • each R f2 , R g3 , R f3 , and R g3 is independently selected from H, Ci-b alkyl, Ci-e alkoxy, Ci- f .haloalkyl, Cj-ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C &-J 4 aryl, Cs-u cycloalkyl, 5-14 membered heteroary l, 4-14 membered heterocycloalkyl, C M 4 ary l-Ci- 6 alkyl-, C3-14 cycloalky 1- Ci- d alkyl-, (5-14 membered heteroaiyi)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R h2 , R 12 , R“ 3 , and R l3 is independently selected from H, Ci. & alkyl, Ci-ehaloalkyl, C2-6 alkenyl, C2-6 alkynyl, C &-J 4 aryd, C3-14 cycloalkyl, 5-14 membered heteroary l, 4-14 membered heterocycloalkyl, Ce-u aryl-Cj-e alkyl-, C3-14 cycloalky 1-Cw alkyl-, (5-14 membered heteroaryl)-Ci.6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-;
  • each R j2 , R k2 , R , and R K3 is independently selected from OH, Ci-e alkoxy, and Ci- 6 haloalkoxy;
  • R j3 and R ⁇ 3 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1 , 2, 3, or 4 substituents independently selected from C -.-e alkyd and Ci-shaloalkyl;
  • each R c , R D , R b , R M , R f' , and R° is independently selected from D, halo, oxo, C1-6 alkyl, Ci-e haloalkyl, C3-6 alkenyl, C2-6 alkynyl, C M * aryl, C3-14 cycloalky 1, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C &.J4 ary l-Ci-6 alkyl-, Cs-ir cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl) -Ci .. 6 alkyl-, (4-14 membered heterocycloalkyl)-Ci ⁇ , alkyl-, CN,
  • R c , R D , R”, R M , R r , and R° are each optionally substituted with 1 , 2, 3, 4, 5, 6, 7, or 8 independently selected R ri substituents;
  • each R a4 , R c4 , and R d4 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2.6 alkenyl, C 2-6 alkynyl, Ce-u aryl, Cj-w cycloalkyl 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C 1.5 alkyl-, C3-14 cycloalky l-Ci-6 alkyl-, (5-14 membered heteroaryd)-Ci-6 alky!-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the Ci-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ce-u aiyi, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci- 6 alkyl-, C3-14
  • each R w is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C 2 -6 alkenyl, C2-6 alkynyl, Ce-u aryl, C3- W cycloalkyl, 5-14 membered heteroaryl 4-14 membered
  • heterocycloalkyl C 6 -i4 aryl-C - 6 alkyl-, Cs-w cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, -wherein the Ci- 6 alkyl, C 2-& alkenyl, C 2-& alkynyl, C u aryl, Ci-u cycloalkyl, 5-14 membered heteroaryl 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-e alkyl-, Cs-u cycloalky l-Ci-6 alkyl-, (5-14 membered heteroaryl)-C]-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl- of R b4 are each optionally substituted with 1 , 2, 3, 4, 5, 6, 7, or 8 independently selected R
  • each R f4 and R g4 is independently selected from H, Ci-e alkyl Ci-e alkoxy, Ci-e haloalkyl, Ci-ehaloalkoxy, C2-6 alkenyl, C 2-6 alkynyl, Cl-ir aiyl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i4 aryl-Cj- 6 alkyl-, Cs-sr cyeloalkyi- C 1-6 alkyl-, (5-14 membered heteroaiy l)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R h4 and R l4 is independently selected from H, Cj-e alkyl, Cs-g haloalkyl, C2-6 alkenyl, Cz-s alkynyl, C&-14 aryl, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C i-e alkyl-, Cl- H cyeloalkyl-Cs-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-C 1.6 alkyl-;
  • each R J4 and R“ 4 is independently selected from OH, Cj-ealkoxy, and Ci-ehaloalkoxy; or, any R j4 and R k+ attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalky 1 group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Cs- 6 alkyl and Cs- 6 haloalkyl;
  • each R H is independently selected from D, halo, oxo, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, €2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-ir aryl-Ci-g alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaiyl)-Ci-6 alkyl-, (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, CN, NO2, OR 85 , SR 3' , NHOR 35 .
  • heterocycloalkyl Ce-u aryl-C i-e alkyl-, €3-14 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl- of R 1 ! are each optionally substituted with 1, 2, 3, or 4 independently selected R !
  • each R a ⁇ R c5 , and R d> is independently selected from H, Ci-e alkyl, Ci-e haloalkyi, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce-i4 aryt-C -6 alkyl-, Cs- M cyeloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.
  • R 3> R c5 , and R d5 are each optionally substituted with 1, 2, 3, or 4 independently selected R 1 substituents;
  • R cS and R d5 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryi or 4-14 membered heterocycloalkyl group is optionally substituted with 1 , 2, 3, or 4 independently selected R 1 substituents;
  • each R b5 is independently selected from H, Ci-e alkyl, Cue haloalkyi, C2-6 alkenyl, C2-6 alkynyl, C&-14 aryl, C3-14 cycloalky 1, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce-u aryl-Ci-e alkyl-, C 3 -i 4 eyeloalkyl-C - 6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-C 1.6 alkyl-, wherein the Ci.
  • each R s5 is independently selected from H, OH, CN, C.-s alkyl, C.-s alkoxy, Ci- 6 haloalkyi, Ci-ehaloalkoxy, C2-6 alkeny l, C2-6 alkynyl, Ce-w aiyl, C3- H cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-ir aiyl-Ci- 6 alkyl-, C3-14 cycloalkyl- Ci- 6 alkyl-, (5-14 membered heteroaryl) -C1-6 alkyl-, and (4-14 membered heterocycloalky 1)-Ci. & alkyd-;
  • each R b and R g5 is independently selected from H, Cm, alkyl, Ci «alkoxy, Ci-e haloalkyi, C -ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ci.-n aryl, C3-14 cycloalky 1, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, C M 4 ary l-Ci- 6 alkyl-, C3-14 cycloalky 1- C [- 6 alkyl-, (5-14 membered heteroaryi) -Ci-g alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R tD and R 15 is independently selected from H, Ci. & alkyl, Ci. & haloalkyi, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, €3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce-i aiyi-Ci-6 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C ue alkyl-; each R Jd and R k5 is independently selected from OH, Ci-e alkoxy, and Cj-ehaloalkoxy; or, any R' 5 and R to attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-mem bered heterocycloalkyl group optionally substituted with 1, 2, 3,
  • heterocycloalkyl Ce- aryl-C 1 -5 alkyl-, C3-14 cycloalky l-Ci-6 alkyl-, (5-14 membered heteroarvd)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C [- 6 alkyl- of R 1 are each optionally substituted with 1 , 2, 3, or 4 independently selected R J substituents;
  • each R a6 , R c6 , and R d5 is independently selected from H, Ci- & alkyl, Ci- & haloalkyl, C 2.. e alkenyl, C 2- e alkynyl, C&-14 aryl, €3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i4 ar l-Ci-6 alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] ⁇ alkyl-, and (4-14 membered heterocycloalky 1)-Cw alkyl-, wherein the Cj- 6 alkyl, C 2-& alkenyl, C 2-6 alkynyl, Ce-u aryl, C3-14 cycloalky l, 5-14 membered heteroaryd, 4-14 membered heterocycloalkyl, CS- M ary l-Ci
  • each R b6 is independently selected from H, Cj- 6 alkyl, Cj- 6 haloalk l, C 2.& alken l, C 2-& alkynyl, Ca-u aryl, C 3-i4 cycloalkyl, 5-14 membered heteroaryd, 4-14 membered
  • heterocycloalkyl Ce-i aryd-Ci-e alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C i-6 alkyl-, wherein the Ci-g alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ce-u arvd, C 3-i 4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CM* aryl-Ci-e alkyl-, C3- M cycloalky 1-Ci-e alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heteroeycloalkyl)-C i-s alkyl- of R Db are each optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R ab is independently selected from H, OH, CN, Cj- 6 alkyl, Ci-e alkoxy, C M haloalkyl, Cj-ehaloalkoxy, C2-6 alkenyl, C 2-6 alkynyl, Ce-u aryl, 63-14 cycloalkyl, 5-14 membered heteroaiyl, 4-14 membered heterocycloalkyl, C&-14 ary l-Ci-6 alkyl-, C3-14 cycloalkyl- C 1-6 alkyl-, (5-14 membered heteroaiy l)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R fb and R g5 is independently selected from H, Ci- 6 alkyl, Cj-e alkoxy, C i- 6 haloalkyl, Ci-ehaioalkoxy, C 2 -s alkenyl, C 2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, aryl-C w, alkyl-, C3-14 cycloalkyl- Ci- 6 alkyl-, (5-14 membered heteroaiyll-Ci-g alkyl-, and (4-14 membered heterocycloalkyll-C]- s alkyl-;
  • each R hb and R lb is independently selected from H, C ue alkyl, C i-b haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, €5-14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C w ary l-Cw alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaiy l)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-;
  • each R Jb and R*° is independently selected from OH, Ci ⁇ alkoxy, and Ci-ehaloalkoxy ; or, any R Jb and R kb attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C i-e alkyl and Chr, haloalkyl;
  • each R J is independently selected from D, halo, oxo, Che alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C2-6 alkynyl, C&-14 aryl, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C i-e alkyl-, C3-i 4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl-, CN, NO2, OR a? ,
  • NR c7 S(0)NR c7 R d7 , NR c7 S(0) 2 R b7 , NR c7 S(0)( NR e7 )R b7 , NR c7 S(0) 2 NR c7 R d7 , S(0)R b7 , S(0)NR c7 R d7 , ScOi -R 1' . S(0) 2 NR c7 R d7 .
  • heterocycloalkyl C w ary l-Cw alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- of R J are each optionally substituted with 1 , 2, 3, or 4 independently selected R substituents;
  • each R a/ , R c ', and R d7 is independently selected from H, C i-s alkyl, Ci-s haloalkyl, C 2-6 alkenyl, C 2 -s alkynyl, C&-14 aryl, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryd-C i-e alkyl-, C3-i4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl- wherein the Ci-e alkyl, C 2-6 alkenyl, C 2-f, alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Cj-
  • each R b/ is independently selected from H, Ci- 6 alkyl, Cj- 6 haloalkyl, C 2 -s alkenyl, C 2 -6 alkynyl, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce-w ary I-C1- & alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wherein the Cj-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cs-w aryl-Ci-e alkyl-, CVw cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1 ⁇ 2 alkyl- of R b? are each optionally substituted with 1 , 2, 3, or 4 independently selected R substituents;
  • each R e ' is independently selected from H, OH, CN, Ci-e alkyl, C2-6 alkenyl, C 5 -6 alkoxy, Ci-b haloalkyl, Cwhaloalkoxy, C2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl;
  • each R f/ and R g? is independently selected from H, C .-s alkyl, Ci « alkoxy, Ci-e haloalkyl, Ci-ehaloalkoxy, C2-6 alkenyl, C 2- e alkynyl, C&-J4 aryl, cycloalkyl, 5-14 membered heteroary l, 4-14 membered heterocycloalkyl, Ce-u ary l-Ci- 6 alkyl-, C3-14 cycloalky 1- C [- 6 alkyl-, (5-14 membered he teroarydi-Ci- f , alkyl-, and (4-14 membered heteroeycioalkyli-Ci- 6 alkyl-;
  • each R h/ and R 1 ' is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C 2 .6 alkenyl, C alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i aiyl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryd)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C i- 6 alkyl-; each R J ' and R K/ is independently selected from OH, Ci-ealkoxy, and C -ehaloalkoxy; or, any R J / and R k ' attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-mem bered heterocycloalkyl group optionally substituted
  • each R K is independently selected from H, D, OH, halo, oxo, CN, C(0)QH, NH 2 ,
  • any heteroaryl group of any of the above-recited substituents optionally comprises an N -oxide on any ring-forming nitrogen.
  • X is N
  • R 2 is selected from H, D, halo, C -6 alkyl, C -6 haloalky l, C 2 - 6 alkenyl, C 2 -e alkynyl, Ce- 14 aryl, C3-14 cycloalky l, 5-14 membered heteroaryl, 4-14 membered heierocycloalkyl, €5-1 aryd-C -6 alkyl-, Cn-i Cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, (4-14 membered heterocycloalkyl)-Cw alkyl-, CN, N0 2 , OR a3 , SR a2 , NHGR ai , C(0)R b2 ,
  • heterocycloalkyl C w aryl-Ci-6 alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- of R 3 are each optionally substituted with 1 , 2, 3, 4, 5, 6, 7, or 8 independently selected R c substituents;
  • Cy ! is C&-14 aryl, €3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the Ce-u aryl, C3 -14 cycloalky 1, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R & substituents;
  • Cy z is Ce-14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the aryl, C3-14 cycloalky 1, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R" substituents;
  • each R al , R ci , R dl , R a2 , R° 2 , and R d2 is independently selected from H, C -e alkyl, Cue haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3.14 cycloalkyl, 5-14 membered heteroaryl, 4- 14 membered heterocycloalkyl, C K aryl -Ci-s alkyl-, C;-i4eyeloalkyi-C 1-6 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci..6 alkyl-, wherein the C -6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aiyl, C3- M cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloal
  • R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroary l or 4-14 membered heterocycloalkyl group is optionally substituted with 1 , 2, 3, or 4 independently selected R° substituents;
  • each R bl and R b2 is independently selected from H, Ci-s alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&-14 aryl, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C i-b alkyl-, C3-i4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1) ⁇ C R> alkyl-, wherein the C M alkyl, C2-6 alkenyl, C2-6 alkynyl, C &-J 4 aryl, C J-M cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C -e alkyl-, Ci-u
  • each R Bl and R e2 is independently selected from H, OH, CN, C i-s aikyl, C i-s alkoxy, Ci- 6 haloalkyl, C -e haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryi, Cs-u cycloalkyi, 5-14 membered heteroaryl, 4-14 membered heierocycloalkyl, CM* ary l-Ci-6 alkyl-, C3-14 cycloalkyl- C 1.6 alkyl-, (5-14 membered heteroaryi) ⁇ Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each G and R g2 is independently selected from H, Ci- 6 alkyl, C -e alkoxy, C M> haloalkyl, Ci-ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce- aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C i-e alkyl-, C3-14 cycloallcyl- Ci- 6 alkyl-, (5-14 membered heteroaiyll-Ci-g alkyl-, and (4-14 membered heterocycloalkyl)-C ] - s alkyl-;
  • each R M and R l2 is independently selected from H, C i-s alkyl C i-b haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C M ary I-C1-& alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-;
  • each R j2 and R*“ is independently selected from OH, Ci-ealkoxy, and Ci-ehaloalkoxy ; or any R j2 and R K attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C i- 6 alkyl and C - 6 haloalkyl;
  • each R b , R c , R , R b , and R G is independently selected from D, halo, oxo, Ci- 6 alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C 2- e alkynyl, aryl, C3.14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-14 aryl-C i-s alky!-, Ci-w cyeloalkyl-C 1.5 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, CN, NO ?.
  • heterocycloalkyl CVM aryl-Ci ⁇ , alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- of R b , R c , R b , R 1' , and R' J are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R h substituents;
  • each R a4 , R c4 , and R d4 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryl, Cj-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-ir aiyl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C i-e alkyl-, wherein the Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-i + aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cs-w aryl-C -
  • each R w is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce-i4 ar t-C -6 alkyl-, Cs-w cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, wherein the Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C -6 alkyl-, Cs-u cycloalky l-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.
  • each R e4 is independently selected from H, OH, CN, Ci-e alkyl, Ci-e alkoxy , Ci- 6 haloalkyl, C -ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C &-J 4 aryl, Cs-u cycloalky 1, 5-14 membered heteroary l, 4-14 membered heterocycloalkyl, Ce-u ary l-Ci- 6 alkyl-, C3-14 cycloalky 1- C [-6 alkyl-, (5-14 membered he teroarydi-Ci- f , alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-
  • each R f4 and R 84 is independently selected from H, Ci- 6 alkyl, Ci- 6 alkoxy, Ci ⁇ haloalkyl, Ci-ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, Ch-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-ir aiyd-Ci- 6 alkyl-, Cs-u cycloalkyi- C 1-6 alkyl-, (5-14 membered heteroaryl) ⁇ Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R h+ and R l4 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2 -s alkynyl, C aryl, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CM* aryl-C i-e alkyl-, C3-i4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
  • each R j4 and R k4 is independently selected from OH, Cj-ealkoxy, and Ci-ehaloalkoxy; or, any R j and R k+ attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalky 1 group optionally substituted -with 1, 2, 3, or 4 substituents independently selected from Cj- 6 alkyl and Cs- 6 haloalkyl;
  • each R H is independently selected from D, halo, oxo, Cue alkyl, C R> haloalkyl, C 2- 6 alkenyl, C 2-f, alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6 -i4 aiyl-Ci-6 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaiyl)-Ci-6 alkyl-, (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, CN, N0 2 , OR 85 , SR 3" , NHOR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)NR c5 (0R a5 ), C(0)0R a5 , 0C(0)R bs , 0C(0)NR
  • heterocycloalkyl CM* aiyl-C [-6 alkyl-, C3-14 cycloalkyl-Cj-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-C R> alkyl- of R H are each optionally substituted with 1, 2, 3, or 4 independently selected R ! substituents;
  • each R 35 , R c5 , and R d " is independently selected from H, Ci-e alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, €5-14 aryl, C3-1 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CM* ar I-C - & alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered
  • R c5 , and R d5 are each optionally substituted with 1 , 2, 3, or 4 independently selected R 1 substituents;
  • R c and R d5 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroary l or 4-14 membered heterocycloalkyl group is optionally substituted with 1 , 2, 3, or 4 independently selected R 1 substituents;
  • each R b5 is independently selected from H, Cue alkyl. Cue haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&-1 aryl, C3-14 cycloalky 1, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce-u aryl-C M alkyl-, ifr-n eyeloalkyl-C alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-C R > alkyl-, wherein the CM alkyl, C ?
  • each R s?' is independently selected from H, OH, CN, C M alky l, Ci-e alkoxy, C haloalkyl, C;i- f! haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-w aiyl, C3- M cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6 -i4 aiyl-Ci- 6 alkyl-, C 3-14 cycloalky!- Ci- 6 alkyl-, (5-14 membered heteroaryl) -C1-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- & alkyl-;
  • each R b and R g5 is independently selected from H, C M alkyl, Ci « alkoxy, Ci- 6 haloalkyl, Cj-ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, ( M-M aryl, C 3-14 cycloalky 1, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce-u ary' i-C 1-6 alkyl-, C 3-i 4 cyc!oalky 1- CM alk l-, (5-14 membered heteroaiyl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R to and R 15 is independently selected from H, CM alkyl, C haloalkyl, C2-6 alkenyl, €2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce-w aiyl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-;
  • each R p and R* 5 is independently selected from OH, Cj-s aikoxy, and Ci-shaloalkoxy; or, any R j5 and R* 5 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C alkyl and C 1-6 haloalkyl;
  • each R 1 is independently selected from D, halo, oxo, C , alkyl, C , haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce-w ary 1-C M alkyl-, C3-14 eyeloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 aikyl-, and (4-14 membered heterocycioalkyi)-Ci- 6 alkyl-, CN, N(3 ⁇ 4, OR a6 ,
  • heterocycloalkyl Ce-ir aiyl-Ci-6 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl- of R ! are each optionally substituted with 1 , 2, 3, or 4 independently selected R J substituents;
  • each R 36 , R c6 , and R d5 is independently selected from H, Ci- & alkyl, Ci- & haloalkyl, C 2.. e alkenyl, C 2- e alkymyl, C &-K aryl, C-t-u cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary l-Ci-6 alkyl-, Ca-i + cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] ⁇ alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, wherein the C - 6 alkyl, C 2-& alkenyl, C 2-6 alkynyl, Ce-u aryl, Cs-u cycloalkyi, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C S-M ary
  • R c6 and R* attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R bo is independently selected from H, CM alkyl, CM haloalk l, C 2.6 alkenyl, C 2-& alkynyl, Ce-w aryl, C3- H cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce-ir aiyl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wherein the C M alkyl, C 2-& alkenyl, C 2-& alkynyl, CV aryl, Ci- K cycloalkyl, 5-14 membered heteroaryd, 4-14 membered heterocycloalkyl, Cs-w aryl-Ci- 6 alkyl-, C3-14 cycloalky l-Ci- 6 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C ue alkyl- of R b6 are each optionally substituted with 1 , 2, 3, or 4 independently selected R J substituents;
  • each R e6 is independently selected from H, OH, CN, C , alkyl, Ci- 6 alkoxy, Ci-6 haloalkyl, C ] -6haloalkoxy, C 2 -s alkenyl, C 2- e alkynyl, C K aryl, €3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i ary l-Ci-6 alkyl-, C3..14 cycloalky 1- C i-6 alkyl-, (5-14 membered heteroaryi)-Ci-s alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-; each R ® and R s ° is independently selected from H, Ci-e alkyl Ci-e alkoxy, Ci-e haloalkyl, C;i- f!
  • haloa3koxy C2-6 alkenyl, C2-6 alkynyl, Ce-w aiyl, C3- H cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Gs-w aryl-C - 6 alkyl-, Cs- M cycloalkyl- Ci- 6 alkyl-, (5-14 membered heteroaryl) -C1-6 alkyl-, and (4-14 membered heterocycloalky 1)-Ci. & alkyl-;
  • each R h6 and R' 6 is independently selected from H, C -6 alkyl, C -e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ci.-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CN- M aryl-Ci-e alkyl-, C -i+ cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl-;
  • each R' 6 and R k6 is independently selected from OH, C -s alkoxy, and C i-ehaloalkoxy; or, any R jf> and R kb attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci-e alky l and Ci-e haloalkyl;
  • each R 1 is independently selected from D, halo, oxo, Ci-b alkyl, Ci-b haloalkyl, C2.6 alkenyl, C2-6 alkynyl, C M aryl, C 3-i 4 cycloalkyl, 5-14 membered heteroaryd, 4-14 membered heterocycloalkyl, Ce- aryi-C 1.5 alkyl-, C3-1 cycloalky I-C1-6 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C [-6 alkyl-, CN, NO2, OR a7 ,
  • Ci-e alkyl C 2-6 alkenyl, C 2-6 alkynyl, Ce-u aryl, €3-14 cycloalky 1, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce-u aryl-C i-e alkyl-, C 3 -i 4 cycloalkyl-C - 6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl- of R ! are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R a/ , R c , and R d ' is independently selected from H, Cj-b alkyl, Ci-e haloalkyl, C2-6 alkenyl, €2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i4 aryl-C -6 alkyl-, Cs-w cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl- wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkymyl, C6-i4 aryl, Ci- H cycloalkyl, 5-14 membered heteroaryd, 4-14 membered heterocycloalkyl, C 6-i4 aryl-Ci-e alkyl-
  • R K substituents are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents; or any R c/ and R d7 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R b is independently selected from H, Ci-e alkyl, Ci-e haloalkyl, C 2-6 alkenyl, C2-6 alkynyl, Ce- aryd, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Cg-w aryl-C 1.5 alkyl-, C3-14 cycloalky 1-Ci- alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloaikyi)-Ci-6 alkyl-, wherein the Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, C -u aryd, C 3-i 4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cg-u aryl-Ci-e alkyl-, C3-34 cycloalk l-Ci ⁇ alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloaikyi) ⁇ Ci-g alkyl- of R B? are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R 57 is independently selected from H, OH, CN, Ci-g alkyl, C2-6 alkenyl, Ci-g alkoxy, Ci-g haloalkyl, Ci-ghaloalkoxy, C2-6 alkynyl, Cg-ir aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, and 4- 14 membered heterocycloalkyl;
  • each R f? and R g/ is independently selected from H, Ci-e alkyl, C 1-6 alkoxy, Ci-e haloalkyl, Ci-ghaloalkoxy, C2-6 alkenyl, C2.6 alkynyl, Cgur aryd, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w aryt-Cj-g alkyl-, Cs-ir eyeloalkyi- Ci- 6 alkyl-, (5-14 membered heteroaryl) -Ci-g alkyl-, and (4-14 membered heterocycloalky 1)-Ci. 6 alkyl-;
  • each R h? and R 1 ' is independently selected from H, Ci- 6 alkyl, Cj-g haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Cg.u aryd, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cg-u aryl-Ci-g alkyl-, Ch-n cycloalkyl-Cj-g alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-C 1.6 alkyl-;
  • each R J ' and R K is independently selected from OH, Cj-g alkoxy, and Ci-ghaloalkoxy; or, any R" and R k/ attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Cj-g alkyl and Cs-g haloalkyl;
  • each R K is independently selected from H, D, OH, halo, oxo, CN, C(0)OH, NH 2 ,
  • any heteroaryl group of any of the above-recited substituents optionally comprises an N-oxide on any ring-forming nitrogen.
  • X is N
  • R 1 is selected from H, C M alkyl, C2-6 alkenyl, C M alkynyl, and C M haloalkyl;
  • R 2 is selected from H, D, halo, C M alkyl, C M haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- 14 and, C3.14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-6 alkyl-, CVw cyctoalkyl-C M alkyl-, (5-14 membered heteroaryl) ⁇ Ci-6 alkyl-, (4-14 membered heterocycloalky 1)-C M alkyl-, CN, N(3 ⁇ 4, GR 32 , SR 32 , NHOR a2 , C(0)R b3 ,
  • heterocycloalkyl Ce- aryl-C alkyl-, C3-1 cycloalky l-Ci-6 alkyl-, (5-14 membered heteroaryl)-C alkyl-, and (4-14 membered heteroeyeloaikyi)-C[-s alkyl- of R 2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R c substituents;
  • Cy 1 is Ce aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the Cs-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R7 or R M substituents;
  • Cy 2 is Ce-14 aryl, C3.14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the C -u and, C3-14 cyeloalkyl, 5-14 membered heteroaryl, or 4-14 membered heteroc cloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R b substituents;
  • each R 32 , R c2 , and R d2 is independently selected from H, C alkyl, C haloalkyl, C M alkenyl, C 2 -s alkynyl, C&-14 aryl, €3-1 + cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C M alkyl-, Ci- H cycloalkyl-C M alkyl-, (5-14 membered heteroaryi)-Ci- 6 alky 1-, and (4-14 membered heterocycloalky 1) ⁇ C alkyl-, wherein the C M alkyl.
  • C M alkenyl, C M alkyny l, C &-J 4 aryl, C 3 -i4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-e alkyl-, Ci-u cycloalkyl-C -6 alky' 1-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl- of R a2 , R c , and R di are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R G substituents;
  • R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1 , 2, 3, or 4 independently selected R u substituents;
  • each R b2 is independently selected from H, C.-s alkyl, C.-s haloalkyl, C2-6 alkenyl, C2.6 alkynyl, C M * aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce-w aryl-Ci-e alkyl-, C -i + cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wherein the C -6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryl, Cs-u cycloalkyi, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, aryl-Cw alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalky l)-C]- 6 alkyl- of R fc2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R ⁇ J substituents;
  • each R G and R g2 is independently selected from H, Ci-e alkyl, Ci-b haloalkyl, C - 6 alkoxy, C 1-6 haloalkyl, Ci-ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Cs-u aryl, C 3-i4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cs-u aryl-Ci-e alkyl-, C3 -14 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-;
  • each R h2 and R l2 is independently selected from H, C - 6 alkyl, C - 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryd, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C M * aryd-C [-6 alkyl-, C 3-H cycloalkyl-C] ⁇ alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocyeloalkyd)-Ci-6 alkyl-;
  • each R J and R k2 is independently selected from OH, Ci- & alkoxy, and Ci-ehaloalkoxy; or any R 2 and R k2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalky 1 group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C M alkyl and C 1-5 haloalkyl; each R c , R E , R M , R f , and R° is independently selected from D, halo, oxo, Ci-e alkyl, C [- 6 haloalkyl, C 2.g alkenyl, C2-6 alkynyl, Cg-u and, C 3-14 cycloalkyl, 5- 14 membered heteroatyl, 4-14 membered heterocycloalky 1, Ce-u aryl-Ci alkyl-, C3- H cycloalkyl-Ci-e alkyl-, (5
  • heterocycloalkyl CM* aiyl-C i-g alkyl-, C 3-14 cycloalkyl-Cj-e alkyl-, (5- 14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyi) ⁇ Ci-g alkyl- of R c , R E , R M , R F , and R G are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R H substituents;
  • each R a4 , R c+ , and R d4 is independently selected from H, Ci-g alkyl, Ci-g haloalkyl, C 2..g alkenyl, C 2-g alkynyl, Cg-u aryl, C -u cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cg-i 4 ary 1-Ci-g alkyl-, C -i+ cycloalkyl-C -g alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl-, wherein the Ci-g alkyl, C 2-g alkenyl, C 2-g alkynyl, Cg-n aryl, C 3-i 4 cycloalkyl, 5-14 membered heteroaryd, 4-14 membered heterocycloalkyl, C -n ar l
  • each R b4 is independently selected from H, Ci-e alkyl, Ci- haloalkyl, C 2-g alkenyl, C 2-g alkynyl, Cg-u aryl, €3-14 cycloalky 1, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Cg-u aryl-C i-g alkyl-, €3-14 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci-g alkyl-, and (4-14 membered heterocycloalky 1)-C R > alkyl-, wherein the CM alkyl, C 2 -g alkenyl, C 2 -g alkynyl, Cg-u aryl, C J-M cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-e alkyl-, Ci-u cycloalkyl-C -6 alky' 1-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl- of R B4 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R ri substitu
  • each R f4 and R 8 * is independently selected from H, C.-s alkyl, Ci «alkoxy, Ci- 6 haloalkyl, Ci- 6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, C K aryl, C3 U 4 cycloalkyl, 5-14 membered heteroary l, 4-14 membered heterocycloalkyl, Ce-u ary l-Ci- 6 alkyl-, C3-14 cycloalky 1- C [-6 alkyl-, (5-14 membered he teroaryl)-Ci- 6 alkyl-, and (4-14 membered heierocyeloalkyli-Ci- 6 alkyl-;
  • each R h4 and R l4 is independently selected from H, Ci. & alkyl, Ci. & haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, Cj-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce- aryl-C 1.5 alkyl-, C3-14 cycloalky l-Ci-b alkyl-, (5-14 membered heteroaiyd)-Ci- 6 alkyl-, and (4-14 membered keterocycloalkyl)-C i-e alkyl-;
  • each R j4 and R“ 4 is independently selected from OH, Ci-ealkoxy, and C -ehaloalkoxy; or, any R
  • each R H is independently selected from D, halo, oxo, C [- 6 alkyl, C [- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryl, Cs-ucycloalkyi, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary l-Ci-6 alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, CN, NO2, OR 35 , SR a5 , NI-IOR 35 , C(0)R b5 , C(0)NR c5 R d5 , C(0)NR c5 (0R a5 ), C(0)0R 35 , 0C(0)R bs , 0C(0)NR c5 R d5 .
  • heterocycloalkyl C 6 -i4 aiyl-Ci- 6 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- of R fl are each optionally substituted with 1 , 2, 3, or 4 independently selected R 1 substituents;
  • each R a5 , R° 5 , and R di is independently selected from H, C i-s alkyl, Ci-s haloalkyl, C 2-6 alkenyl, C 2-G alkynyl, C G-M aryl, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CG- M aryl-C i-e alkyl-, C3-i4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-C R> alkyl-, wherein the C M alkyl, C 2 -e alkenyl, C 2-6 alkynyl, CG-M aryd, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CG-M aryl-C -6 al
  • R 05 and R da attached to the same N atom, together with the N atom to winch they are attached, form a 5- or 6-membered heteroary l or a 4-14 membered heterocycloalkyl group, wirerein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R ! substituents;
  • each R to is independently selected from H, C J-G alkyl, C2-6 alkenyl, C2-0 alky nyl, C 6 -i4 aryl, C3 -14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CG- M aryl- Ci- f, alkyl-, C3-14 cycloalkyl-Ci- G alkyl-, (5-14 membered heteroary!)-Ci-e, alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl-, wirerein the Ci-e alkyl, C 2-6 alkenyl, C2-6 alkynyl, CG- 1 aryi, C3-1 + cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloaikyi, C G-M aryi-Ci-e alkyl-, Cs-w cycloaikyl-
  • each R e5 is independently selected from H, OH, CN, C I -G alkyl, Ci-e alkoxy, Ci-e haloalkyl, Ci-ehaloalkoxy, C 2-G alkenyl, C 2 « alkynyl, C G-M aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloaikyi, Cs- 14 aryi-Ci-e alkyl-, C3-14 cycloalkyl- Ci-5 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alky 1-;
  • each R f5 and R 85 is independently selected from H, Ci-e alkyl Ci-e alkoxy, C1-6 haloalkyl, Cwehaloalkoxy, C 2-G alkeny l, C 2-G alkynyl, C G-M aryl, C3- M cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloaikyi, C G- M ar l-C -6 alkyl-, Cs- M cycloalkyi- Ci-6 alkyl-, (5-14 membered heteroaryl) -C I-G alkyl-, and (4-14 membered heterocycloalky 1)-Ci. 6 alkyi-;
  • each R 115 and R 15 is independently selected from H, Ci-s alkyl, Ci-s haloalkyl, C 2 -e alkenyl, C 2-6 alkynyl, C &-J 4 aryi, C 3- cycloalkyl, 5-14 membered heteroary l, 4-14 membered heterocycloalkyl, Ce-u ary i-Ci-6 alkyl-, C -i+ cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] ⁇ alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-;
  • each R Ji and R ’ ° is independently selected from OH, C -s alkoxy, and C i-ehaloalkoxy; or, any R jd and R k5 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci-e alky l and Ci- 6 haloalkyl; each R l is independently selected from D, halo, oxo, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 a!kynyl, Ce-u aryl, C -ir cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce- aryl-C i- d alkyl-, C3-1 cycloalky I-C1-6 alkyl-, (5-14 membered heteroar
  • heterocycloalkyl Ce-14 ary i-Ci- 6 alkyl-, Ca-i+ cycloalkyl-C -e alkyl-, (5-14 membered heteroaryi)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyi)-C 1.6 alkyl- of R 1 are each optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R a6 , R cf> , and R d6 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2.6 alkenyl, C 2-& alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-ir aiyl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.
  • R ao , R c6 , and R d6 are each optionally substituted with 1, 2, 3, or 4 independently selected R J substituents; or any R CR and R d6 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered
  • each R b6 is independently selected from H, Ci- 6 alkyl, Cue haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ci.-n aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4- 14 membered heterocycloalkyl, 65-14 ary 1-6 i-e alkyl-, C -i+ cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] ⁇ alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wherein the C -6 aikyi, C‘ alkenyl, C2-6 alkyny!, 65-14 aryl, €3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, 65-14 ar l-Cw alkyl-, C3-14 cycloalkyl-Ci-e al
  • each R e6 is independently selected from H, OH, CN, Ci-e alkyl, Ci-e alkoxy, Ci- & haloalkyl, Ci-ehaloalkoxj', 6 2-5 alkenyl, C 2-6 alkynyl, 6 5-14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, 6 5-1 aryl-6 i-s alkyl-, C 3-14 cycloalky 1- Ci- 6 alkyl-, (5-14 membered heteroaryl)-C ]-6 alkyl-, and (4-14 membered heterocycioalkyi)-Oi- 6 alkyl-;
  • each R f6 and R g6 is independently selected from H, Ci-e alkyl, Ci-e alkoxy, Ci- & haloalkyl, Oi-ehaloalkoxy, C2-6 alkenyl, 62-5 alkynyl, 65-14 aryl, 63-14 cycloalkyl, 5-14 membered heteroaiyl, 4-14 membered heterocycloalkyl, 65-14 ary l-Ci- 6 alkyl-, C3..14 cycloalky 1- C i-6 alkyl-, (5-14 membered heteroaryi)-C i-s alkyl-, and (4-14 membered heterocycloalkyl)-6 i- 6 alkyl-;
  • each R h6 and R l6 is independently selected from H, C - 6 alkyl, haloalkyl, C2-6 alkenyl, C2-6 alkynyl, 65-14 aryl, 63-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, 65-1 aryl-61.5 alkyl-, C3-14 cycloalky l-Ci-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heteroeyeloalkyi)-O i-s alkyl-;
  • each R Jf> and R* 6 is independently selected from OH, Ci-ealkoxy, and Ci-ehaloalkoxy; or, any R j6 and R kb attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalky 1 group optionally substituted with 1, 2, 3, or 4 substituents independently selected from 61-5 alkyl and Ci-6 haloalkyl;
  • each R J is independently selected from 13, halo, oxo, Ci-6 alkyl, 61-5 haloalkyl, C 2 -6 alkenyl, C2-6 alkynyl, 65.14 aryl, 63-1 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, 65-14 ar I-C1-& alkyl-, 63-14 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-6 ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-6i-6 alkyl-, 6N, NO2, OR a/ , SR a? , NHOR 87 , 6(0)R b7 , 6(0)NR c7 R d7 , 6(0)NR c7 (QR a7 ), C(0)0R* 7 , 06(0)R b7 ,
  • heterocycloalkyl C M * aiyl-C [-6 alkyl-, C3-14 cycloalkyl-Cj-e alkyl-, (5-14 membered heteroaryd)-C 1-6 alkyl-, and (4-14 membered heteroeyeloaikyi)-C[-s alkyl- of R J are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R a7 , R c7 , and R d is independently selected from H, Cj- 6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, Ce-u aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C M * ar I-C1- & alkyl-, C3- 14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- wherein the C1-6 alkyl, C 2-6 alkenyl, C 2 « alkynyl, Ce-u aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, €5-14 atyl-Ci-s alkyl-,
  • R substituents are each optionally substituted with 1, 2, 3, or 4 independently selected R substituents; or any R c/ and R d7 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R b7 is independently selected from H, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, Ce- aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce- aryl-C 1.5 alkyl-, C 3-14 cycloalky I-C 1 -6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocy cloaikyi)-Ci-6 alkyl-, wherein the Ci-s alkyl, €2-5 alkenyl, C 2 -s alkynyl, C&-14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C * aryl-Ci-e alkyl-, C3-34 cycloalkyl-Ci-s alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloaikyi) ⁇ C [-6 alkyl- of R 0/ are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R s ' is independently selected from H, OH, CN, Ci-e alkyl, C 2-6 alkenyl, C 1-6 alkoxy, Ci. & haloalkyl, Cj-shaloalkoxy, C2-6 alkynyl, Ce-i aryl, C 3-1 cycloalkyl, 5-14 membered heteroaryl, and 4- 14 membered heterocycloalkyl;
  • each R f? and R g/ is independently selected from H, Ci-e alkyl, Cue alkoxy, Ci-e haloalkyl, C;i- f! haloalkoxy, C2-6 alkenyl, C 2-6 alkynyl, Ce-w aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w aryl-Cj- 6 alkyl-, Cs-w cycloalkji- Ci- 6 alkyl-, (5-14 membered heteroaryl) -C 1-6 alkyl-, and (4-14 membered heterocycloalky 1)-Ci. & alkyd-;
  • each R h? and R 1 ' is independently selected from H, Ci- 6 alkyl, Cj ⁇ haloalkyl, C2-6 alkenyl, C 2-f , alkynyl, G M 4 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u ary l-Ci-6 alkyl-, C -i + cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] ⁇ alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-;
  • each R j7 and R k ' is independently selected from OH, C -salkoxy, and Ci-ehaloalkoxy; or, any R j ' and R k/ attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci-e alky l and Ci-b haloalkyl;
  • each R is independently selected from H, D, OH, halo, oxo, CN, C(0)0H, NH2, NO2, SFs, C - 6 alkyl, C -e alkoxy, Ci-ehaloalkoxy, C-- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce ⁇ l and, C3.14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloaikyi, Ce-ir aryl-Ci- 6 alkyl-, CVw cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl-; and
  • any heteroaryl group of any of the above-recited substituents optionally comprises an N-oxide on any ring-forming nitrogen.
  • each R J is independently selected from 13, halo, oxo, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryl, C 3-1 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloaikyi, C M ar I-C1- & alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered
  • each R a ', R c ', and R d ' is independently selected from H, €1-5 alkyl, C - 6 haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, C &.14 aryl, C 3-1 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloaikyi, C M aryl-Ci ⁇ , alkyl-, C 3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered
  • heteroaryl C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-;
  • each R b/ is independently selected from H, Cj-6 alkyl, Cj-6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ce-u aryl, 6(3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary i-Ci-6 alkyl-, C -i+ cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] ⁇ alkyl-, and (4-14 membered heterocycloa3kyl)-Ci-6 alkyl-.
  • each R 1 is independently selected from D, halo, oxo, C .-s alkyl, C .-s haloaikyl, C 2.6 alkenyl, C2-6 alkynyl, Ce-w aryl, Cj-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyi, Ce-ir aiyl-Ci-6 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C [- 6 alkyl-, CN, NO2, OR a6 , SR a6 , NHOR a6 , C(0)R b6 , C(0)NR c6 R d6 , C(0)NR c6 (0R a6 ), C(0)OR a6 , OC(0)R b6 ,
  • each R a6 , R c6 , and R' fo is independently selected from H, Ci-e alkyl, Ci-e haloaikyl, C 2-6 alkenyl, C 2-6 alkynyl, Ce-w aryl, Cj-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyi, Ce- aryl-C 1.5 alkyl-, C 3-14 cycloalky I-C 1-6 alkyl-, (5-14 membered heteroaryl)-Ci ⁇ alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-;
  • R 06 and R do attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14-membered heterocycloalkyi group;
  • each R bo is independently selected from H, C - 6 alkyl, C - 6 haloaikyl, C 2.& alkenyl, C 2-& alkynyl, Ce-w aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyi Ce-ir aiyl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-.
  • each R h is independently selected from D, halo, oxo, C - 6 alkyl, Ci-6 haloaikyl, C 2- e alkenyl, C2-6 alkynyl, CN, Ci.& alkoxy, Ci-b haloalkoxy, amino, Ci-6 alkylamino, di-Ci -s alkylamino, Cw, alkylsulfonyl, aminosulfonyl, C - 6 aikyiaminosulfonyi, di-Ci- 6 alkylaminosulfonyl, and C - 6 alkylsulfonylamino; wherein said Cl -6 alkyl is optionally substituted by 1, 2, 3, 4, 5, 6, 7, or 8 independently selected halogens.
  • each R 35 , R°, and R d: ’ is independently selected from H, Ci- 6 alkyl, Ci « haloaikyl, C2-6 alkenyl, C « alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyi, phenyl-Ci-e alkyl-, Crw- cyeloalkyi-Ci-e alkyl-, (5-6 membered heteroaryi)-C i- 6 alkyl-, and (4-7 membered heterocycloalkyl)-C ]-6 alkyl-, wherein the Ci- 6 alkyl, C 2-6 alkenyl, C 2-& alkynyl, phenyl, C3- ?
  • each R to is independently selected from H, C alkyl, C haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C i- 6 alkyl-, C 3-7 cycloalkyl-Ci-e alkyl-, (5-6 membered heteroaryl)-Ci- 6 alkyl-, and (4-7 membered heterocycloalky 1)-C M alkyl-, wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C3-7 cycloalkyl, 5-6 membered heteroaryi, 4-7 membered heterocycloalkyl, phenyl-Ci- 6 alkyl-, Cfr cycloalkyl-C M alkyl-, (5-6 membered heteroaryl)-Ci
  • each R 5 is independently selected from H, OH, CN, C , alkyl, C M , alkoxy, C M , haloalkyl, and C M haioalkoxy;
  • each R ft and R 83 is independently selected from H, C M alkyl, C M haloalkyl, C2-6 alkenyl, C2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-Ci-6 alkyl-, C3-7 cycloalky I-C M alkyl-, (5-6 membered heteroaryl)-Ci- 6 alkyl-, and (4-7 membered heterocycloalkyi)-C M alkyl-;
  • each R to and R 15 is independently selected from H, C M haloalkyl, C alkyl, C 2-6 alkenyl, C2-6 alkynyl, phenyl, C 3-7 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl-C -6 alkyl-, C3-7 cycloalky 1-C alkyl-, (5-6 membered heteroaryl)-Cj- 6 alkyl-, and (4-7 membered heterocycloalky 1)-O M alkyl-;
  • each R j5 and R* 5 is independently selected from OH, C M alkoxy, and Ci ⁇ haloalkoxy;
  • each R 1 is D, halo, oxo, C M alkyl.
  • each R ! and R 3 is independently selected from D, halo, oxo, C M alkyl, C M haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, C M alkoxy.
  • C haioalkoxy, amino, Ci-6 alkylamino, di-C M alkylamino, C M alkylsulfonyl, aminosulfonyl.
  • alkylaminosulfonyl di-C M alkylaminosulfonyl, and C M alkylsulfonylamino;
  • each R K is independently selected from H, D, OH, halo, oxo, CN, C(0)GH, NH 2 ,
  • X is N
  • R 2 is selected from H, D, halo, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- 14 a d, €3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-ir aryi-Ci-6 alkyl-, C3 -14 cycloalkyl-C 1-6 alkyl-, (5-14 membered heieroaryl)-Ci- 6 alkyl-, (4-14 membered heterocycloalkyl) ⁇ Ci-6 alkyl-, CN, N0 2 , OR 32 , SR 32 , NHOR 32 , C(0)R b2 ,
  • heterocycloalkyl, Ce-i aiyl-Ci-6 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycioalkyl)-C 1 ⁇ 2 alkyl- of R 2 are each optionally substituted with 1 , 2, 3, 4, 5, 6, 7, or 8 independently selected R c substituents;
  • Cy 1 is C-6-14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the Cg-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R h substituents;
  • Cy 1 is not pyridin-4-yl optionally substituted with 1, 2, 3, or 4 independently selected R' substituents; provided that Cy 1 is not pyrimidin-4-yl optionally substituted with 1, 2, or 3, independently selected R fc substituents;
  • Cy 1 is not quinolin-4-yl optionally substituted with 1, 2, 3, 4, 5, or 6 independently selected R substituents;
  • Cy 2 is Ce- M aryl, C B-M cycloalkyl, 5-14 mem bered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the Ce-u aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 1' substituents;
  • each R al , R cl , R d! , R a2 , R c2 , and R d2 is independently selected from H, Cw alkyl, Cw haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C M 4 aryl, Cs-wcycloalkyl, 5-14 membered heteroaryl, 4- 14 membered heterocycloalkyl, C 4 aryl-Ci-6 alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered he ternary l)-Ci- & alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, wherein the C]- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalky
  • R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1 , 2, 3, or 4 independently selected R ' substituents;
  • each R bi and R b2 is independently selected from H, C.-s alkyl, C.-s haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C M 4 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary i-C 1-6 alkyl-, Cj- H cycloalkyl-Cj-e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloa3kyl)-Ci-6 alkyl-, wherein the Cj-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C&-34 aryl, €3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 4 aryl-Cw alkyl-, C3-14 cycloalky
  • each R c and R g2 is independently selected from H, C -- 6 alkyl, Ci-e alkoxy, Ci- 6 haloalkyl, Ci-ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ci.-n aryl, C3-14 cycloalky 1, 5-14 membered heteroary l, 4-14 membered heterocycloalkyl, C M 4 ary l-Ci- 6 alkyl-, C3-14 cycloalky 1- Ci- d alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R h2 and R l3 is independently selected from H, Ci-s alkyl, Ci ⁇ haloalkyl, C2-6 alkenyl, €2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i aiyl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaiyl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R j2 and R* 2 is independently selected from OH, Cj-s alkoxy, and Ci-ehaloalkoxy; or any R j2 and R k2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci-e alkyl and C 1-6 haloalkyl;
  • R F , and R G is independently selected from D, halo, oxo, Ci-b alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, € 6 - ⁇ 4 aryl, C3-1 cycloalkyd, 5-14 membered heteroaryl, 4-14 membered heterocycloalky 1, C&.14 ary l-Ci-6 alkyl-, C3-14 cycloalky 1-Cw alkyl-, (5-14 membered heteroaryl)-Ci -f, alkyl-, (4-14 membered heterocycloalkyi)-Ci -f, alkyl-, CN,
  • R B , R c , R E , R F , and R & are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R H substituents; each R a+ , R c4 , and R d4 is independently selected from H, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heieroaryl, 4-14 membered heterocycloalkyl, Ce-w aryl-C -6 alkyl-, Cs-w eyeloalkyl,
  • each R M is independently selected from H, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&-14 aryl, C3-14 cycloalkyl, 5-14 membered heieroaryl, 4-14 membered
  • heterocycloalkyl Ce-n ary I-C1- & alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wherein the C -e alkyl, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heieroaryl, 4-14 membered heterocycloalkyl, Cs-w aryl-Ci-e alkyl-, CVw cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.
  • each R e4 is independently selected from H, OH, CN, Ci-e alkyl, Ci ⁇ alkoxy, Ci-e haloalkyl, Ci-ghaloalkoxy, C2-6 alkenyl, €2-5 alkynyl, C G-M aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u axyl-Ci-e alkyl-, C3-14 cycloalkyl- Ci- d alkyl-, (5-14 membered heteroary r l)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alky 1-;
  • each R f4 and R s‘! is independently selected from H, Ci-e alkyl, Ci-ealkoxy, Ci-e haloalkyl, Ci-ehaloalkoxy, C2-6 alkeny l, C2-6 alkynyl, Ce-w aiyl, C3- W cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary!-Cs-e alkyl-, Cs-w cycloalkyi- Ci- 6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-Ci. & alkyd-;
  • each R h4 and R' 4 is independently selected from H, C -b alkyl, C -b haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C f .-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w aryi-Ci-e alkyl-, C -i+ cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloaikyl)-Ci-6 alkyl-;
  • each R Jd and R k4 is independently selected from OH, C -s alkoxy, and C i-ehaloalkoxy; or, any R j4 and R k4 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci-e alkyl and Ci- 6 haloalkyl; each R H is independently selected from D, halo, oxo, Ci- 6 alkyl, Cw haloalkyl, C 2-6 alkenyl, C2-6 alkynyi, Ce-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-e alkyl-, C3- 1 cycloalky l-Ci-b alkyl-, (5-14 membered heteroaryl)-C
  • heterocycloalkyl Ce-w aryl-Ci- 6 alkyl-, C3-i4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-C 1.6 alkyl- of R H are each optionally substituted with 1, 2, 3, or 4 independently selected R : substituents;
  • each R a ⁇ R c5 , and R db is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C 2-f, alkynyi, Ce-w aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i aiyl-Ci-6 alkyl-, Cs- H cycloalkyi-Ci-e alkyl-, (5-14 membered heteroatyl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, wherein the C1.6 alkyl, C 2-6 alkenyl, C2-6 alkynyi, Ce-w aryl, Ci- K cycloalkyl, 5-14 membered heteroaryd, 4-14 membered heterocycloalkyl, Cs-w aryl-Ci ⁇ alkyl
  • R cS and R d5 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1 , 2, 3, or 4 independently selected R 1 substituents;
  • each R b5 is independently selected from H, C - 6 alkyl, Cue haloalkyl, C 2-6 alkenyl, C2-6 alkynyi, C &-J 4 aryl, C B-U cycloalkyl, 5-14 membered heteroaryl, 4- 14 membered heterocycloalkyl, Ce-u aryl-Ci ⁇ alkyl-, Cs-ir cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wherein the CM alkyl, C2-6 alkenyl, C 2-6 alkymyl, C &-14 aryl, €3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Cw alkyl-, C 3-14 cycloalkyl-C
  • each R e5 is independently selected from H, OH, CN, CM alkyl, Ci-s alkoxy, Ci- & haloalkyl, Ci-ehaioalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce- aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-e alkyl-, C3-1 cycloalky 1- C -e alkyl-, (5-14 membered heteroaryl)-C ]-6 alkyl-, and (4-14 membered heterocycloalkyi)-C - 6 alkyl-;
  • each R e and R is independently selected from H, Cue alkyl, Ci-e alkoxy, Ci- & haloalkyl, C -ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryi, C3- M cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u ary l-Ci- 6 alkyl-, C3..14 cycloalky 1- C i-6 alkyl-, (5-14 membered heteroaryl)-C i-s alkyl-, and (4-14 membered heterocycloalkyl)-C i- 6 alkyl-;
  • each R h5 and R l5 is independently selected from H, C - 6 alkyl, haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryd, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C 1.5 alkyl-, C3-1 cycloalky l-Ci-b alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocyeloaikyi)-C i-6 alkyl-;
  • each R Jd and R k5 is independently selected from OH, Ci-e alkoxy, and Ci-ehaloalkoxy; or, any R j5 and R ⁇ attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalky 1 group optionally substituted with 1, 2, 3, or 4 substituents independently selected from CM alkyl and Ci- 6 haloalkyl;
  • each R 1 is independently selected from 13, halo, oxo, CM alkyl, CM haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C &.14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u ary I-C 1 -& alkyl-, C 3-14 cycloalkyl-Cw alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, CN, NO2, OR ao , SR a6 , NHOR 85 , C(0)R b6 , C(0)NR c6 R d6 , C(0)NR c6 (QR afr ), C(0)0R 36 , OC(Q)R b6 ,
  • heterocycloalkyl C M * aiyl-C -6 alkyl-, C3-14 cycloalkyl-Cj-e alkyl-, (5-14 membered heteroaryd)-C 1-6 alkyl-, and (4-14 membered heteroeyeloaikyl)-C -s alkyl- of R 1 are each optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R 3b , R c6 , and R d6 is independently selected from H, C - 6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, Ce-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C M * ar I-C1- & alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, wherein the C -e alkyl, C2-6 alkenyl, C2-6 alkynyl, C&.34 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cs-w aryi-C -e al
  • R c6 and R df> attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with i, 2, 3, or 4 independently selected R J substituents;
  • each R b6 is independently selected from H, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- aryd, C 3-i 4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce- aryl-C 1.5 alkyl-, C3-14 cycloalky I-C1-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocyeloalkyl)-Ci-s alkyl-, wherein the Ci-s alkyl, €2-5 alkenyl, C 2 « alkynyl, C&-14 aryd, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C * aryl-Ci-e alkyl-, C 3 -u cycioalkyl-Ci-s alkyl-, (5-14 membered heteroaryi)-Ci- 6 alkyl-, and (4-14 membered heterocycloaikyi) ⁇ C [-6 alkyl- of R 00 are each optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R 86 is independently selected from H, OH, CN, Cj- 6 alkyl, Ci-e alkoxy, Cw haloalkyl, Ci-ehaloalkoxy, C 2.6 alkenyl, C 2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroasyl, 4-14 membered heterocycloalkyl, CM* ary l-Ci-6 alkyl-, C 3-i 4 cycloalky 1- Ci- 6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloaiky ⁇ ) ⁇ Ci- 6 alkyl-;
  • each R fb and R g5 is independently selected from H, Ci- 6 alkyl, C -e alkoxy, Ci-e haloalkyl, Ci-ghaloalkoxy, C 2-6 alkenyl, C 2 « alkynyl, Ce-n aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-e alkyl-, C3-14 cycloalkyl- Ci- 6 alkyl-, (5-14 membered heteroaiyli-Ci-g alkyl-, and (4-14 membered heterocycloalkyil-C - 6 alkyl-; each R ho and R l5 is independently selected from H, C aikyi, C haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl,
  • each R j6 and R K6 is independently selected from OH, C -salkoxy, and Ci-shaloalkoxy; or, any R j6 and R kf> attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C alkyl and C M haloalkyl;
  • each R J is independently selected from D, halo, oxo, C M alkyl, C M haloalkyl, C M alkenyl, C M alkynyl, C &-K aryl, C-t-u cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w aryl-C M alkyl-, C - cycloalkyl-C -e alkyl-, (5-14 membered
  • heteroaiyl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- of R J are each optionally substituted with 1 , 2, 3, or 4 independently selected R substituents;
  • each R a ', R c/ , and R d/ is independently selected from H, C M alkyl, C M haloalkyl, C M alkenyl, C 2 -s alkynyl, C&-14 aryd, C 3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C M alkyl-, €3-14 cycloalkyl-C M alkyl-, (5-14 membered
  • R a/ , R c ', and R d ' are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents; or any R c/ and R d ' attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a
  • heterocycloalkyl CX-w aryl-Cs- 6 alkyl-, Cs-w eyeloalkyi-Ci-e alkyl-, (5-14 membered heteroaiyl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, wherein the C1.6 alkyl, C2-6 alkenyl, C2-6 alkynyl, CV 14 aryl, Ci- K cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C -e alkyl-, CS- M cycloalky l-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heierocycloalkyl)-C ue alkyl- of R s? are each optionally substituted with 1 , 2, 3, or 4 independently selected R substituent
  • each R e ' is independently selected from H, OH, CN, Cue alkyl, C2-6 alkenyl, Ci-e alkoxy, Ci ⁇ haloalkyl, Cwhaloalkoxy, C2-6 alkynyl, C M * aryl, Cs-wcycloalkyl, 5-14 membered heteroaryi, and 4-14 membered heterocycloalkyl;
  • each R ⁇ and R s ' is independently selected from H, Ci-e alkyl, C [-6 alkoxy, Ci- & haloalkyl, C -ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryi, C3- H cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i4 ar l-Ci-6 alkyl-, C3..14 cycloalky 1- C i-6 alkyl-, (5-14 membered heteroaryl)-Ci-s alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R h7 and R 1 ' is independently selected from H, C - 6 alkyl, haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryd, C3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Ce- aryl-C 1 -5 alkyl-, C3-14 cycloalky l-Ci-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyi)-Ci-s alkyl-;
  • each R J ' and R K/ is independently selected from OH, Ci- & alkoxy, and Ci-ehaloalkoxy; or, any R j7 and R k ' attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalky 1 group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci-e alkyl and C 1.6 haloalkyl;
  • each R K is independently selected from H, D, OH, halo, oxo, CN, C(0)OH, NH 2,
  • any heteroaryi group of any of the above-recited substituents optionally comprises an N-oxide on any ring-forming nitrogen
  • X is N
  • R 1 is selected from H, CVe alkyl, C2-6 alkenyl, C2-6 alkynyl, and Cw haloalkyl
  • R 2 is selected from H, D, halo, Ci-s alkyl, Ci-s haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- i4 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C C-M aryl-Ci-6 alkyl-, CVw cyctoalkyl-Ci-e alkyl-, (5-14 membered heteroaryi) ⁇ Ci-6 alkyl-, (4-14 membered heterocycloalky 1)-Ci. 5 alkyl-, CN, N0 2 , OK" ' . SR w M IOR" . C(0)R b2 ,
  • heterocycloalky 1 C M * aiy r i-C i-b alkyl-, C3-14 cycloalkyl-Cj-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl- of R 2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R c substituents;
  • Cy 1 is C W 4 aryl, C J-M cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl, wherein the C S-M aryl, C 3-i4 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R 11 or R M substituents;
  • Cy 2 is C&-14 aryl, C 3-i4 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalky 1, wherein the C5-14 aryl, C 3-] 4 cycloalkyl, 5-14 membered heteroaryl, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R r substituents;
  • each R 32 , R c2 , and R d2 is independently selected from H, Ci-b alkyl, Ci-b haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C M * ary I-C1- & alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, wherein the C -e alkyl, C2-6 alkenyl, C2- & alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CX-w aryl-Ci-e
  • R 3 , R c2 , and R d2 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R & substituents; or any R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R° substituents;
  • each R b2 is independently selected from H, Cue alkyl. Cue haloalky!, C2-6 alkenyl, C2-6 aikynyl, Ce-u aryl, C3- H cycioalkyi, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl C w ar I-C1- & alkyl-, C3-14 cycloalkyl-Cw alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wherein the Cj-e alkyl, C2-6 alkenyl, C2-6 aikynyl, C&.34 aryl, C3-1 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-H aryl-Ci-e alkyl-, CVw cyctoalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C]- 6 alkyl-, and (4-14 membered heterocy cloalkyl)-Ci- 6 alkyl- of R b2 are each optionally substituted with 1 , 2, 3, 4, 5, 6, 7, or 8 independently
  • each R 12 and R g2 is independently selected from H, Ci-e alkyl, Cue haloalkyl, Ci-e alkoxy, Ci. & haloalkyl, Cj-shaloalkoxy, C2-6 alkenyl, C2-6 aikynyl, Cs-ir aryl, Csur cycloalkyl, 5-14 membered heteroaiyl, 4-14 membered heterocycloalkyl, C S-H aryl-C 1-6 alkyl-, C3- 14 cycloalkyl-C 1-6 alk l-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl-;
  • each R 12 and R i is independently selected from H, Cj-e alkyl, Cj-e haloalkyl, C2-6 alkenyl, C2-6 aikynyl, C&-14 aryd, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C i-e alkyl-, C 3 -i 4 cycloalkyl-Cj- 6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl-;
  • each R J and R K is independently selected from OH, C3-6 alkoxy, and Ci-ghaloalkoxy; or any R' 2 and R K attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Cj- 6 alkyl and Cj- 6 haloalkyl;
  • each R c , R E , R M , R ⁇ and R° is independently selected from D, halo, oxo, C-- 6 alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 aikynyl, CS- M aryd, C3- 14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-n ar l-C] - 6 alkyl-, Cs-ircycioalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C i- 6 alkyl-, (4-14 membered heterocy cloalkyl)-C [- 6 alkyl-, CN,
  • R c , R E , R M , R " , and R° are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R h substituents;
  • each R a+ , R c4 , and R d4 is independently selected from H, Cj- 6 alkyl, Cj- 6 haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C&-14 aryl, C3-u cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ar l-Ci-6 alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyi)-Cs- 6 alkyl-, wherein the Cj- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, €5-14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C -r ary 1-Cw alkyl-
  • each R b4 is independently selected from H, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C 2 « alkynyl, C&-J4 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4- 14 membered
  • heierocycloalkyi Ce-14 ary' 1-C 1-6 alkyl-, Ca-i+ cycloalkyl-Cj-e alkyl-, (5-14 membered heteroary l)-Cj- 6 alkyl-, and (4-14 membered heterocycloalky l)-Ci- 6 alkyl-, w'herein the Cj- 6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C&-14 aryl, Cs-i+ cyeloalkyi, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CS- M ar l-Cw alkyl-, C3-14 cycloalky 1-C 1-6 alkyl-, (5-14 membered heteroaryl)-Cj-6 alkyl-, and (4-14 membered heterocycloalkyl)-Cj-6 alkyl- of R b4 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently
  • haloa3koxy C2-6 alkenyl, C2-6 alkynyl, Ce-w aiyl, C3- W cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, € 6 - aryl-C - 6 alkyl-, Cs-u eyeloalkyi- Ci- 6 alkyl-, (5-14 membered heteroaryl) -C1-6 alkyl-, and (4-14 membered heterocycloalky 1)-Ci. & alkyl-;
  • each R f4 and R g4 is independently selected from H, CM alkyl, Ci-e alkoxy, C haloalkyl, C -ehaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, (M-M aryl, C 3-14 cycloalky 1, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CM 4 ary l-Ci- 6 alkyl-, C 3 -1 4 cycloalky 1- CM alkyl-, (5-14 membered heteroaryl)-C alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R M and R 14 is independently selected from H, CM alkyl, CM haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-ir aiyl-Ci-6 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci.6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-;
  • each R j4 and R K4 is independently selected from OH, C -s alkoxy, and Ci-shaloalkoxy; or, any R J+ and R k4 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci-e alkyl and C M haloalkyl;
  • each R H is independently selected from D, halo, oxo, CM alkyl, CM haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C & -K aryl, C-t-u cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary l-Ci-6 alkyl-, C3-14 eyeloalkyl-Cw alkyl-, (5-14 membered heteroaryl)-C ] .s alkyl-, (4-14 membered heterocycloalky l)-Ci-6 alky!-, CN, NO2, OR 3 , SR ®5 ,
  • CM alkyl CM alkenyl, C2-6 alkynyl, Ce-w aryl, C3- H cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl C 6 -i4 aryl-C M alkyl-, C3-i4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaiyl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1 ⁇ 2 alkyl- of R h are each optionally substituted with 1 , 2, 3, or 4 independently selected R 1 substituents;
  • each R 35 , R° 5 , and R d5 is independently selected from H, CM alkyl, CM haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ci.-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary i-Ci-e alkyl-, Cj-i + cycloalkyl-Cj-e alkyl-, (5-14 membered heteroaryl)-C ] ⁇ alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wherein the Cj-6 aikyi, C‘ alkenyl, C2-6 alkyny!, C &-K aryl, €3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cg-n ar l-Cw alkyl-
  • R c5 and R ds attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R : substituents;
  • each R to is independently selected from H, Cj-g alky l, C2-6 alkenyl, C2-6 alkynyl, Cg- 14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cg-w aryl- Ci- 6 alkyl-, Cs-u cycloalkyl-Ci-g alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, wherein the Ci-g alkyl, €2-5 alkenyl, C2-6 alkynyl, Cg.
  • each R e is independently selected from H, OH, CN, Ci-e alkyl, Ci-e alkoxy , Ci-g haloalkyl, Cj-ghaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Cg-u aryl, Ca-s cycloalkyl, 5-14 membered heteroaiyl, 4-14 membered heterocycloalkyl, Cg-14 aryl-Ci- 6 alkyl-, C3..14 cycloalky 1- C [-6 alkyl-, (5-14 membered he teroaiyl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R ft and R 83 is independently selected from H, Ci-g alkyl, Ci- 6 alkoxy, Ci-g haloalkyl, Ci-ghaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ca-u aryd, C3-i4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalky 1, Cg.44 aryl-Ci-g alkyl-, C3-14 cycloalky 1- Ci- f, alkyl-, (5-14 membered heteroaryl) -Ci-g alkyl-, and (4-14 membered heterocycloalkyl)-Cj- 6 alkyl-;
  • each R to and R' 5 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalky l, C2-6 alkenyl, C 2-6 alkynyl, Cg-k aryl, C-t-u cycloalkyl, 5-14 membered heteroaiyl, 4-14 membered heterocycloalkyl, Ce-w ary l-Ci-6 alkyl-, C3-14 cycloalkyl-Cw alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-C ] - 6 alkyl-;
  • each R ⁇ ' 5 and R ki is independently selected from OH, Cj-g alkoxy, and Ci-ghaloalkoxy; or, any R j5 and R k? ' attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C - 6 alkyl and C - 6 haloalkyl; each R 1 is independently selected from D, halo, oxo, C .-s alkyl, C .-s haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C B-H cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-ir aiyl-Ci-6 alkyl-, Cs-u cycloalkyi-Ci-e alkyl-, (5-14
  • heterocycloalkyl Ce-u aryl-C i-e alkyl-, C B -i 4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-C 1.6 alkyl- of R 1 are each optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R 86 , R cf> , and R d6 is independently selected from H, C -b alkyl, C -b haloalkyl, C2-6 alkenyl, C 2- e alkynyl, C ⁇ 5-i 4 aryl, C3-1 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i4 aryl-C -e alkyd-, Cs-w cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, wherein the Ci-e alkyl, C 2-& alkenyl, C 2-& alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C
  • each R fc5 is independently selected from H, Cue alkyl. Cue haloalkyl, C 2-6 alkenyl, C 2-& alkynyl, C &-14 aryl, € 3-14 cycloalky 1, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce-u aryl-Ci-e alkyl-, € 3-14 cycloalkyl-Ci- 6 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalky 1)-C R, alkyl-, wherein the CM alkyl, C 2 -e alkenyl, C 2 -e alkynyl, C &-J 4 aryl, C J-M cycloalky 3, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C -e alkyl-, C 3-i 4 cycloalkyl-C M alkyl-, (5-14 membered heteroaryl)-C ] ⁇ alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- of R b6 are each optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R e6 is independently selected from H, OH, CN, C M alkyl, C .-s alkoxy, Ci- 6 haloalkyl, C M haloalkoxy, C2-6 alkenyl, C 2-& alkynyl, Ce-u aryl, C 3-i 4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i4 aiyl-Ci- 6 alkyl-, C 3-i 4 cycloalkyl- Ci- f, alkyl-, (5-14 membered heteroaryl)-C ]-6 alkyl-, and (4-14 membered heterocycloalkyl)-C - 6 alkyl-;
  • each R ® and R g6 is independently selected from H, Cm, alkyl, Ci-ealkoxy, Ci- 6 haloalkyl, Ci- 6 haloalkoxy, C2-6 alkenyl, C 2-6 alkynyl, C K aryl, C 3-i 4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C M 4 aryl-C alkyl-, C 3-i 4 cycloalky 1- C -6 alkyl-, (5-14 membered heteroaryl)-C alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R h6 and R 5 is independently selected from H, C alkyl, C M haloalkyl, C 2.6 alkenyl, C M alkynyl, Ce-w aryl, Cj-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C 1 -5 alkyl-, C 3-14 cycloalky l-Ci-6 alkyl-, (5-14 membered heteroar l)-Ci-6 alkyl-, and (4-14 membered keterocycloalkyl)-C M alkyl-;
  • each R Jf> and R k5 is independently selected from OH, Ci-e alkoxy, and C -ehaloalkoxy; or, any R
  • each R J is independently selected from D, halo, oxo.
  • heterocycloalkyl, Ce-ir aryl-Ci- 6 alkyl-, CN-u cycloalkyi-Ci-e alkyl-, (5-14 membered heteroaryl)-C]-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- of R J are each optionally substituted with 1 , 2, 3, or 4 independently selected R substituents;
  • each R a/ , R 0 ', and R d7 is independently selected from H, C i-s alkyl, C i-s haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C&-14 aryl, C 3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C i-e alkyl-, C3-i 4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocy cloalky 1)-C R> alkyl- wherein the Ci-e alkyl, C 2-6 alkenyl, C 2-f, alkynyl, Ce-w aryl, C 3-i 4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C
  • each R b/ is independently selected from H, Cj- 6 alkyl, Cj- 6 haloalkyl, C 2 -s alkenyl, C 2 -6 alkynyl, C &.14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl C M ary I-C1- & alkyl-, C 3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocy cloalkyl)-Ci-6 alkyl-, wherein the Cj-e alkyl, C2-6 alkenyl, C2-6 alkynyl, C &.14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cs-w aryi-Cj- 6 alkyl-, CVw cy cloalky 1-C i-s alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1.6 alkyl- of R b? are each optionally substituted with 1 , 2, 3, or 4 independently selected R substitu
  • each R e ' is independently selected from H, OH, CN, Ci-e alkyl, C 2 _6 alkenyl, C 5 -6 alkoxy, Ci-b haloalkyl, Cwhaloalkoxy, C2-6 alkynyl, Ce-w aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl;
  • each R f/ and R g? is independently selected from H, C .-s alkyl, Ci « alkoxy, Ci-e haloalkyl, Cj-ehaloalkoxy, C2-6 alkenyl, C 2- e alkynyl, C &-J 4 aryl, Cji-u cy cloalkyi, 5-14 membered heteroary l, 4-14 membered heterocycloalkyl, C M 4 ary' i-C 1-6 alkyl-, C 3-i 4 cyc!oalky 1- C i- 6 alkyl-, (5-14 membered he teroarydi-Ci- f , alky!-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-;
  • each R h/ and R 1 ' is independently selected from H, Ci-6 alkyl, Ci-6 haloalkyl, C 2 .6 alkenyl, C 2- 6 alkynyl, Ce-w aryl, €3-14 ey cloalkyi, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-ir aiyl-Ci-6 alkyl-, Cs-u cycloalky!-Ci-e alkyl-, (5-14 membered heteroaryd)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C i-6 alkyl-; each R J ' and R K/ is independently selected from OH, Ci-ealkoxy, and Ci ⁇ haloalkoxy; or, any R J / and R k ' attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-mem bered heterocycloalkyl group optionally substitute
  • each R K is independently selected from H, D, OH, halo, oxo, CN, C(0)QH, NH 2 ,
  • any heteroaryl group of any of the above-recited substituents optionally comprises an N -oxide on any ring-forming nitrogen.
  • X is N
  • R 1 is selected from H, Ci-b alkyl, C2-6 alkenyl, €2-6 alkynyl, and Ci- 6 haloalkyl;
  • R 2 is selected from H, 13, halo, Ci-s alkyl, Ci-s haloalkyl, C 2- e alkenyl, C2-6 alkynyl, Cs- 14 and, C3.14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-r aryl-Ci- 6 alkyl-, C3-14 cycloalkyl-C ue alkyl-, (5-14 membered heteroaiyl)-Ci-6 alkyl-, (4-14 membered heterocycloalky l)-C -6 alkyl-, CN, N0 2 , OR az , SR 32 , NHOR a2 , C(0)R b3 ,
  • heterocycloalkyl, Ce- aryd-C 1.5 alkyl-, C3-14 cycloalky l-Ci-e alkyl-, (5-14 membered heteroaryd)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C ue alkyl- of R 2 are each optionally substituted with 1 , 2, 3, 4, 5, 6, 7, or 8 independently selected R c substituents;
  • Cy 1 is Ce- 14 aryl, C3-14 cycloalkyl, or 5-14 membered heteroaryl, wherein the C C-M aryl, C3-14 cycloalkyl, or 5-14 membered heteroaryd is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R or R M substituents;
  • Cy 2 is C M * aryl, C3-14 cycloalkyl, 5-14 membered heteroaryd, or 4-14 membered heterocycloalkyl, wherein the Ce-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryd, or 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R b substituents;
  • each R”, R° 2 , and R tl2 is independently selected from H, C i-s alkyl, C i-s haloalkyl, C 2-6 alkenyl, C 2 -s alkynyl, C&-14 aryd, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-C i-e alkyl-, C3-i 4 cycloalkyl-Cj- 6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-C R , alkyl-, wherein the C M alkyl, C2-6 alkenyl, C 2-6 alkynyl, Ci.-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyi, Cs-u aryl-Ci-
  • R c2 and R d2 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyi group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyi group is optionally substituted with 1 , 2, 3, or 4 independently selected R ⁇ 1 substituents;
  • each R b2 is independently selected from H, Cj- 6 alkyl, Cj- 6 haloalkyl, C 2.& alkenyl, C 2-& alkynyl, Ci.-n aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • each R is independently selected from H, OH, CN, C.-s alkyl, C.-s alkoxy, Ci- 6 haloalkyl, Cj-ehaloalkoxy, C2-6 alkenyl, C 2-& alkynyl, Ca-u aryd, Ch-w eye
  • each R c and R g2 is independently selected from H, Ci-e alkyl, Cw, haloalkyl, Cj- 6 alkoxy, Ci ⁇ aloalkyl, Cj-ehaloalkoxy, C2-6 alkenyl, C 2-6 alkynyl, CS- M aryd, Cs-wcycloalkyl, 5-14 membered heteroary l, 4-14 membered heterocycloalkyi, C M * aryl-C 1-6 alkyl-, C3 -14 eycloalkyd-C]- 6 alkyl-, (5-14 membered heteroaryd)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-: each R h2 and R l3 is independently selected from H, Ci-s aikyi, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-14
  • each R j2 and R* 2 is independently selected from OH, C -s alkoxy, and Ci-shaloalkoxy; or any R j2 and R k2 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci- 6 alkyl and C 1-6 haloalkyl; each R c , R E , R M , R r , and R° is independently selected from D, halo, oxo, Ci-e alkyl, Ci-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C 6- H aryl, C3-14 cyctoalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C&04 ary l-Ci-s alkyl-, Cs-ir cycloalkyi-C
  • R c , R b , R M , R r , and R u are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R H substituents;
  • each R a4 , R c4 , and R d4 is independently selected from H, Ci-e alkyl, Ci- 6 haloalkyl, C 2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce- aryl-C 1.5 alkyl-, C3-14 cycloalky I-C1-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1-6 alkyl-, wherein the Ci-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ce-u aryi, Cs-u cycloalkyi, 5-14 membered heteroaiyd, 4-14 membered heterocycloalkyl, C -u aryl-Ci-e alkyl-, C3-
  • heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R H substituents;
  • each R b4 is independently selected from H, C alkyl, C M haloaikyl, C2-6 alken l, C2.6 alkynyl, Ca-u aryl, C 3-i 4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Ce-ir aryd-Ci-e alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryd)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-C alkyl-, wherein the C M alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryl, C 3-i 4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cs-w ary 1-C M alkyl-, C3-14 cycloalky l-Ci-6 alkyl-, (5-14 membered heteroaryl)-C 1-6 alkyl-, and (4-14 membered heterocycloaikyi)-Ci-6 alkyl- of R D4 are each optionally substituted with 1 , 2, 3, 4, 5, 6, 7, or 8 independently selected R H substituents; each R ®
  • each R f4 and R* 4 is independently selected from H, C M , alkyl, C M alkoxy, Ci-6 haloaikyl, Ci-ehaloalkoxj', C2-6 alkenyl, C2-6 alkynyl, Ce- aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalky 1, Ce-i4 aryd-C M alkyl-, C3-14 cycloalky 1- Cs-6 alkyl-, (5-14 membered heteroaiyl) -C 1-5 alkyl-, and (4-14 membered heterocycloalkyl)-C ] - 6 alkyl-;
  • each R 1 * 4 and R l4 is independently selected from H, Ci-g alkyl.
  • C haloaikyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaiyi, 4-14 membered heterocycloalkyl, Ce-w ary l-Ci-6 alkyl-, C3-14 cycloalkyl-Cw alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyi-, and (4-14 membered heterocycioalkyi)-Cs-6 alkyl-;
  • each R ⁇ ' 4 and R k4 is independently selected from OH, Ci-ealkoxy, and Ci-ehaloalkoxy ; or, any R j+ and R k4 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C M alkyl and C M haloaikyl;
  • each R H is independently selected from D, halo, oxo, C M alkyl, C M haloaikyl, C2-6 alkenyl, C2-6 alkynyl, C&-14 aryl, C3..1+ cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryd-C 1-6 alkyl-, C 3-i 4 cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, (4-14 membered heterocycloalky 1)-C M alkyl-, CN, NO2, OR 85 , SR 85 , NHQR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)NR c5 (0R a5 ), C(0)0R a5 , 0C(0)R b5 , 0C(0)NR c5 R d5 , NR
  • heterocycloalkyl C MA ary 1-Ci-e, alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- of R h are each optionally substituted with 1, 2, 3, or 4 independently selected R 1 substituents;
  • each R a5 , R° 5 , and R di is independently selected from H, C i-s alkyl, 61- 5 haloalkyl, C2-6 alkenyl, 62-5 alkynyl, 65-11 a d, 63-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C * aryl-6 -6 alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-6i-6 alkyl-, and (4-14 membered heterocycloalky 1) ⁇ 6 R> alkyl-, wherein the 61-6 alkyl 6 2 -s alkenyl, 62 « alkynyl, 6 5-14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, 65-114 aryl-61-6 alkyl-, 63-1 cycioal
  • R 05 and R da attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R ! substituents;
  • each R to is independently selected from H, 61-5 alkyl, 6 2-6 alkenyl, 6 2-f! alkynyl, Ce-w ary l, 63-14 cycloalkyl, 5-14 membered heteroaiyl, 4-14 membered heterocycloalkyl, 65-14 aryl- Ci-6 alkyl-, C3-14 eyeloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-6i-5 alkyl-, and (4-14 membered heterocycloalkyl)-6i-6 alkyl- wherein the 1-5 alkyl, C 2-& alkenyl, C2-6 alkynyl, Ce ⁇ lt and, 63.14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloaikyl, 5-1 aryl-61-6 alkyl-, C3-14 cycloalkyl-6 ue alkyl-, (5-14 membered heteroar d)-Ci
  • each R e5 is independently selected from H, OH, 6N, 64-5 alkyl, Ci-ealkoxy, 61 -5 haloalkyl, 6i-6haioalkoxy, 62-5 alkenyl, 62-5 alkynyl, 65-14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloaikyl, 65-14 aryl-6 i-e alkyl-, 63-14 cycloalkyl- 61-5 alkyl-, (5-14 membered heteroaiyll-Oi-g alkyl-, and (4-14 membered heterocycloalkyl)-6i- 5 alkyl-; each R f5 and R S3 is independently selected from H, Ci-e alkyl Ci-e alkoxy, Ci-e haloalkyl, C;i- f!
  • haloa3koxy C2-6 alkenyl, C2-6 alkynyl, Ce-w aiyl, C3- H cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, €b- aryl-C - 6 alkyl-, Cs-i cydoalkyi- Ci- 6 alkyl-, (5-14 membered heteroaryl) -C1-6 alkyl-, and (4-14 membered heterocycloalky 1)-Ci. & alkyl-;
  • each R 115 and R 1' is independently selected from H, C -g alkyl, C -g haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Cg-u aryl, C -u cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w aryl-Ci-g alkyl-, C -i+ cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-C 1.6 alkyl-;
  • each R Ji and R ’ ° is independently selected from OH, C .g alkoxy, and C i-ghaloalkoxy; or, any R j5 and R k? ' attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from Ci-e alky l and C -g haloalkyl;
  • each R 1 is independently selected from D, halo, oxo, C .-g alkyl, C .-g haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, Cj-w cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cg-u aryl-C 1.5 alkyl-, C3-1 cycloalky I-C1-6 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C [-6 alkyl-, CN, NO2, OR a6 ,
  • heterocycloalkyl Cg-u aryl-C i-g alkyl-, C 3 -i 4 cycloalkyl-C - 6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky l)-C 1.6 alkyl- of R 1 are each optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R 86 , R cf> , and R d6 is independently selected from H, Cj-b alkyl, Ci-e haloalkyl, C2-6 alkenyl, €2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6 -i4 aryl-C -g alkyl-, C3- M cycloalky l-C -6 alkyl-, (5-14 membered heteroaryl)-Ci.
  • R a6 , R c5 , and R d6 are each optionally substituted with 1, 2, 3, or 4 independently selected R' substituents;
  • R c6 and R d6 attached to the same N atom, together with the N atom to which they are attached, form a 5- or 6-membered heteroaryl or a 4-14 membered heterocycloalkyl group, wherein the 5- or 6-membered heteroaryl or 4-14 membered heterocycloalkyl group is optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R b6 is independently selected from H, Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce- aryd, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl Cg-w aryl-C 1.5 alkyl-, C 3-14 cycloalky l-Ci-g alkyl-, (5-14 membered heteroaryiVC i-g alky 1-, and (4-14 membered heterocyeloaikyi)-C[-s alkyl-, wherein the Ci-s alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-u aryd, C 3-i4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cg-u aryl-Ci-g alkyl-, C3- M cycloalk l-C -g alkyl-, (5-14 membered heteroaryl)-Ci- 6 alky 1-, and (4-14 membered heterocycloaikyi) ⁇ Ci-g alkyl- of R Bb are each optionally substituted with 1, 2, 3, or 4 independently selected R J substituents;
  • each R 66 is independently selected from H, OH, CN, Cj-g alkyl, Cfr-g alkoxy, Cw haloalkyl, Ci-ghaloalkoxy, C2-6 alkenyl, C2.6 alkynyl, Cg-ir aryl, C3- 14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C &-14 ar l-Ci- 6 alkyl-, C 3-14 cycloalkyl- Ci- 6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloaikyl) ⁇ Ci- 6 alkyl-;
  • each R fb and R g5 is independently selected from H, Cfr-g alkyl, Cs-g alkoxy, Ci-g haloalkyl, Ci-ghaloalkoxy, C2-6 alkenyl, €2-5 alkynyl, Cg-n aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalky 1, Cg-u and -Ci-g alkyl-, C 3-14 cycloallcyl- Ci-g alkyl-, (5-14 membered heteroaiyll-Ci- alkyl-, and (4-14 membered heterocycloalkyl)-C ].
  • each R hb and R 16 is independently selected from H, Ci-g aikyd, Ci-g haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Cg-j 4 aryd, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary I-C 1 -& alkyl-, C 3-14 cycloalkyl-Cw alkyl-, (5-14 membered heteroaryl)-C ] - 6 alkyl-, and (4-14 membered heterocycioalkyl)-Ci-g alkyl-;
  • each R j5 and R te is independently selected from OH, Ci-galkoxy, and C -ghaloalkoxy ; or, any R j6 and R k5 attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1 , 2, 3, or 4 substituents independently selected from Cb-g aikyd and Ci-g haloalkyl;
  • each R 3 is independently selected from D, halo, oxo, C _g alkyl, C _g haloalkyl, Cb-g alkenyl, C ? _-g alkynyl, Cg-u aryd, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w ary l-Ci-6 alkyl-, Cj-i+ cycloalkyl-Cj-e alkyl-, (5-14 membered heteroaryl)-C ] ⁇ alkyl-, and (4-14 membered heterocycloa3kyl)-Ci-6 alkyl-, CN, NO2, OR a?
  • heterocycloalkyl, Ce-i4 aryl-Cj-6 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocy cloalkyi)-Ci-6 alkyl- of R J are each optionally substituted with 1 , 2, 3, or 4 independently selected R substituents;
  • each R a/ , R c7 , and R d7 is independently selected from H, Ci- 6 alkyl Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&-1 aryl, C3..14 cycloalky 1, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryd-C i-e alkyl-, C3-i cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-C 1.6 alkyl- wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl Ce-w aryl, C3-14 cycloalky 1, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-u aryl-Ci-e alkyl-, C3-14 cycl
  • each R b7 is independently selected from H, Cj- 6 alkyl, Cj- 6 haloalkyl C2-6 alkenyl, C2-6 alkynyl, C&-14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl 4-14 membered
  • heterocycloalkyl Ce-w ary I-C1-& alkyl-, C3-14 cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, wherein the Cj-e alkyl, C 2-& alkenyl, C 2-& alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6 -H aryl-Ci-e alkyl-, CVw cycloalkyl-C i-e alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-C 1 ⁇ 2 alkyl- of R b7 are each optionally substituted with 1 , 2, 3, or 4 independently selected R substituents; each R
  • each R n and R g/ is independently selected from H, Ci-e alkyl, C M alkoxy, C haloalkyl, C -ghaloalkoxy, C2-6 alkenyl, C2-6 alkynyl, Ca-u aryl, C;-w eyeloalkyi, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cg-i 4 aryl-Ci-g alkyl-, C3-14 cycloalkyl- C M alkyl-, (5-14 membered heteroaryl) -C M alkyl-, and (4-14 membered heterocycloalkyI)-C - 6 alkyl-;
  • each R h? and R" is independently selected from H, C M alkyl, C haloalkyl, C2-6 alkenyl, C 2-6 alkynyl, Cg-k aryl, C-t-u cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cg-w ary 1-C M alkyl-, C -i + cycloalkyl-C -e alkyl-, (5-14 membered heteroaryl)-C ⁇ alkyl-, and (4-14 membered heterocycloalkyi)-Ci-6 alkyl-;
  • each R j7 and R k ' is independently selected from OH, C M alkoxy, and Ci-ghaloalkoxy; or, any R j ' and R k/ attached to the same B atom, together with the B atom to which they are attached, form a 5- or 6-membered heterocycloalkyl group optionally substituted with 1, 2, 3, or 4 substituents independently selected from C M alkyl and Ci-g haloalkyl;
  • each R K is independently selected from H, D, OH, halo, oxo, CN, C(0)0H, NH 2 ,
  • SFs C -g alkyl, C alkoxy, Ci-ghaloaikoxy, CM haloalkyl, Ch-g alkenyl, CC-g alkynyl, Cg. 1 and, C3.14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cg-i 4 aryl-Ci- 6 alkyl-, CVw cycloalkyl-Ci-e alkyl-, (5-14 membered heteroard)-Ci-g alkyl-, and (4-14 membered heterocycloalky 1)-C M alkyl-; and
  • any heteroaryl group of any of the above-recited substituents optionally comprises an N-oxide on any ring-forming nitrogen.
  • the compound of Formula (I) is a compound of Formula (II):
  • the compound of Formula (I) is a compound of Formula (III):
  • Cy 1 is CS-M aryl, wherein the C M 4 aryl is optionally substituted with 1, 2, 3, or 4 independently selected R E substituents.
  • Cy 1 is C3-14 cycloalkyl, wherein the C3-14 cycloalkyl is optionally substituted with I, 2, 3, or 4 independently selected R E substituents.
  • Cy J is 5-14 membered heteroaryl, wherein the 5-14 membered heteroaryl is optionally substituted with 1 , 2, 3, or 4 independently selected R E substituents.
  • C ! is 4-14 membered heterocycloalkyl, wherein the 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 independently selected R E substituents.
  • Cy 1 is C -10 aryl, wherein the Ce-io aryl is optionally substituted with 1, 2, 3, or 4 independently selected R E substituents.
  • Cy 1 is C3..7 cycloalkyl, wherein the C3-7 cycloalkyl is optionally substituted with 1, 2, 3, or 4 independently selected R E substituents.
  • C ! is 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 independently selected R : substituents.
  • Cy 1 is 4-10 membered heterocycloalkyl, wherein the 4-10 membered heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 independently selected R E substituents.
  • Cy 1 is phenyl or 5-10 membered heteroaryl, wherein the phenyl or 5-10 membered heteroaryl is optionally substituted with l, 2, 3, or 4 independently selected R E substituents.
  • Cy J is phenyl, optionally substituted with 1, 2, 3, or 4 independently selected R M substituents, or C7-14 aryl or 5-14 membered heteroaryl wherein the Cj-uaryl and 5-14 membered heteroaryl are optionally substituted with I, 2, 3, or 4 independently selected R r substituents, and
  • each R M is independently selected from D, halo, oxo, C - 6 alkyl, C - 6 haloalkyl, Ci-e alkoxy, C2-6 alkenyl, C2-6 alkynyl, C 4 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyi, 2-CN, 3-CN, N0 2 , OR 84 , SR a4 , NHOR a4 ,
  • Cy 1 is selected from phenyl, pyridinyl, furanyl, benzofuranyl, and pyrazolyl, each of which is optionally substituted with 1, 2, or 3 substituents selected from C - 3 alkyl, halo, CN, and C 1-3 alkoxy.
  • the optionally substituted Cy 1 is selected from cyanophenyl, cyanofluorophenyl, 2, 3-dihydro- l f-pyrrolo[2, 3, -6]pyridine, phenyl, methoxyphenyl, fluorophenyl, pyridinyl, methylfuranyi, benzofuranyl, and methyl-l/Z-pyrazolyl.
  • the optionally substituted Cy ! is selected from cyanophenyl, 2,3-dihydro-l//-pyrrolo[2,3,-h]pyridine, phenyl, methoxyphenyl, fluorophenyl, pyridinyl, methylfuranyi, benzofuranyl, and methyl- l//-pyrazolyl.
  • Cy 1 is selected from 2-cyanophenyl, 3 -cyanophenyl, 3-cyano-
  • the optionally substituted Cy 1 is selected from 2-cyanophenyl
  • the optionally substituted Cy ! is selected from 3-cyanophenyl and phenyl.
  • Cy 1 is 3-cyanophenyl.
  • Cy 2 is Cg-ir aryl, Cs- M cycloalkyi, 5-14 membered heteroaryl or 4-14 membered heterocycloalkyi wherein the CV-r arcl, C 4-14 cycloalkyl, 5-14 membered heteroaryl and 4-14 membered heterocycloalkyi are optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R b substituents.
  • Cy 2 is C S-H aryl, wherein the Ce-n aryl is optionally substituted with 1, 2, 3, or 4 independently selected R h substituents. In some embodiments, Cy 2 is C -u cycloalkyl, wherein the C3-14 cycloalkyl is optionally substituted with 1 , 2, 3, or 4 independently selected R " substituents.
  • Cy 2 is 5-14 membered heteroaryl, wherein the 5-14 membered heteroaiyl is optionally substituted with 1, 2, 3, or 4 independently selected R r substituents.
  • Cy 2 is 4-14 membered heterocycloalkyl, wherein the 4-14 membered heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 independently selected R F substituents.
  • Cy 2 is Cg-io aryl, wherein the Ce-io aryl is optionally substituted with I, 2, 3, or 4 independently selected R F substituents.
  • Cy 2 is C3-7 cycloaikyi, wherein the C3-7 cycloalkyl is optionally substituted with 1, 2, 3, or 4 independently selected R f substituents.
  • Cy 2 is 5-10 membered heteroaryl, wherein the 5-10 membered heteroaryl is optionally substituted with 1, 2, 3, or 4 independently selected R F substituents.
  • Cy 2 is 4-10 membered heterocycloalkyl, wherein the 4-10 membered heterocycloalkyl is optionally substituted with 1, 2, 3, or 4 independently selected R r substituents.
  • Cy 2 is selected from C cycloalkyl, phenyl, 5-10 membered heteroaryl, and 5-10 membered heterocycloalkyl;
  • the 5-10 membered heteroaiyl and 5-10 membered heterocycloalkyl each comprise one, two, or three nitrogen atoms as ring-forming heteroatoms, wherein one of the one or two nitrogen atoms is optionally an N-oxide, and wherein a ring-forming carbon atom is optionally substituted by oxo;
  • C3-6 cycloaikyi, phenyl, 5-10 membered heteroaryl, and 5-10 membered heterocycloalkyl are each optionally substituted with I, 2, or 3 substituents selected from C 1..3 alkyl, Ci alkyi-OH, halo, CM, C K; alkoxy, and C(0)NH 2
  • Cy 2 is selected from C cycloaikyi, phenyl, 5-10 membered heteroaiyl, and 5-10 membered heterocycloalkyl;
  • the 5-10 membered heteroaryl and 5-10 membered heterocycloalkyl each comprise one or two nitrogen atoms as ring-forming heteroatoms, where in one of the one or two nitrogen atoms is optionally an N-oxide, and wirerein a ring-forming carbon atom is optionally substituted by oxo;
  • C cycloaikyi, Ce-aryi, 5-10 membered heteroaiyl, and 5-10 membered heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents selected from C 1-3 alkyl, halo, CN, C 1-3 alkoxy, and C(0)NH>; .
  • Cy 2 is selected from pyridinyl, tetrahydropyridinyl, piperidinyl, pvridine-N-oxide, oxo-dihydropyridinyl, phenyl, pyrazolo[l,5-a]pyridin-3-yl, pyrazolo[l,5-b]pyridazinyl, pyrazolyl, pyrimidinyl, quinolinyl, oxazolyl, 2,3-dihydro- [l,4]dioxino[2,3-b]pyridin-8-yl, and triazolyl each of which is optionally substituted with I,
  • Cy 2 is selected from pyridinyl, tetrah dropyridinyl, piperidinyl, pyridine-N-oxide, oxo-dihydropyridinyl, phenyl, pyrazolo[l,5-a]pyridin-3-yl, pyrazolo[l,5-b]pyridazinyl, pyrazolyl, pyrimidinyl, quinolinyl, oxazolyl, and 2,3-dihydro- [l,4]dioxino[2,3-b]pyridin-8-yl, each of which is optionally substituted with 1, 2, or 3 substituents selected from Ci- 3 alkyl, halo, CN, Ci- 3 alkoxy, and C(0)NH 2 .
  • Cy 2 is selected from pyridinyl, tetrahydropyridinyl, piperidinyl, pyridine-N-oxide, oxo-dihydropyridinyl, phenyl, pyrazolo
  • Cy 2 is cyclopropyl optionally substituted with 1, 2, or 3 substituents selected from Cu alkyl, halo, CN, C1-3 alkoxy, and C(0)NH 2 .
  • the optionally substituted Cy 2 is selected from 2,6- dimethy!pyridin-4-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 1 -carbamoy 1-1, 2,3,6- tetrahydropyridin-4-yl, 1 -carbamoy lpiperidin-4-yl, 2-methoxypyridin-4-yl, 2-methoxy-6- methylpyridin-4-yl, 2,6-dimethylpyridin-4-yl-oxide, l-ethyl-6-oxo- l,6-dihydropyridin-3-yl, 3-methyipyridin-4 ⁇ yi, 3-fluoropyridin ⁇ 4-yl, 3-chloropyridin-4-yl, 3-methoxypyridin-4-yl, 3- cyanopyridin-4-yl, 4-carbamoylphenyl, pyrazolo[l,
  • the optionally substituted Cy 2 is selected from 2,6- dimethylpyridin-4-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 1 -carbamoy 1-1 , 2,3,6- tetrahydropyridin-4-yl, 1 -carbamoy lpiperidin-4-yl, 2-methoxypyridin-4-yl, 2-methoxy -6- methylpyridin-4-yl, 2,6-dimethylpyridin-4-yl-l -oxide, l-ethyl-6-oxo-l,6-dihydropyridin-3-yl, 3-methylpyridin-4-yl, 3-f]uoropyridin-4-yl, 3-chloropyridin-4-yl, 3-methoxypyridin-4-yl, 3- cyanopyridin-4-yl, 4-carbamoylphenyl, pyrazolo[ l,5-
  • the optionally substituted Cy 2 is selected from 2,6- dimethy lpyridin-4-y 1, p ridin-4-y 1, 2-methylpyridin-4-y 1, 1 -carbamoyl- 1, 2,3,6- tetrahydropyridin-4-yl, l-carbamoylpiperidin-4-yl, 2-methoxypyridin-4-yl, 2,6- dimethy lpyridin-4-y 1- 1 -oxide, 1 -ethy 1-6-oxo- 1 ,6-dihydropyridin-3 -y 1, 3 -methy lpyridin-4-y 1, 3-fluoropyriditi-4-yl, 3-chloropyriditi-4-yl, 3-methoxypyridin-4-yl, 3-cyanopyridin-4-yl, 4- carbamoy lpheny 1, pyrazolo [ 1 ,5 -a jpy ridin-3 -
  • R ! is selected from H, D, Ci-b alkyl, Ci- 6 haloalkyl, C 2.6 alkenyl, C 2-6 alkynyl, C f .- r aryl, C 3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-w aryl-Ci-e alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, (4-14 membered heterocycloalky l)-Ci-6 alkyl-, OR ai , C(0)R b!
  • d alkyl- of R 1 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R B substituents.
  • R ! is selected from H, D, Ci-b alkyl, Cue haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl, C f .- + aryl, C 3-14 cycloalkyl, 5-8 membered heteroaryl, 4- 14 membered heterocycloalkyl, Ce-w aiyd-Ci-e alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-8 membered heteroaryl)- C -6 alkyl-, (4-14 membered heterocycioalkyl)-Ci-6 lkyl-, OR ai , C(0)R b l , C(0)NR c!
  • R 1 is selected from H, Ch-s alkyl, and 5-8 membered heteroaryl, wherein the 5-8 membered heteroaryl is optionally subsituted by 1 or 2 independently selected K B substituents.
  • R ! is H, Cj-e alkyl, or a 5-8 membered heteroaryl
  • 1 is H or Ci-e alkyl.
  • R ! is H or C 1-3 alkyl.
  • R ! is H, ethyl, or nicotinonitrile.
  • R 1 is H or ethyl.
  • R 1 is H.
  • R ! is 5-8 membered heteroary l which is optionally subsituted by 1 or 2 independently selected R B substituents.
  • R 1 is 5-8 membered heteroaryl.
  • R 1 is pyridyl which is optionally substituted by 1 or 2 R B substituents.
  • R 1 is pyridyl which is optionally substituted by cyano.
  • R 1 is nicotinonitrile
  • R ! is 3-cyanopyridyl
  • R 2 is selected from halo, Cs- 6 alkyl, Cj-5 haloalkyl, C2-0 alkenyl, C2-6 alkynyl, C&-14 aryl, C3..14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalky 1, CM* aiyl-C w, alkyl-, C3-14 cycloalkyl-Cj-e alkyl-, (5- 14 membered heteroaryl)-Ci-6 alkyl-, (4-14 membered heterocycloalk l)-Ci-6 alkyl-, CN, NO2, OR 32 , SR 82 ,
  • heterocycloalkyl Ce-w ary l-Ci-6 alkyl-, C3-14 cycloalkyl-Cw alkyl-, (5-14 membered heteroaryl)-C ] -6 alkyl-, and (4-14 membered heterocycIoalkyl)-C ] -6 alkyl- are each optionally substituted with I, 2, 3, 4, 5, 6, 7, or 8 independently selected R c substituents; and wherein the C -e alkyl is substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R c substituents.
  • R 2 is selected from Cs- 6 alkyl, C M 4 aryl, C ? ,-u cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Ce-i4 ary l-Ci-6 alkyl-, C3..14 cycloalky 1- C i-6 alkyl-, (5-14 membered heteroary l)-Ci-s alkyl-, (4-14 membered heterocycloalkyl)-Ci-6 alkyl-, C(0)R b2 , C(0)NR e2 R d2 , C(0)0R a2 , and NR c2 R d2 , wherein the C M4 aryl, C 3 -i 4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cw4 aryl-Ci- 6 alkyl-, C3-14 cycloalky 1-C alkyl-, (5-14
  • R 2 is selected from C S-M aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 4 aryl-Ci-6 alkyl-, C3-14 cycloalky 1-Cw alkyl-, (5-14 membered heteroaryl) -Cs- 6 alkyl-, (4-14 membered heterocycloalkyl)-C]- 6 alkyl-, C(0)R b3 , C(0)NR c2 R d2 , C(0)QR a2 , and ⁇ R- R ! .
  • R 2 is selected from Ce-u and, C 3-i4 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloaikyl, C 6-M aryl-Ci- 6 alkyl-, C3- W cycloalky 1-C 1-6 alkyl-, (5-14 membered heteroary 1)-C 1-6 alkyl-, and (4-14 membered heterocycloalkyll-Ci-e alkyl-, wherein the Ce-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaiyl, 4-14 membered heterocycloaikyl, Ce-u aryl-C 1-6 alkyl-, C 3 -i 4 cycloalkyl-C - 6 alkyl-, (5-14 membered heteroary l)-Ci- 6 alkyl-, and (4-14 membered heterocycloalky 1)-C 1.6 alkyl- are each optionally substituted with 1, 2, 3, 4, or 5
  • R 2 is selected from H, Ci-e alky l, C3-14 cycloalkyl, C 4aryl, 5- 14 membered heteroary!, 4-14 membered heterocycloalky 1, C H aryl-Ci- 6 alkyl-, C3-14 cycloalky 1-C 1-6 alkyl-, (5-14 membered heteroary l)-C]- 6 alkyl-, (4-14 membered
  • heterocycloalkyl -Ci- 6 alkyi-, NR c2 R d2 , C(0)R B2 , C(0)NR c2 R d2 , and C(0)0R a2 , wherein the Cj. 6 alkyl, C 3-i 4 cycloalkyl, C6-i4 aryl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloaikyl C 6 -i4 aiyd-Ci- 6 alkyl-, Cs-u cycloalkyl-Ci-e alkyl-, (5-14 membered heteroaryl)-C]-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl- are each optionally substituted with 1 , 2, or 3 independently selected R c substituents.
  • R 2 is selected from H, Ci-e alkyl, Ce- M aryi, C3-1 4 cycloalkyl, 5- 14 membered heteroaryl, 4-14 membered heterocycloalkyl, C G-M aiyl-Ci-e alkyl-, C S-M cycloalkyl-Ci-6 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, (4-14 membered
  • R 2 is selected from H, C -- 6 alky l, Ce- M aryl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, C 6-M aryl-Ci- 6 alky!-, (5-14 membered heteroary l)-Ci- 6 alkyl-, (4-14 membered heterocycloalky l)-Ci- 6 alkyl-, NR c2 R d2 , C(0)R b2 , C(0)NR c2 R a2 , and C(G)OR a2 , wherein the Ci-e alkyl, Ce-n aryl, 5-14 membered heieroaryd, 4- 14 membered heterocycloalkyl, C G-M aryl -C I-G alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- are each optionally substituted
  • R 2 is selected from H, C - -6 alky l, Ce- M aryl, €3-54 cycloalkyl, 5- 14 membered heteroaryl, 4-14 membered heterocycloalkyl, aryl-C 1-6 alkyl-, C3.14 cycloalkyl-Ci- G alkyl-, (5-14 membered heteroary l)-C ]-6 alkyl-, (4-14 membered
  • R 2 is selected from H, C J .. G alkyl, C G-M aryl, C3-14 cycloalkyl, 5- 14 membered heteroaryl, 4-14 membered heterocycloalkyl, C G-M aryl-C - 6 alkyl-, C3-M cycloalkyl-Ci- 6 alkyl-, (5-14 membered heteroary l)-Ci- 6 alkyl-, (4-14 membered
  • heterocycloalkyl Ce- ary 1-C I -G alkyl-, C3- cycloalkyl-Cw alkyl-, (5-14 membered heteroary l)-C ]-6 alkyl-, and (4-14 membered heterocycioalkyi)-Cs- 6 alkyl- are each substituted with 1, 2, or 3 independently selected R '- substituents.
  • R' is selected from H, Ce-uaryl, 5-14 membered heteroaryl, C(0)R b2 , C(0)NR c2 R ® , and C(0)0R a2 , wherein the C o -u aryl and 5-14 membered heteroaryl are each optionally substituted wdth 1, 2, or 3 independently selected R c substituents.
  • R is selected from H, C.-s alkyl, phenyl, 5-6 membered heteroaryl, 4-10 membered heterocydoalkyi, Ce-io aryl-Ci-s alkyl-, (5-10 membered heteroaryl)-Ci- 6 alkyl-, (4-10 membered heterocycloalk I)-Cw alkyl-, NR c2 R d2 , C(0)R b2 , C(0)NR c2 R a2 , and C(0)OR a2 , wherein the C - 6 alkyl, phenyl, 5-6 membered heteroaryl, 4-10 membered heterocydoalkyi, Ce-io aryl-C -e alkyl-, (5-10 membered heteroaryl)-Ci- 6 alkyl-, and (4-10 membered heterocycloalkyl)-Ci..
  • R 6 alkyl- are each optionally substituted with 1 or 2 independently selected R c substituents.
  • R 2 is selected from H, phenyl, 5-6 membered heteroaryl, C(0)R b/ , C(0)NR c2 R a2 , and C(Q)OR a2 , wherein the phenyl and 5-6 membered heteroaryl are each optionally substituted with 1 or 2 independently selected R c substituents.
  • R is selected from H, C(0)OEt, CONH 2 , and C(0)NHEt.
  • R 2 selected from phenyl and 5-6 membered heteroaryl, each of which is optionally substituted with C(0)OMe.
  • the optionally substituted R is selected from pyridinyhnethyl, hydroxy(phenyl)meth I, hydroxyethylamino(phenyl)ethyi, cyclohexyhnethyl, fluorobenzyl, hydroxy (fluoropheny I j methy 1, (me thy lpy ridiny I j methy L (fluoropy ridiny l)methy 1,
  • benzoisoxazolylmethyl (methylindazolyl)methyl, (hydro xyazetidinyl)methyl, benzoyl, phenylcyclopropyi, (cyano(phenyl)meihyl)amino, tetxahydrofiuanyl,
  • the optionally substituted R z is selected from pyridinyhnethyl, hydroxy (pheny l)methyl, hydroxy ethylamino(phenyl)ethyl, cyclohexyhnethyl, fluorobenzyl, hydroxy (fluoropheny l)m ethyl, (methylpyridinyi)methyl, (fluoropyridinyl)methyi,
  • R 2 is selected from pyridinyimethyl, hydroxy(phenyi)methyl, hydroxy ethylami:no(phe:nyl)ethyl, eyclohexyimethyl, fluorobenzyl,
  • R 2 is selected from pyridin-2-ylmethyl
  • R 2 is selected from pyridin-2-ylmethyl
  • R 2 is selected from pyridin-2-ylmethyl
  • R 32 is selected from H and Ci-s alkyl, wherein the C -5 alkyl is optionally substituted 1, 2, or 3 independently selected R 11 substituents.
  • R b2 is selected from H, Ci- 6 alkyl, Ce-w asyl, and 4- 14 membered heterocycloalkyl, wherein the C -e alkyl, Ce-u ary l, and 4-14 membered heterocycloalkyl are each optionally substituted with 1, 2, or 3 independently selected R° substituents.
  • R c2 and R d2 are each independently selected from H, Ci-b alkyl, 5-14 membered heteroaryl, and Ce-u ary l-C - 6 alkyl-, wherein the C -e alkyl, 5- 14 membered heteroaryl, and Ce-u ary l-Ci- 6 alkyl- are each optionally substituted with 1, 2, or 3 independently selected R° substituents.
  • each R° is indepedently selected from CN, OR a4 , and Ci-s alkyl, wherein the Ci- 6 alkyl is optionally substituted I, 2, or 3 independently selected R fl substituents.
  • each R c is independently selected from halo, Ci-b alkyl, Ce-u aryl, 5-14 membered heteroaryd, (4-14 membered keterocycloalkyl)-Ci- 6 alkyl-, OR 34 , C(0)0R a+ , and NR c4 R d4 , wherein the Ci- 6 alkyl, 5-14 membered heteroaryl, and (4-14 membered heterocycloalkyl)-Ci-6 alkyl- are optionally substituted with I, 2, or 3
  • each R '- is independently selected from halo, Ci-e alkyl, C 6 -i4 aryl, 5-14 membered heteroaryl, (4-14 membered heterocycloalkyl)-Ci- 6 alkyl-, OR 34 , C(0)0R a4 , and NR c4 R d4 , wherein the C M alkyl, 5-14 membered heteroaryl, and (4-14 membered heterocycloalky3)-Ci- 6 alkyl- are substituted with 1, 2, or 3 independently selected R ri substituents.
  • R* 4 is selected from H, C M alkyl, Ce-w aryl, and 5-14 membered heteroaryi.
  • each R c4 and R d4 are independently selected from H and C M alkyl, wherein the C M , alkyl is optionally substituted by I , 2, or 3 independently selected R' 1 substituents.
  • each R' 1 is independently selected from halo, oxo, C M alkyl, Cs-6 haloalkyi, OR 85 , C(0)GR a5 , and NR c5 S(0) 2 R b5 .
  • each R a' , and R c5 is selected from H and C M alkyl.
  • R to is selected from H and C M alkyl.
  • R 3 is selected from H, D, halo, oxo, C M alkyl, C M haloalkyi, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, Cs-w ar i-C alkyl-, CVw cycloalkyl-C M alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, (4-14 membered heterocycloalky l)-Ci-6 alkyl-, CN, NO2, GR aJ , SR 83 ,
  • heterocycloalkyl Ce-i4 aryd-C M alkyl-, C3-1 cycloalky 1-C alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalky 1)-C M alkyl- of R 3 are each optionally substituted with 1, 2, 3, 4, 5, 6, 7, or 8 independently selected R ! substituents.
  • R is selected from H, halo, C M alkyl, C M haloalkyi, C &-J 4 aryl, 5-14 membered heteroaryi, CN, and GR a;i , wherein the C M alkyl, Ce-uaryl, and 5-14 membered heteroaryi are each optionally substituted with 1, 2, or 3 independently selected substituents.
  • R’ is selected from H, C M alkyl, halo, CN, morpholinomethyl, 4-ethoxyphenyi, 2-hydroxyethoxy, and pyridinyl.
  • R J is selected from H, methyl, bromo, CN, morpholinomethyl, 4- ethoxyphenyl, 2 -hydroxy ethoxy, and pyridinyl.
  • X is CR 3 ; and R ! is H or Cj-e alkyl.
  • X is CR 3 ; and R ! is H or Ci- 3 alkyl.
  • X is CR 3 ;
  • R 1 is selected from H and Ci-e alkyl
  • R 2 is selected from H, D, Ce-u aiyl, 5-14 membered heteroaryi, C(0)R b2 ,
  • R 3 is selected from H, D, halo, Ci-b alkyl, Ci-b haloalkyl, Ce-u aryl, 5-14 membered heteroaryl, CN, and OR a3 , wherein the Ci- 6 alkyl, Ce-n aryl, and 5-14 membered heteroaryl of R 5 are each optionally substituted with 1, 2, 3, or 4 independently selected R° substituents;
  • Cy 1 is phenyl optionally substituted with 1 , 2, 3, or 4 independently selected R M substituents, or Cio-i4 aryl or 5-14 membered heteroaryi, wherein the Cio-u aryl and 5-14 membered heteroaryi of Cy 1 is optionally substituted with I, 2, 3, or 4 independently selected R E substituents;
  • Cy 2 is C&.14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi or 4-14 membered heterocycloalkyl, wherein the Cg-w aryl, Cso 4 cycloalkyl, 5- 14 membered heteroaryi and 4-14 membered heterocycloalkyl of Cy 2 are each optionally substituted with 1, 2, 3, or 4 independently selected R" substituents;
  • each R 32 , R c2 , R d2 , and R a3 is independently selected from H, Ci- 6 alkyl, C1 -6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C & .i 4 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi, and 4-14 membered heterocycloalkyl, wherein the Cj- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cg-w aryl, C3-14 cycloalky l, 5-14 membered heteroaryi, and 4-14 membered heterocycloalkyl of R a2 , R c2 , R d2 , and R a3 are each optionally substituted with 1, 2, 3, or 4 independently selected R° substituents;
  • each R b2 is independently selected from Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ci.-n aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi, and 4-14 membered heterocycloalkyl, wherein the Cj-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Gs-rr aryl, Cs-n cycloaikyd, 5-14 membered heteroaryi, and 4-14 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R° substituents;
  • each R c , R [) , R E , R “ , and R G is independently selected from D, halo, oxo, Ci- 6 alk l, C i-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C3-i 4 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloaikyi, CN, NO2, OR 34 , SR ®4 , NHOR a4 , C(0)R b4 , C(0)NR c4 R d4 , C(0)OR a4 , OC(0)R b4 , 0C(0)NR c4 R d4 , ⁇ R !
  • each R a4 , R c4 , and R d4 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CVw aryl, C-t-u cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, wherein the Cm alkyl, C2-6 alkenyl, C2-6 alkynyl, Cs-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl of R a4 , R c4 , and R d4 are each optionally substituted with 1, 2, 3, or 4 independently selected R H substituents; each R b4 is independently selected from Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C&-14 aryl, €3-14
  • each R e4 is independently selected from H, OH, CN, C .-s alkyl, C .-s alkoxy, Ci- 6 haloalkyl, and C i-shaloalkoxyy
  • each R H is independently selected from D, halo, oxo, Ci- 6 alkyl, Ci-b haloalk l, C2-6 alkenyl, C2-6 alkynyl, C &-J 4 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CN, N0 2 ,
  • NR c5 S(G)2NR c5 R d5 wherein the Ci-6 alkyl, C2.6 alkenyl, C2.6 alkynyl, Ce-i4 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryd, 4-14 membered heterocycloalkyl, of R H are each optionally substituted with 1, 2, 3, or 4 independently selected R 1 substituents; each R 3 ' 5 , R c5 , and R d> is independently selected from H, Cj-b alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C -u cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, wherein the C i-s alkyl, C2-6 alkenyl, C2-6 alkynyl, Cs-w ary!, C 3- w cycloalkyl, 5
  • each R b5 is independently selected from Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, Ci.-w aryl, C 3 -i cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, -wherein the C -e alkyl, C 2-6 alkenyl, C2-6 alkynyl, C b-u aryl, C 3- w cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R 1 substituents;
  • each R 85 is independently selected from H, OH, CN, Ci-e alkyl, Ci-e alkoxy, Ci-e haloalkyl, and Ci-ehaloalkoxy;
  • each R 36 , R cf> , and R d6 is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, €2-6 alkynyl, Ce-w aryl, C J-M cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, wherein the CM alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-w aryl, C 3 -w cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl of R a6 , R CR , and R d6 are each optionally substituted with 1, 2, 3, or 4 independently selected R J substituents; each R b6 is independently selected from Ci « alkyl, Ci « haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C &-J 4 aryl, C 3-i
  • each R e6 is independently selected from H, OH, CN, C .-s alkyl, C .-s alkoxy, Ci- 6 haloalkyl, and C i-ehaloalkoxy;
  • each R 3 is independently selected from D, halo, oxo, C -e alkyl, C -e haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C w aryl, C3- cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CN, N0 2 , OR 37 , SR 37 , NHOR a? , C(0)R b7 , C(0)NR c7 R d7 , C(0)OR a7 ,
  • Ci-6 alkyl, C2.6 alkenyl, C2.6 alkynyi, €5-14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryd, 4-14 membered heterocycloalkyl, of R H are each optionally substituted with 1, 2, 3, or 4 independently selected R K substituents;
  • each R a/ , R e ', and R d ' is independently selected from H, Ci- 6 alkyl, Ci- 6 haloalkyl, C2-6 alkenyl, C2-6 alkynyi, Ce-i + aiyl, C3-14 cycloalkyl, 5-14 membered heteroaryd, and 4-14 membered heterocycloalkyl, wherein the Ci.
  • each R b ' is independently selected from Ci-e alkyl, Ci-e haloalkyl, C2-6 alkenyl, C2-6 alkynyi, Ce-u aryl, fb-ir cycloalkyl, 5-14 membered heteroaiyi, and 4-14 membered heterocycloalkyl, wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyi, Gs-14 aryl, C 3-14 cycloalkyl, 5-14 membered heteroary l, and 4-14 membered heterocycloalkyl,
  • each R e7 is independently selected from H, OH, CN, Ci-e alkyl, Ci-e alkoxy, Ci- & haloalkyl, and Ci-shaloalkoxy;
  • each R K is independently selected from H, D, OH, halo, oxo, CN, C(0)0H, NH 2 , NO 2 , SF 5 , C I-6 alkyl, Ci-e alkoxy, C -ehaloalkoxy, C *- 6 haloalkyl, tb-s alkenyl, C 2-6 alkynyi, C &. 14 aryl, C3-14 cycloalkyl, 5-14 membered heteroaiyi, 4-14 membered heterocycloalkyl; and wherein any heteroaryl group of any of the above-recited substituents optionally comprises an N-oxide on any ring-forming nitrogen.
  • X is CR 3 ;
  • R ! is selected from H and Ci- 6 alkyl
  • R 2 is selected from H, D, C f, -i4 ryl, 5-14 membered heteroaryl, C(0)R bi ,
  • R 3 is selected from H, D, halo, C - & alkyl, Ce-u aryl, 5-14 membered heteroaryd, CN, and OR 33 , wherein the Ci-e alkyl, Ce-w ar l, and 5-14 membered heteroaryd of R 3 are each optionally substituted with 1 , 2, 3, or 4 independently selected R D substituents;
  • Cy 1 is pheny l, optionally substituted with 1, 2, 3, or 4 independently selected R M substituents; or Cy 1 is Cio-u and or 5-14 membered heteroaryd, wherein the C IO-H and and 5- 14 membered heteroaryl of Cy 1 are each optionally substituted with 1, 2, 3, or 4
  • Cy z is Ce-u aryl, C B-M cycloalkyl, 5-14 membered heteroaryl or 4-14 membered heterocycloalkyl, wherein the Ce-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl and 4-14 membered heterocycloalkyl of Cy 2 are each optionally substituted with 1, 2, 3, or 4 independently selected R' substituents;
  • each R 32 , R”, R di , and R a3 is independently selected from H, Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-n aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, wherein the C M alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-war l, C3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl of R 32 , R c2 , R d2 , and R 33 are each optionally substituted with 1, 2, 3, or 4 independently selected R substituents;
  • each R b2 is independently selected from C alkyl, C2-6 alkenyl, C2-6 alkynyl, CM ⁇ » ary l, C3- ! 4 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, wherein the Ci-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C&.14 aryd, C3. 14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R° substituents;
  • each R c , R D , R E , R r , and R° is independently selected from D, halo, oxo, C M alkyl, C2-6 alkenyl C M alkynyl, Ce-u aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, CN, N0 2 , OR 3 , SR 34 , NHOR 34 , C(0)R b4 , C(Q)NR c4 R d4 ,
  • each R M is independently selected from D, halo, oxo, Ci- 6 alk l, C2.6 alkenyl, C2-6 alkynyl, Cw4ai l, C3- W cycloalkyl, 5-14 membered heteroaryl, 4-14 membered
  • NR c4 S(0) 2 NR c4 R d4 wherein the Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, €5-14 aryi, C3..14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl of R M are each optionally substituted with 1, 2, 3, or 4 independently selected R H substituents; each R a+ , R c4 , and R d4 is independently selected from H, Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-i + aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, wherein the Ci-b alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-n aryl, Cs-w cycloalky 1, 5-14 membered heteroaryl, and 4-14 membered
  • each R M is independently selected from C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, C3-! 4 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, wherein the C -e alky l, C2-6 alkenyl, C2-6 alky nyl, Ce-u aryl, €3-5 + cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalk l are each optionally substituted with 1, 2, 3, or 4 independently selected R H substituents;
  • each R s+ is independently selected from H, OH, CN, C-- 6 alky l, C -e alkoxy, C1-6 haloalkyl, and Ci-ehaloalkoxy;
  • each R H is independently selected from D, halo, oxo, Ci-e alkyl, CN, NO2, OR ®5 , SR 33 ,
  • each R a5 , R ®3 , and R ds is independently selected from H, and Ci-b alkyl;
  • each R b3 is independently selected from Ci-e alkyl, C 2 -e alkeny l, C2-6 alkynyl, Ce-n aryl, C3 -14 cycloalkyl, 5-14 membered heteroaryd, and 4-14 membered heterocycloalkyl; and each R e5 is independently selected from H and C - 6 alkyl.
  • X is CR 3 ;
  • R ! is selected from H and C -e alky l
  • R 2 is selected from H, D, Ce-io aryl, 5-10 membered heteroaryl, C(G)R b2 ,
  • R 3 is selected from H, D, halo, C - 6 alkyl, Cwo aiyl, 5-10 membered heteroaryl, CN, and OR 83 , wherein the Ci-b alkyl, Ce-ic. aryl, and 5-10 membered heteroaryl of R 3 are each optionally substituted with 1 , 2, 3, or 4 independently selected 4 ' substituents;
  • Cy ! is pheny l, optionally substituted with 1 , 2, 3, or 4 independently selected R M substituents; or Cy 1 is C10 aryl, 4-10 membered heterocycloalkyl, or 5-10 membered heteroaryl, wherein the C10 aryl, 4-10 membered heterocycloalkyl, and 5-10 membered heteroaryl of Cy 3 are each optionally substituted with 1, 2, 3, or 4 independently selected R substituents; Cy 2 is C b -io aiyl, C3-7 cycloalkyl, 5-10 membered heteroaryl or 4-10 membered heterocycloalkyl, wherein the C b -io aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl and 4-10 membered heteroeyeloalkyl of Cy 2 are each optionally substituted with 1, 2, 3, or 4 independently selected R r substituents;
  • each R 32 , R ci , R d2 , and R 33 is independently selected from H, Ci-s alkyl, C 2 -s alkenyl, C2-6 alkynyl, Ce-io ary l, C3-7 cycloalkyl, 5-10 membered heteroaryi, and 4-10 membered heteroeyeloalkyl, wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-io aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heteroeyeloalkyl of R a2 , R c2 , R d2 , and R 3J are each optionally substituted with 1, 2, 3, or 4 independently selected R G substituents;
  • each R b2 is independently selected from Cw alkyl, C2-6 alkenyl, C2-6 alkynyl, C S-JO aryl, €3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heteroeyeloalkyl, wherein the C , alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-io aryl, C3-7 cycloalkyl, 5-10 membered heteroaryi, and 4-10 membered heteroeyeloalkyl are each optionally substituted with 1 , 2, 3, or 4 independently selected R° substituents;
  • each R c , R D , R E , R" , and R G is independently selected from D, halo, oxo, Cw alkyl, €2-5 alkenyl, C2- S alkynyl, C b -io aryl, C3-7 cycloalkyl, 5-10 membered heteroaryi, 4-10 membered heteroeyeloalkyl, CN, N0 2 , OR !, i . SR 34 , NHOR a4 , C(0)R b4 , C(0)NR c4 R d4 ,
  • each R M is independently selected from D, halo, oxo, Ci-s alkyl, €2-5 alkenyl, C2- S alkynyl, Ce-io aryl, C3-7 cycloaikyl, 5-10 membered heteroaryi, 4-10 membered
  • each R 34 , R c4 , and R d4 is independently selected from H, C M alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-ioatyi, C 3-7 cycloalkyl, 5-10 membered heteroaiyl, and 4-10 membered heteroeyeloalkyl, wherein the C M alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ce- aryl, CV C yclQalky!, 5-10 membered heteroaiyl, and 4-10 membered heterocycloalkyl of R a4 , R c4 , and R d+ are each optionally substituted with 1 , 2, 3, or 4 independently selected R M substituents;
  • each R fc+ is independently selected from Cw alkyl, C 2- e alkenyl, C2-6 alkynyl, C S-JO aryl, C3.7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, wherein the Cj- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Cs-io aryl, C3-7 cycloalkyl, 5-10 membered heteroaiyl, and 4-10 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R ri substituents;
  • each R 84 is independently selected from H, OH, CN, Ci-e alky l, Ci-e alkoxy, Ci-e haloalkyl, and Ci-ehaloalkoxy;
  • each R H is independently selected from D, halo, oxo, C - 6 alkyl, CN, NO2, OR 35 , SR a' , NHOR 35 , C(0)R b5 , C(0)NR c5 R d5 , C(0)OR a5 , OC(0)R b5 , 0C(0)NR c5 R d5 , NR c5 R d5 ,
  • each R a ⁇ R c y and R ds is independently selected from H, and Ci-b alkyl;
  • each R to is independently selected from Cs- 6 alkyl, C 2-& alkenyl, C2-6 alkynyl, C 10 aryl, C3 -10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl; and each R e5 is independently selected from H and C - 6 alkyl.
  • X is N
  • R 1 is selected from H, C - 6 alkyl, and a 5-14 membered heteroaryl, wherein the Ci-e alkyl and a 5-14 membered heteroaryl are each optionally substituted with 1, 2, or 3 independently selected R B substituents;
  • R 2 is selected from H, D, Ci- 6 alkyl, Ce-uaryl, 5-14 membered heteroaryl, 4-14 membered heterocycloalkyl, Cs-ir ary l-Ci-e alkyl-, (5-14 membered heteroaryi)-Ci-6 alkyl-, ( - 14 membered heterocycloalkyl)-C ] ⁇ alkyl-, NR ⁇ R ⁇ .CCOiR 02 , C(0)NR c2 R d2 , and C(0)OR a2 , wherein the Ci-e alkyl, Ce- aryl, 5-14 membered heteroaryl, 4-14 membered
  • heterocycloalkyl C M ar I-C1- & alkyl-, (5-14 membered heteroar l) -C -6 alkyl-, (4-14 membered heterocycloalkyi)-Ci- 6 alkyl- of R 2 are each optionally substituted with 1, 2, 3, or 4 independently selected R c substituents;
  • Cy ! is pheny l, optionally substituted with 1, 2, 3, or 4 independently selected R M substituents, or Cio-u aryl or 5-14 membered heteroaryl, wherein the C IO-M aryl and 5-14 membered heteroaryi of Cy !
  • Cy 2 is Ce-i+ aiyl, C3-14 cycloalkyl, 5-14 membered heteroaryi or 4-14 membered heterocycloalkyl, wherein the CVi aiyi, C3-14 cycloalkyl, 5-14 membered heteroaryl and 4-14 membered heterocycloalkyl of Cy 2 are each optionally substituted with 1, 2, 3, or 4 independently selected R r substituents;
  • each R 32 , R ci , and R d2 is independently selected from H, C 1-5 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-n aryl, Ce-ir aryl-C -.e alkyl-, C S-M cycloalkyl, 5-14 membered heteroaryi, and 4-14 membered heterocy cloalkyl, wherein the Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-i+aiyl, C M aryl-Ci-6 alkyl-, C3- M cycloalkyl, 5-14 membered heteroaryi, and 4-14 membered
  • heterocycloalkyl of R 32 , R ci , and R 02 are each optionally substituted with 1, 2, 3, or 4 independently selected R° substituents;
  • each R b2 is independently selected from C1-6 alkyl, C2-6 alkeny l, C2-6 alkynyl, Ce-n aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi, and 4-14 membered heterocycloalkyl, wherein the Ci-e alkyl, C2-6 alkenyl, C 2-6 alkynyl, C S-M aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi, and 4-14 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 independently selected R u substituents;
  • each R b , R c , R , R b , and R G is independently selected from D, halo, oxo, C1.6 alkyl, C2-6 alkenyl, C 2-6 alkynyl, Ce-w aryl, C3-14 cycloalkyl, 5-14 membered heteroaryi, 4-14 membered heterocycloalkyl, CN, N0 2 , OR 34 , SR ®4 , NHOR ®4 , C(0)R M , C(0)NR c4 R d4 ,
  • each R M is independently selected from D, halo, oxo, Cs- 6 alkyl, C 2-6 alkenyl, C2-6 alkynyl, Ck-i+ aryl, C3-14 cycloalky 1, 5-14 membered heteroaryi, 4-14 membered
  • NR c S(0) 2 NR c R d4 wherein the Cs- 6 alkyl, C2-6 alkenyl, C 2-6 alkynyl, CVw axyl, C3- M cycloalkyl, 5-14 membered heteroaryi, and 4-14 membered heterocycloalky 1 of R M are each optionally substituted with 1 , 2, 3, or 4 independently selected R H substituents;
  • each R 34 , R c+ , and R d4 is independently selected from H, Ci- 6 alkyl, C 2-6 alkenyl, C2-6 alkynyl, C f, - 4 aiyl, C3-i 4 cycioalkyl, 5-14 membered heteroaryd, and 4-14 membered heterocycloalkyl, wherein the Ci-e alkyl, C2-6 alkenyl, C2-6 alkynyl, Ce-waxyl, €3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl of R 34 , R 64 , and R d4 are each optionally substituted with 1, 2, 3, or 4 independently selected R H substituents;
  • each R M is independently selected from Ci « alkyl, C 2 « alkenyl, C2-6 alkynyl, Ce-14 a d, Cs- 14 cycloalkyl 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, wherein the C -6 alkyl, C2-6 alkenyl, C 2 -6 alkynyl, CS- M aryl, Cs- cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl are each optionally substituted with 1 , 2, 3, or 4 independently selected R ri substituents;
  • each R e4 is independently selected from H, OH, CN, Cue alkyl, Ci-e alkoxy , Ci-e haloalkyl, and Ci-ehaloalkoxy;
  • each R M is independently selected from D, halo, oxo, Cue alkyl, CN, NO2, OR a> , SR 35 , NHOR a5 , C(0)R b5 , C(0)NR c5 R d5 , C(0)OR a5 , OC(0)R b5 , 0C(0)NR c 3 ⁇ 4 d5 , NR c5 R d5 ,
  • each R 3 , R c5 , and R d5 is independently selected from H, and Cs- 6 alkyl;
  • each R b5 is independently selected from Ci- 6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C S-M aryl, C3-! 4 cycloalky 1, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl; and each R e5 is independently selected from H and Ci- 6 alkyl.
  • X is N
  • R 1 is H or a 5-14 membered heteroaryl optionally substituted with 1, 2, or 3 independently selected R B substituents;
  • R 2 is selected Ci- 6 alkyl, 4-14 membered heterocycloalkyl, C f r.34 ary I-C1-6 alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, (4-14 membered heterocycloalkyl)-C 1-5 alkyl-, and NR c2 R d2 , wherein the C - 6 alkyl, 4-14 membered heterocycloalkyl, Ce-ir aryd-C i-b alkyl-, (5-14 membered heteroaryl)-Ci-6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci..6 alkyl- of R 2 are each optionally substituted with 1, 2, or 3 independently selected R c substituents;
  • Cy ! is phenyl optionally substituted with 1, 2, or 3 independently selected R' substituents
  • Cy 2 is 5-14 membered heteroaryl optionally substituted with 1 , 2, or 3 independently selected R r substituents.
  • X is N; R ! IS H or a 5-14 membered heteroaryl optionally substituted with 1, 2, or 3 independently selected R H substituents;
  • each R B is independently selected from D, halo, oxo, C - 6 alkyl, C - 6 haloalkyi, C2-6 alkenyl, CN, NO2 and OH;
  • R 2 is selected C i-s alkyl, 4-14 membered heterocycloalkyl, Ce-u ary l-Ci- 6 alkyl-, (5-14 membered heteroaryl)-Ci ⁇ alkyl-, (4-14 membered heterocycloalky 1)-C i-b alkyl-, and NR“R d/ ⁇ , wherein the Ci-e alkyl, 4-14 membered heterocycloalkyl, Ce-i4 ary 1-Ci-e, alkyl-, (5-14 membered heteroaryl)-Ci- 6 alkyl-, and (4-14 membered heterocycloalkyl)-Ci- 6 alkyl- of R 2 are each optionally substituted with 1, 2, or 3 independently selected R c substituents;
  • each R c2 and R d2 are independently selected from H, C i-s alkyl, Ce-w aiyl-Ci- 6 alkyl-, wherein the C -e alky l and Ce-u ary I-C1-6 alkyl- of R c2 and R d2 are each optionally substituted with 1, 2, or 3 independently selected R u substituents;
  • each R c is independently selected from D, halo, oxo, C - 6 alkyl, C 6 -i4 aryl, C3-14 cycloalkyl, 5-14 membered heteroaryl, 4-14 membered heteroc cloalk l, OR 34 , C(0)NR c4 R d4 and NR c4 R d4 , wherein the Ci-e alkyl, C 6 -w aryl, €3-14 cycloalkyl, 5-14 membered heteroaryl, and 4-14 membered heterocycloalkyl, of R c is optionally substituted with 1, 2, or 3 independently selected R H substituents;
  • each R 84 , R c4 , and R d4 is independently selected from H, Ci-b alkyl, Cj- 6 haloalkyi, C2-6 alkenyl, and 5-14 membered heteroaryl, wherein the Ci-b alkyl, C2-6 alkenyl, and 5-14 membered heteroaryl, of R ®4 , R 0 *, and R d are each optionally substituted with 1 , 2, or 3 independently selected R d substituents;
  • each R G is independently selected from D, halo, oxo, Ci-e alkyl, CN, NO2, and OH;
  • Cy 1 is phenyl optionally substituted with 1, 2, or 3 independently selected R substituents
  • each R E is independently selected from D, halo, oxo, Ci-e alkyl, CN, O2 and OH;
  • Cy 2 is 5-14 membered heteroaryl optionally substituted with 1, 2, or 3 independently selected R r substituents;
  • each R* is independently selected from D, halo, oxo, Ci- 6 alkyl, C2-6 alkenyl, CN,
  • each R 34 is independently selected from H, Ci- 6 alkyl and Ci-b alkoxy; and each R H is independently selected from D, halo, oxo, CVe alkyl, CN, NO and OH.
  • X is N; R ! IS H or a 5-10 membered heteroaryl optionally substituted with 1, 2, or 3 independently selected R H substituents;
  • each R B is independently selected from D, halo, oxo, C - 6 alkyl, C - 6 haloalkyi, C2-6 alkenyl, CN, NO2 and OH;
  • R 2 is selected Ci-s alkyl, 4-10 membered heterocycloalkyl, Cs-io ary l-Ci- 6 alkyl-, (5-10 membered heteroaryl)-Ci ⁇ alkyl-, (4-10 membered heterocycloalkyl)-Ci-6 alkyl-, and NR“R d/ ⁇ , wherein the Ci-e alkyl, 4-10 membered heterocycloalkyl, Ce-io ary 1-Ci-e, alkyl-, (5-10 membered heteroaryl)-Ci- 6 alkyl-, and (4-10 membered heterocycloalkyl)-Ci- 6 alkyl- of R 2 are each optionally substituted with 1, 2, or 3 independently selected R c substituents;
  • each R c2 and R d2 are independently selected from H, Ci-s alkyl, CV10 asyl-Ci- 6 alkyl-, wherein the C -e alkyl and Ce-io ary l-Ci- 6 alkyl- of R c2 and R d2 are each optionally substituted with 1, 2, or 3 independently selected R u substituents;
  • each R c is independently selected from D, halo, oxo, C - 6 alkyl, C 6 -io aryl, C 3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heteroc cloalk l, OR 34 , C(0)NR c4 R d4 and NR c4 R d4 , wherein the Ci-e alkyl, C 6 -io aryl, C3- ? cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, of R c is optionally substituted with 1, 2, or 3 independently selected R rf substituents;
  • each R 84 , R c4 , and R d4 is independently selected from H, Cj-b alkyl, Ci-e haloalkyi, C2-6 alkenyl, and 5-10 membered heteroaryl, wherein the Ci-b alkyl, C2-6 alkenyl, and 5-10 membered heteroaryl, of R ®4 , R 0 *, and R d4 are each optionally substituted with 1, 2, or 3 independently selected R d substituents;
  • each R G is independently selected from D, halo, oxo, Ci-e alkyl, CN, NO2, and OH;
  • Cy 1 is phenyl optionally substituted with 1, 2, or 3 independently selected R substituents
  • each R E is independently selected from D, halo, oxo, Ci-e alkyl, CN, O2 and OH;
  • Cy 2 is 5-10 membered heteroaryl optionally substituted with 1, 2, or 3 independently selected R r substituents;
  • each R* is independently selected from D, halo, oxo, Ci- 6 alkyl, C2-6 alkenyl, CN,
  • each R 34 is independently selected from H, Ci- 6 alkyl and Ci-b alkoxy; and each R H is independently selected from D, halo, oxo, CVe alkyl, CN, NO and OH.
  • X is N; R ! is H or nicotinonitriie;
  • R 2 is pyridinylmethyl, hydroxy(phenyl)methyl, hydroxyetiiylamino(phenyl)ethyl, cyelohexyimethyi, fluorobenzyl, hydroxy (fluorophenyl)methyl, methylpyridinylmetliyl, fluoropyridinylmethyl, melhoxypyridinylmethyl, methylpyrazolylbenzyl- benzoisoxazolylmethyl, methylindazoly!methyl, hydroxyazetidinylmethyl, benzoyl, phenyicyclopropyl, cyano(phenyl)methylamino, tetrahydrofuranyl, or phenyl(pyridin-2- yloxy)methy5;
  • Cy ! is cyanophenyl
  • Cy 2 is pyrimidinyl, eth lpyrazolyl propylpyrazol l, quinolinyl, iluoropyrimidinyl, pyridinyl, methylpyridinyl, methoxy-methylpyridinyl, pyrazolopyridazinyl, methyloxazolyl, hydroxymethyl-methyloxazolyl, or methoxymethyl-methyloxazolyl.
  • X is N
  • R* is H
  • R 2 is selected from pyridin-2-ylmethyl, hydroxy(phenyl)methyl, (2 ⁇
  • Cy 1 is cyanophenyl
  • Cy 2 is selected from 2,6-dimethylpyridin-4-yl, pyridin-4-yl, 2-methylpyridin-4-yl, 1- carbamoyl- 1 ,2,3,6-tetrahydrop ridin-4-yl, l-carbamoylpiperidin-4-yl, 2-methoxypyridin-4-yl, 2-meihoxy-6 ⁇ methylpyridin-4-yl, 2,6 ⁇ dimethyipyridin-4 ⁇ yT ⁇ l-oxide, l-ethyl-6-oxo-l,6- dihydropyridin-3-yl, 3-methylpyridin-4-yl, 3-fluoropyridin-4-yl, 3-chloropyridin-4-yl, 3- methoxypyridin-4-y 1, 3 -cyanopyridin -4-yl, 4-carbamoy lpheny 1 , pyrazolo[ 1,5 -a ⁇ pyridin -3 -yl,
  • the compound is the (S) -enantiomer of one of the preceding compounds, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is the (R) -enantiomer of one of the preceding compounds, or a pharmaceutically acceptable salt thereof.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PCT/US2019/019582 2018-02-27 2019-02-26 Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors Ceased WO2019168847A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
MX2020008949A MX2020008949A (es) 2018-02-27 2019-02-26 Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
PE2020001285A PE20211001A1 (es) 2018-02-27 2019-02-26 Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
EP19713602.1A EP3759112A1 (en) 2018-02-27 2019-02-26 Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
IL276873A IL276873B2 (en) 2018-02-27 2019-02-26 Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
PE2024003132A PE20251291A1 (es) 2018-02-27 2019-02-26 Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b
BR122023024273-4A BR122023024273A2 (pt) 2018-02-27 2019-02-26 Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
CR20230030A CR20230030A (es) 2018-02-27 2019-02-26 Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441)
CA3092470A CA3092470A1 (en) 2018-02-27 2019-02-26 Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
BR112020017421-1A BR112020017421A2 (pt) 2018-02-27 2019-02-26 Imidazopirimidinas e triazolopirimidinas como inibidores de a2a/a2b
CN202311603774.9A CN117903140A (zh) 2018-02-27 2019-02-26 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
JP2020567459A JP7474709B2 (ja) 2018-02-27 2019-02-26 Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
CN201980027624.3A CN112384515B (zh) 2018-02-27 2019-02-26 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
KR1020207027865A KR20200139153A (ko) 2018-02-27 2019-02-26 A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
IL303087A IL303087B2 (en) 2018-02-27 2019-02-26 Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
EA202092016A EA202092016A1 (ru) 2019-01-16 2019-02-26 Имидазопиримидины и триазолопиримидины в качестве ингибиторов a2a/a2b
CR20200441A CR20200441A (es) 2018-02-27 2019-02-26 Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
AU2019227607A AU2019227607C1 (en) 2018-02-27 2019-02-26 Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
PH12020551332A PH12020551332A1 (en) 2018-02-27 2020-08-26 Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
CONC2020/0011908A CO2020011908A2 (es) 2018-02-27 2020-09-25 Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b
AU2022283611A AU2022283611B2 (en) 2018-02-27 2022-12-05 Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
JP2023096889A JP7624476B2 (ja) 2018-02-27 2023-06-13 Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862635926P 2018-02-27 2018-02-27
US62/635,926 2018-02-27
US201862718216P 2018-08-13 2018-08-13
US62/718,216 2018-08-13
US201862721312P 2018-08-22 2018-08-22
US62/721,312 2018-08-22
US201962793015P 2019-01-16 2019-01-16
US62/793,015 2019-01-16

Publications (1)

Publication Number Publication Date
WO2019168847A1 true WO2019168847A1 (en) 2019-09-06

Family

ID=65911247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/019582 Ceased WO2019168847A1 (en) 2018-02-27 2019-02-26 Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors

Country Status (19)

Country Link
US (4) US20190292188A1 (https=)
EP (1) EP3759112A1 (https=)
JP (2) JP7474709B2 (https=)
KR (1) KR20200139153A (https=)
CN (2) CN112384515B (https=)
AU (2) AU2019227607C1 (https=)
BR (2) BR122023024273A2 (https=)
CA (1) CA3092470A1 (https=)
CL (2) CL2020002198A1 (https=)
CO (1) CO2020011908A2 (https=)
CR (2) CR20230030A (https=)
EC (1) ECSP20060827A (https=)
IL (2) IL303087B2 (https=)
MA (1) MA52422A (https=)
MX (2) MX2020008949A (https=)
PE (2) PE20211001A1 (https=)
PH (1) PH12020551332A1 (https=)
TW (2) TWI877770B (https=)
WO (1) WO2019168847A1 (https=)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020052631A1 (en) * 2018-09-12 2020-03-19 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Triazolo-pyrimidine compounds and uses thereof
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020106558A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020108590A1 (zh) * 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN111362939A (zh) * 2020-04-26 2020-07-03 济南磐石医药科技有限公司 一种帕布昔利布母核结构化合物的制备方法
EP3575301A4 (en) * 2017-03-16 2020-08-05 Jiangsu Hengrui Medicine Co., Ltd. HETEROARYL [4,3-C] PYRIMIDINE-5-AMINE DERIVATIVE, PROCESS FOR PREPARATION AND MEDICAL USES
WO2020159905A1 (en) * 2019-01-29 2020-08-06 Incyte Corporation Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
EP3611174A4 (en) * 2017-04-07 2020-09-09 Medshine Discovery Inc. [1,2,4] TRIAZOLO [1,5-C] PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR
WO2021041360A1 (en) * 2019-08-26 2021-03-04 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
WO2021138498A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
WO2021138512A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
WO2021156439A1 (en) * 2020-02-06 2021-08-12 Astrazeneca Ab Triazole compounds as adenosine receptor antagonists
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
WO2022147092A1 (en) 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
WO2023091604A1 (en) * 2021-11-19 2023-05-25 Crossignal Therapeutics, Inc. Adenosine receptor antagonists
US11673894B2 (en) 2018-02-27 2023-06-13 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
US12018089B2 (en) 2020-01-03 2024-06-25 Incyte Corporation Anti-CD73 antibodies and uses thereof
US12606564B2 (en) 2019-11-19 2026-04-21 Ildong Pharmaceutical Co., Ltd. Adenosine receptor antagonist compounds

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111163780A (zh) 2017-07-18 2020-05-15 诺维逊生物股份有限公司 作为腺苷拮抗剂的杂环化合物
CA3070073A1 (en) 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
CA3124088A1 (en) 2018-12-20 2020-06-25 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
AU2020208644A1 (en) 2019-01-18 2021-08-26 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
CN119365461A (zh) * 2022-06-23 2025-01-24 成都恒昊创新科技有限公司 一种非螯合性非还原性铁死亡抑制剂及其制备方法和用途
KR102621694B1 (ko) * 2022-09-15 2024-01-08 주식회사 스탠다임 아데노신 a2a 수용체 길항제 및 이의 용도
CN120022278A (zh) * 2023-11-22 2025-05-23 英诺湖医药(杭州)有限公司 用于治疗癌症的化合物

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP0976753A1 (en) * 1997-03-24 2000-02-02 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
WO2000053595A1 (en) 1999-03-06 2000-09-14 Astrazeneca Ab Pyrimidine compounds
WO2001014402A1 (en) 1999-08-19 2001-03-01 Isis Pharmaceuticals, Inc. Antisense modulation of focal adhesion kinase expression
WO2001064655A1 (en) 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
WO2002000196A2 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
WO2003037347A1 (en) 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003044021A2 (en) * 2001-11-16 2003-05-30 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2003048164A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Adenosine a2a receptor antagonists
WO2003099771A2 (en) 2002-05-29 2003-12-04 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2004005281A1 (en) 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
WO2004046120A2 (en) 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles useful as inhibitors of protein kinases
WO2004056786A2 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivates for the treatment of abnormal cell growth
WO2004080980A1 (en) 2003-03-14 2004-09-23 Novartis Ag 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2005028444A1 (en) 2003-09-24 2005-03-31 Novartis Ag 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
EP1544200A1 (en) * 2002-09-24 2005-06-22 Kyowa Hakko Kogyo Co., Ltd. 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE
WO2018166493A1 (zh) * 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
WO2018184590A1 (zh) * 2017-04-07 2018-10-11 南京明德新药研发股份有限公司 作为A 2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物

Family Cites Families (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
DE19629378A1 (de) 1996-07-20 1998-01-29 Boehringer Ingelheim Kg Neue Triazolopurine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2000017201A1 (en) 1998-09-22 2000-03-30 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
JP5004390B2 (ja) 1999-08-23 2012-08-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 新規ｂ７−４分子およびその用途
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
AU2001259142C1 (en) 2000-04-25 2006-11-23 Biogen Idec Inc. Intrathecal administration of rituximab for treatment of central nervous system lymphomas
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
CN1446202A (zh) * 2000-08-11 2003-10-01 卫材株式会社 2－氨基吡啶化合物及其作为药物的用途
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
EP1406611A2 (en) 2001-05-30 2004-04-14 Alteon, Inc. Method for treating fibrotic diseases or other indications
WO2002096318A2 (en) 2001-05-30 2002-12-05 Alteon, Inc. Method for treating glaucoma v
US20030143199A1 (en) 2001-10-09 2003-07-31 Carson Dennis A. Use of STAT-6 inhibitors as therapeutic agents
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
JPWO2003068776A1 (ja) 2002-02-15 2005-06-02 協和醗酵工業株式会社 ［１，２，４］トリアゾロ［１，５−ｃ］ピリミジン誘導体
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
WO2004079013A1 (en) 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
RU2366655C2 (ru) 2003-03-14 2009-09-10 Оно Фармасьютикал Ко., Лтд. Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004092172A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
WO2004092173A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
WO2004092177A1 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
KR20060037252A (ko) 2003-06-10 2006-05-03 교와 핫꼬 고교 가부시끼가이샤 불안 장애의 치료 방법
EP1639014B1 (en) 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
AU2004265101B2 (en) 2003-08-14 2009-06-11 F. Hoffmann-La Roche Ag Gabanergic modulators
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
GB0403819D0 (en) 2004-02-20 2004-03-24 Merck Sharp & Dohme New compounds
ES2328047T3 (es) 2004-03-19 2009-11-06 Warner-Lambert Company Llc Derivados de imidazopiridina e imidazopirimidina como agentes antibacterianos.
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
CA2571675A1 (en) 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
AU2005260031B2 (en) 2004-06-25 2008-10-09 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2583741C (en) 2004-10-15 2014-10-14 Verisign, Inc. An algorithm to create and validate a one time password
US20060211739A1 (en) 2005-02-08 2006-09-21 Arturo Perez-Medrano Use of selective P2X7 receptor antagonists
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
WO2006125140A2 (en) 2005-05-18 2006-11-23 Biogen Idec Inc. Methods for treating fibrotic conditions
WO2006129626A1 (ja) 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
EP2258372B8 (en) 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
JP4986451B2 (ja) 2005-06-30 2012-07-25 信一郎 礒部 マーキング剤
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
WO2007011759A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
US20070117804A1 (en) 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors
ES2365869T3 (es) 2005-11-17 2011-10-11 OSI Pharmaceuticals, LLC COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR.
EP2010505B1 (en) 2006-03-28 2012-12-05 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
PT2029602E (pt) 2006-05-31 2010-07-08 Galapagos Nv Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias
EP2049518B1 (en) 2006-05-31 2011-08-31 Takeda San Diego, Inc. Indazole and isoindole derivatives as glucokinase activating agents.
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
MX2009000170A (es) 2006-06-23 2009-01-23 Incyte Corp Derivados de purinona como agonistas de hm74a.
JP5382692B2 (ja) 2006-07-10 2014-01-08 学校法人藤田学園 抗体の分類法、抗原の同定法、抗体又は抗体セットの取得法、抗体パネルの作成法、並びに抗体又は抗体セット及びその用途
AU2007275221A1 (en) 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
DE102006041292A1 (de) 2006-09-01 2008-03-06 Henkel Kgaa Wasserstoffperoxid-Aktivierung mit N-Heterocyclen
WO2008037607A1 (de) 2006-09-25 2008-04-03 Basf Se Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
US7825261B2 (en) 2006-12-05 2010-11-02 National Taiwan University Indazole compounds
DE102007012645A1 (de) 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
WO2008124153A1 (en) 2007-04-10 2008-10-16 H. Lundbeck A/S Heteroaryl amide analogues as p2x7 antagonists
US8039505B2 (en) 2007-04-11 2011-10-18 University Of Utah Research Foundation Compounds for modulating T-cells
ES2395583T3 (es) 2007-05-10 2013-02-13 Ge Healthcare Limited IMIDAZOL (1,2-A)PIRIDINAS y compuestos relacionados con actividad frente a los receptores cannabinoides CB2
WO2008138843A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyridines and triazolopyrimidines useful for the treatment of joint degenerative & inflammatory diseases
HUP0700395A2 (en) 2007-06-07 2009-03-02 Sanofi Aventis Substituted [1,2,4] triazolo [1,5-a] quinolines, process for their preparation, pharmaceutical compositions thereof, and intermediates
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
CA2693232A1 (en) 2007-07-18 2009-01-22 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
CA2695989A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
BRPI0818003A2 (pt) 2007-10-18 2019-09-24 Novartis Ag inibidores de csf-1r, composições e métodos de uso
US20090118301A1 (en) 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
EP2217069A4 (en) 2007-11-09 2012-03-14 Salk Inst For Biological Studi INHIBITORS OF NON-NUCLEOSIDE INHIBITORS OF THE REVERSE TRANSCRIPTASE
PE20091074A1 (es) 2007-12-13 2009-07-26 Bayer Healthcare Ag Triazolotriazinas y triazolopirazinas y su uso
AU2008343813B2 (en) 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
EA201001030A1 (ru) 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5620365B2 (ja) 2008-03-21 2014-11-05 エンソン インコーポレイテッド 多官能分子システムを用いた積層体への金属の接着促進
US20090281089A1 (en) 2008-04-11 2009-11-12 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
EP2277881A4 (en) 2008-04-18 2011-09-07 Shionogi & Co HETEROCYCLIC COMPOUND HAVING INHIBITORY ACTIVITY ON P13K
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
KR20110040856A (ko) 2008-07-23 2011-04-20 교와 핫꼬 기린 가부시키가이샤 편두통 치료제
WO2010032874A1 (ja) 2008-09-19 2010-03-25 住友化学株式会社 農業用組成物
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
US8546405B2 (en) 2008-12-23 2013-10-01 Abbott Laboratories Anti-viral compounds
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
KR20100101055A (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동 관련 질환의 치료 또는 예방용 약학적 조성물
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
EP2509983B1 (en) 2009-11-16 2014-09-17 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011078143A1 (ja) 2009-12-22 2011-06-30 塩野義製薬株式会社 ピリミジン誘導体およびそれらを含有する医薬組成物
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
EP2347769A1 (en) 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
CA2793086C (en) 2010-03-18 2018-08-21 Institut Pasteur Korea Substituted imidazo[1,2-a]pyridine compounds and their use in the treatment of bacterial infections
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
GB201007187D0 (en) 2010-04-29 2010-06-09 Iti Scotland Ltd Ubiquitination modulators
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
US20120083498A1 (en) 2010-06-17 2012-04-05 Fatah Kashanchi Modulators of Viral Transcription, and Methods and Compositions Therewith
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EA201300282A1 (ru) 2010-08-27 2013-08-30 Мерк Патент Гмбх Производные триазолопиразина
MX338327B (es) 2010-10-25 2016-04-12 G1 Therapeutics Inc Inhibidores de cdk.
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
EP2604265A1 (en) 2011-12-17 2013-06-19 Royal College of Surgeons in Ireland (RCSI) P2x7 antagonists as frontline or adjunctive treatment against status epilepticus
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
PE20142366A1 (es) 2012-05-30 2015-01-10 Hoffmann La Roche Compuestos triazolo como inhibidores de pde 10
EP2865671B1 (en) 2012-06-22 2017-11-01 Sumitomo Chemical Company, Ltd Fused heterocyclic compound
JP2015528013A (ja) 2012-07-27 2015-09-24 ビアル−ポルテラ エ コンパニア，ソシエダッド アノニマ 置換ウレア化合物の合成方法
CA2890897A1 (en) 2012-11-14 2014-05-22 The Board Of Regents Of The University Of Texas System Inhibition of hif-2.alpha. heterodimerization with hif 1.beta. (arnt)
WO2014126580A1 (en) 2013-02-15 2014-08-21 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
EP3495357B1 (en) 2013-03-14 2021-05-05 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
US9975896B2 (en) 2013-07-25 2018-05-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
RU2715038C2 (ru) 2014-07-11 2020-02-21 Дженентек, Инк. Антитела анти-pd-l1 и способы их диагностического применения
KR20170095814A (ko) 2014-10-06 2017-08-23 플랫틀리 디스커버리 랩, 엘엘씨 트라이아졸로피리딘 화합물 및 낭성 섬유증의 치료 방법
EP3204417B1 (en) 2014-10-10 2020-07-22 Innate Pharma Cd73 blockade
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
GB2537445A (en) 2014-11-10 2016-10-19 Medimmune Ltd Binding molecules specific for CD73 and uses thereof
GB2538120A (en) 2014-11-11 2016-11-09 Medimmune Ltd Therapeutic combinations comprising anti-CD73 antibodies and uses thereof
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
AU2016216963B2 (en) 2015-02-12 2020-04-30 Nissan Chemical Corporation Condensed heterocyclic compounds and pesticides
AU2016229268B2 (en) 2015-03-06 2020-09-10 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
WO2017070089A1 (en) 2015-10-19 2017-04-27 Incyte Corporation Heterocyclic compounds as immunomodulators
SG10202004618TA (en) 2015-11-19 2020-06-29 Incyte Corp Heterocyclic compounds as immunomodulators
CN114805575B (zh) 2015-12-09 2024-07-23 科尔沃斯制药股份有限公司 人源化抗cd73抗体
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3393475B1 (en) 2015-12-24 2025-02-05 Corvus Pharmaceuticals, Inc. Ciforadent alone or in combination with atezolizumab for use in treating cancer
CN109071546B (zh) 2016-02-24 2021-03-02 辉瑞大药厂 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
HUE060256T2 (hu) 2016-06-20 2023-02-28 Incyte Corp Heterociklusos vegyületek mint immunmodulátorok
US10138248B2 (en) * 2016-06-24 2018-11-27 Incyte Corporation Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
WO2018004478A1 (en) 2016-06-29 2018-01-04 Hayat Kimya San. A. Ş. An improved method of soft nonwoven fabric production
WO2018013611A1 (en) 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018044783A1 (en) 2016-08-29 2018-03-08 Incyte Corporation Heterocyclic compounds as immunomodulators
SI3507291T1 (sl) 2016-09-02 2021-11-30 Cyclerion Therapeutics, Inc. Kondenzirani biciklični SGS stimulatorji
RU2754058C2 (ru) 2016-12-13 2021-08-26 Астеллас Фарма Инк. Антитело к cd73 человека
LT3558990T (lt) 2016-12-22 2022-12-27 Incyte Corporation Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
US20180179202A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
WO2018119221A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
JP7101678B2 (ja) 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
US20210107989A1 (en) 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
US11530273B2 (en) 2017-05-23 2022-12-20 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Anti-CD73 monoclonal antibody, encoding nucleic acids and method for producing
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
MY204117A (en) 2017-06-22 2024-08-08 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
WO2019002606A1 (en) 2017-06-30 2019-01-03 Selvita S.A. ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS
CN109535161B (zh) * 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
WO2019081353A1 (de) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Substituierte imidazopyridinamide und ihre verwendung
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
PE20211455A1 (es) 2018-01-31 2021-08-05 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
CN117186134A (zh) 2018-02-17 2023-12-08 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
WO2019170131A1 (zh) 2018-03-07 2019-09-12 复旦大学 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
EP3762030A4 (en) 2018-03-09 2022-01-05 Phanes Therapeutics, Inc. ANTI-CD73 ANTIBODIES AND USES THEREOF
WO2019173692A2 (en) 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
SMT202500157T1 (it) 2018-03-30 2025-05-12 Incyte Corp Composti eterociclici come immunomodulatori
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
BR112020020826A2 (pt) 2018-04-12 2021-01-19 Bristol-Myers Squibb Company Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
HUE061503T2 (hu) 2018-05-11 2023-07-28 Incyte Corp Tetrahidro-imidazo[4,5-C]piridin-származékok mint PD-L1 immunmodulátorok
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
US12448448B2 (en) 2018-06-20 2025-10-21 Incyte Corporation Anti-PD-1 antibodies and uses thereof
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
AU2019322161A1 (en) 2018-08-13 2020-11-12 F. Hoffmann-La Roche Ag New heterocyclic compounds as monoacylglycerol lipase inhibitors
PE20211089A1 (es) 2018-08-13 2021-06-14 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
MA53427B1 (fr) 2018-08-22 2024-06-28 Astrazeneca Ab Inhibiteurs de l'arginase et leurs méthodes d'utilisation
AR116315A1 (es) * 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
CN111295384B (zh) 2018-10-10 2022-08-12 江苏豪森药业集团有限公司 双环类衍生物抑制剂、其制备方法和应用
UY38437A (es) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020108613A1 (zh) 2018-11-30 2020-06-04 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩
PE20230372A1 (es) 2019-08-26 2023-03-06 Incyte Corp Triazolopirimidinas como inhibidores de a2a/a2b
PE20221038A1 (es) 2019-09-30 2022-06-17 Incyte Corp Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores
CA3160131A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
PE20221409A1 (es) 2020-01-03 2022-09-20 Incyte Corp Anticuerpos anti-cd73 y usos de estos
US20210205311A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
CR20230230A (es) 2020-11-06 2023-07-27 Incyte Corp Proceso para hacer un inhibidor de pd-1/pdl1 y sales y formas cristalinas del mismo
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
TW202241441A (zh) 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
EP0976753A1 (en) * 1997-03-24 2000-02-02 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
WO2000053595A1 (en) 1999-03-06 2000-09-14 Astrazeneca Ab Pyrimidine compounds
WO2001014402A1 (en) 1999-08-19 2001-03-01 Isis Pharmaceuticals, Inc. Antisense modulation of focal adhesion kinase expression
WO2001064655A1 (en) 2000-03-01 2001-09-07 Astrazeneca Ab 2, 4-di(hetero-)arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
WO2002000196A2 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
WO2003024967A2 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
WO2003037347A1 (en) 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003044021A2 (en) * 2001-11-16 2003-05-30 Amgen Inc. Substituted indolizine-like compounds and methods of use
WO2003048164A2 (en) * 2001-11-30 2003-06-12 Schering Corporation Adenosine a2a receptor antagonists
WO2003099771A2 (en) 2002-05-29 2003-12-04 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2004005281A1 (en) 2002-07-05 2004-01-15 Novartis Ag Inhibitors of tyrosine kinases
EP1544200A1 (en) * 2002-09-24 2005-06-22 Kyowa Hakko Kogyo Co., Ltd. 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE
WO2004046120A2 (en) 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles useful as inhibitors of protein kinases
WO2004056786A2 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivates for the treatment of abnormal cell growth
WO2004080980A1 (en) 2003-03-14 2004-09-23 Novartis Ag 2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
WO2005028444A1 (en) 2003-09-24 2005-03-31 Novartis Ag 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
WO2018166493A1 (zh) * 2017-03-16 2018-09-20 江苏恒瑞医药股份有限公司 杂芳基并[4，3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
WO2018184590A1 (zh) * 2017-04-07 2018-10-11 南京明德新药研发股份有限公司 作为A 2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
A. KEREKES, J. MED. CHEM., vol. 2011, no. 54, pages 201 - 210
ALAN F. THOMAS: "Deuterium Labeling in Organic Chemistry", 1971, APPLETON-CENTURY-CROFTS
ALLARD, B. ET AL., CURRENT OPINION ;N PHARMACOLOGY, vol. 29, 2016, pages 7 - 16
ALLARD, B. ET AL., CURRENT OPINION IN PHARMACOLOGY, vol. 29, 2016, pages 7 - 16
ANTONIOLI, L. ET AL., NATURE REVIEWS CANCER, vol. 13, 2013, pages 842 - 857
ANTONIOLI. L. ET AL., NATURE REVIEWS CANCER, vol. 13, 2013, pages 842 - 857
BARALDI ET AL., CHEM. REV., vol. 108, 2008, pages 238 - 263
BEAVIS PA. ET AL., PROC NAIL ACAD SCI. USA, vol. 110, 2013, pages 14711 - 14716
BOMNANN, T. ET AL., J. MED. CHEM., vol. 52, no. 13, 2009, pages 3994 - 4006
BORRMANN, T. ET AL., J. MED. CHEM., vol. 52, no. 13, 2009, pages 3994 - 4006
CARLSSON, J. ET AL., J. MED. CHEM.., vol. 53, 2010, pages 3748 - 3755
CEKIC C ET AL., J LMMUNOL, vol. 188, 2012, pages 198 - 205
COLLINS, L. E. ET AL., PHARMACOL. BIOCHEM. BEHAV., vol. 100, 2012, pages 498 - 505
EISENSTEIN, A. ET AL., J. CELL PHYSIOL., vol. 230, no. 12, 2015, pages 2891 - 2897
FIGLER, R. A. ET AL., DIABETES, vol. 60, no. 2, 2011, pages 669 - 679
HASKO', G., PHARMACOL. THER., vol. 113, 2007, pages 264 - 275
IANNONE, R. ET AL., AM. J. CANCER RES., vol. 4, 2014, pages 172 - 181
IANNONE, R. ET AL., NEOPLASIA, vol. 15, 2013, pages 1400 - 1410
JAMES R. HANSON: "The Organic Chemistry of Isotopic Labelling", 2011, ROYAL SOCIETY OF CHEMISTRY
JENS ATZRODT; VOLKER DERDAU; THORSTEN FEY; JOCHEN ZIMMERMANN: "The Renaissance of H/D Exchange", ANGEW. CHEM. INT. ED., 2007, pages 7744 - 7765, XP055192405, DOI: doi:10.1002/anie.200700039
JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, no. 2, 1977
K. BLOM.: "Two-Pump At Column Dilution Configuration for Preparative LC-MS", J. COMBI. CHEM.., vol. 4, 2002, pages 295
K. BLOM; B. GLASS; R. SPARKS; A. COMBS: "Preparative LCMS Purification: Improved Compound Specific Method Optimization", J. COMB. CHEM., vol. 6, 2004, pages 874 - 883
K. BLOM; B. GLASS; R. SPARKS; A. COMBS: "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", J. COMBI. CHEM, vol. 6, 2004, pages 874 - 883
K. BLOM; R. SPARKS; J. DOUGHTY; G. EVERLOF; T. HAQUE; A. COMBS: "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", J. COMBI. CHEM., vol. 5, 2003, pages 670
LIVINGSTON, M. ET AL., INFLAMM. RES., vol. 53, 2004, pages 171 - 178
MATSUMOTO, T. ET AL., PHARMACOL. RES., vol. 65, 2012, pages 81 - 90
R. XU, J. LABEL COMPD. RADIOPHARM., vol. 58, 2015, pages 308 - 312
RYZHOV. S. ET AL., NEOPLASIA, vol. 10, 2008, pages 987 - 995
SACHDEVA, S.; GUPTA. M., SAUDI PHARMACEUTICAL JOURNAL, vol. 21, 2013, pages 245 - 253
SATTIN, A.; RAIL, T.W., MOL. PHARMACOL., vol. 6, 1970, pages 13 - 23
TAUTENHAHN. M. ET AL., NEUROPHARMACOLOGY, vol. 62, 2012, pages 1756 - 1766

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3575301A4 (en) * 2017-03-16 2020-08-05 Jiangsu Hengrui Medicine Co., Ltd. HETEROARYL [4,3-C] PYRIMIDINE-5-AMINE DERIVATIVE, PROCESS FOR PREPARATION AND MEDICAL USES
EP3611174A4 (en) * 2017-04-07 2020-09-09 Medshine Discovery Inc. [1,2,4] TRIAZOLO [1,5-C] PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR
US11673894B2 (en) 2018-02-27 2023-06-13 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
US11873304B2 (en) 2018-05-18 2024-01-16 Incyte Corporation Fused pyrimidine derivatives as A2A/A2B inhibitors
US11168089B2 (en) 2018-05-18 2021-11-09 Incyte Corporation Fused pyrimidine derivatives as A2A / A2B inhibitors
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US11999740B2 (en) 2018-07-05 2024-06-04 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US10858365B2 (en) 2018-09-12 2020-12-08 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Triazolo-pyrimidine compounds and uses thereof
JP2022500402A (ja) * 2018-09-12 2022-01-04 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド トリアゾロ−ピリミジン化合物およびそれらの使用
US20210009600A1 (en) * 2018-09-12 2021-01-14 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Triazolo-pyrimidine compounds and uses thereof
US11629147B2 (en) 2018-09-12 2023-04-18 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Triazolo-pyrimidine compounds and uses thereof
KR20210075996A (ko) * 2018-09-12 2021-06-23 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 트리아졸로-피리미딘 화합물 및 그의 용도
WO2020052631A1 (en) * 2018-09-12 2020-03-19 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Triazolo-pyrimidine compounds and uses thereof
JP2024123079A (ja) * 2018-09-12 2024-09-10 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド トリアゾロ－ピリミジン化合物およびそれらの使用
JP7572353B2 (ja) 2018-09-12 2024-10-23 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド トリアゾロ－ピリミジン化合物およびそれらの使用
KR102841843B1 (ko) 2018-09-12 2025-08-01 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 트리아졸로-피리미딘 화합물 및 그의 용도
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
EP3883576A4 (en) * 2018-11-20 2022-06-22 Merck Sharp & Dohme Corp. SUBSTITUTED AMINOTRIAZOLOPYRIMIDINES AND AMINO-TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020106558A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
US12466831B2 (en) 2018-11-20 2025-11-11 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
EP3883575A4 (en) * 2018-11-20 2022-06-15 Merck Sharp & Dohme Corp. SUBSTITUTED AMINOTRIAZOLOPYRIMIDINES AND AMINO-TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE
WO2020108590A1 (zh) * 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN113906022A (zh) * 2019-01-29 2022-01-07 因赛特公司 作为a2a/a2b抑制剂的吡唑并吡啶和三唑并吡啶
KR102854890B1 (ko) 2019-01-29 2025-09-04 인사이트 코포레이션 A2a/a2b 저해제로서의 피라졸로피리딘 및 트라이아졸로피리딘
US11390624B2 (en) 2019-01-29 2022-07-19 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
AU2020215673B2 (en) * 2019-01-29 2025-09-11 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
WO2020159905A1 (en) * 2019-01-29 2020-08-06 Incyte Corporation Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
KR20210133224A (ko) * 2019-01-29 2021-11-05 인사이트 코포레이션 A2a/a2b 저해제로서의 피라졸로피리딘 및 트라이아졸로피리딘
US11884665B2 (en) 2019-01-29 2024-01-30 Incyte Corporation Pyrazolopyridines and triazolopyridines as A2A / A2B inhibitors
CN113906022B (zh) * 2019-01-29 2024-08-09 因赛特公司 作为a2a/a2b抑制剂的吡唑并吡啶和三唑并吡啶
CN114585625A (zh) * 2019-08-26 2022-06-03 因赛特公司 作为a2a/a2b抑制剂的三唑并嘧啶
WO2021041360A1 (en) * 2019-08-26 2021-03-04 Incyte Corporation Triazolopyrimidines as a2a / a2b inhibitors
US12606564B2 (en) 2019-11-19 2026-04-21 Ildong Pharmaceutical Co., Ltd. Adenosine receptor antagonist compounds
WO2021138498A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
US12018089B2 (en) 2020-01-03 2024-06-25 Incyte Corporation Anti-CD73 antibodies and uses thereof
WO2021138512A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Combination therapy comprising a2a/a2b and pd-1/pd-l1 inhibitors
US12060433B2 (en) * 2020-01-03 2024-08-13 Incyte Corporation CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy
US20210230294A1 (en) * 2020-01-03 2021-07-29 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
JP2023509442A (ja) * 2020-01-03 2023-03-08 インサイト・コーポレイション Ｃｄ７３阻害剤とａ２ａ／ａ２ｂアデノシン受容体阻害剤の併用療法
JP2023509456A (ja) * 2020-01-03 2023-03-08 インサイト・コーポレイション Ａ２ａ／ａ２ｂ及びｐｄ－１／ｐｄ－ｌ１阻害剤を含む併用療法
JP7657230B2 (ja) 2020-01-03 2025-04-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ及びｐｄ－１／ｐｄ－ｌ１阻害剤を含む併用療法
CN115551595A (zh) * 2020-01-03 2022-12-30 因赛特公司 Cd73抑制剂和a2a/a2b腺苷受体抑制剂组合疗法
WO2021156439A1 (en) * 2020-02-06 2021-08-12 Astrazeneca Ab Triazole compounds as adenosine receptor antagonists
CN111362939A (zh) * 2020-04-26 2020-07-03 济南磐石医药科技有限公司 一种帕布昔利布母核结构化合物的制备方法
WO2022147092A1 (en) 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
US12065444B2 (en) 2021-11-19 2024-08-20 Crossignal Therapeutics, Inc. Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists
WO2023091604A1 (en) * 2021-11-19 2023-05-25 Crossignal Therapeutics, Inc. Adenosine receptor antagonists
AU2022390153B2 (en) * 2021-11-19 2025-11-13 Crossignal Therapeutics, Inc. Adenosine receptor antagonists

Also Published As

Publication number Publication date
JP7474709B2 (ja) 2024-04-25
CR20230030A (es) 2023-03-10
PE20211001A1 (es) 2021-06-01
TWI853802B (zh) 2024-09-01
CR20200441A (es) 2021-03-15
BR112020017421A2 (pt) 2020-12-22
BR122023024273A2 (pt) 2024-02-20
KR20200139153A (ko) 2020-12-11
CN117903140A (zh) 2024-04-19
CL2022003185A1 (es) 2023-05-19
CL2020002198A1 (es) 2021-01-29
TWI877770B (zh) 2025-03-21
JP2021515036A (ja) 2021-06-17
TW202400599A (zh) 2024-01-01
PH12020551332A1 (en) 2021-09-06
AU2022283611A1 (en) 2023-02-02
CN112384515A (zh) 2021-02-19
EP3759112A1 (en) 2021-01-06
AU2022283611B2 (en) 2025-02-06
CO2020011908A2 (es) 2020-10-30
AU2019227607B2 (en) 2023-04-27
IL303087B1 (en) 2024-08-01
US20190292188A1 (en) 2019-09-26
AU2019227607C1 (en) 2023-07-20
US20250313567A1 (en) 2025-10-09
ECSP20060827A (es) 2020-12-31
US11673894B2 (en) 2023-06-13
IL276873A (en) 2020-10-29
JP2023123569A (ja) 2023-09-05
US20230357255A1 (en) 2023-11-09
IL303087A (en) 2023-07-01
IL276873B1 (en) 2025-07-01
AU2019227607A1 (en) 2020-10-15
IL303087B2 (en) 2024-12-01
CN112384515B (zh) 2024-12-10
MA52422A (fr) 2021-01-06
MX2020008949A (es) 2021-01-08
US20210139485A1 (en) 2021-05-13
PE20251291A1 (es) 2025-05-14
TW202000666A (zh) 2020-01-01
MX2022014648A (es) 2022-12-15
JP7624476B2 (ja) 2025-01-30
IL276873B2 (en) 2025-11-01
CA3092470A1 (en) 2019-09-06

Similar Documents

Publication Publication Date Title
JP7624476B2 (ja) Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン
JP7700196B2 (ja) Ａ２ａ／ａ２ｂ阻害剤としての縮合ピラジン誘導体
KR20210116488A (ko) 액티빈 수용체-유사 키나제-2의 억제제로서의 이미다조피리다진 및 이미다조피리딘 화합물
EA048695B1 (ru) Производные конденсированных пиразинов как ингибиторы a2a/a2b

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19713602

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020567459

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3092470

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20207027865

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2020/0011908

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2019713602

Country of ref document: EP

Effective date: 20200928

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020017421

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2019227607

Country of ref document: AU

Date of ref document: 20190226

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: NC2020/0011908

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112020017421

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200826

WWE Wipo information: entry into national phase

Ref document number: 12024552486

Country of ref document: PH

WWC Wipo information: continuation of processing after refusal or withdrawal

Ref document number: 1020207027865

Country of ref document: KR